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Every year there is 2% increase in the reported cases of glioma. It is important to treat 
glioma from materials that are readily available in nature. One of the interesting 
properties of liposomes is their ability to target tumours and facilitate the cellular uptake 
of therapeutic agents compared to the agent alone. In this project, liposomes were 
prepared from SPC (Soy phosphatidylcholine) and HSPC (Hydrogenated soy 
phosphatidylcholine)  phospholipids.  Drug-free  liposomes  prepared  by  proliposomes 
were compared with the conventional method of producing liposomes. Conventional 
liposomes are biocompatible and biodegradable, however, they are physically and 
chemically unstable. The instability problems were avoided by formulating liposomes 
using the ethanol-based proliposome technology. In ethanol-based proliposome method, 
aqueous  phase  (e.g.  water)  was  added  to  an  ethanolic  solution  of  phospholipid  to 
generate liposomes. In this work, natural anticancer materials such as Paclitaxel (PTX) 
and  Momordica  charantia  extracts  (Whole  fruit,  Fruit  alone  and  Seed  alone)  from 
Africa, China and India were incorporated in liposome formulations. These liposomes 
were analysed by investigating, the resultant size, size distribution and zeta potential of 
the vesicles. Either, the anticancer drug or extract of Momordica charantia was mixed 
with liposomes and checked for the efficacy of the anticancer-liposome formulations on 
the viability of glioma cell lines and the molecular mechanism of the cell death were 
also investigated. The results show that liposomes prepared by the conventional thin- 
film method were comparatively large in size as compared to liposomes generated from 
proliposomes. Liposomes generated from proliposomes (made from SPC or HSPC), 
iv  
when generated by hydration with Momordica charantia extracts (WF – Whole fruit, FA 
 
– Fruit alone or SA – Seed alone) from Africa, China or India respectively, or when 
prepared using PTX in the lipid phase had significantly larger size and wider size 
distribution   as   compared   to   drug   free   liposomes.   Liposomes   generated   from 
proliposomes were neutral or negatively charged and were a mixture of oligolamellar 
and multilamellar vesicles regardless of formulation. Particle size and size distribution 
of HSPC liposomes were larger than SPC liposomes on inclusion of either Paclitaxel or 
Momordica charantia extracts. Liposome generated by proliposome method using the 
Momordica  charantia  extracts  (FA,  SA  and  WF)  exerted  cytotoxic  effects  against 
glioma cells 1321N1, Gos-3 and U87-MG at the higher concentrations with or without 
liposomes. Momordica charantia extracts showed either slight or no significant effect on 
the normal glial cells. The liposome formulations were more effective against glioma 
cells as compared to drug-free liposomes. FA extract of Momordica charantia was very 
effective with and without liposomes but less than PTX liposomes. The activities of 
caspase 3/7, caspase 9 and cytochrome c release were elevated in cancerous glial cell 
line indicating apoptosis via mitochondrial cell death or intrinsic pathway. 
 
In conclusion, the study showed that liposomes generated from proliposomes were 
appropriate  to  target  cancerous  glial  cells  by  binding  plant  extracts  Momordica 
charantia and PTX to SPC and HSPC phospholipids. The cell death was induced by 


































Table of Contents 
 
Liposomes generated from proliposomes for treatment of glioma using Momordica 
charantia extracts ..............................................................................................................i 
 
Abstract ........................................................................................................................... iii 
Index .................................................................................................................................vi 
Acknowledgement ...................................................................................................... xviii 
List of Abbreviation .......................................................................................................xx 
Chapter 1.   Introduction................................................................................................1 
1.1 Cancer ..................................................................................................................2 
1.2 Glioma ..................................................................................................................6 
1.2.1 Grading of gliomas.........................................................................................6 
1.2.2 Classification of glioma .................................................................................7 
1.2.3 Statistics of Brain tumour...............................................................................9 
1.2.4 Statistics for tumour-specific glioma (CBTRUS, 2011). ...............................9 
1.2.5 Treatment of glioma .....................................................................................10 
1.2.5.1 Radiotherapy .........................................................................................11 
1.2.5.2 Chemotherapy to treat cancers ..............................................................11 
1.2.5.3 Alkylating agents ..................................................................................12 
1.3 Study of Tissue culture .....................................................................................12 
1.3.1 Importance of growth media in tissue culture ..............................................13 
1.3.2 WHO grading of glioma based on genetics and histopathology 
characteristics ...........................................................................................................14 
1.4 Cell viability MTS assay to identify proliferation or inhibition of glioma 
cells 16 
1.5 Capase and cytochrome c assay used to identify pathways of cell death. ....17 
1.5.1 Mechanism of apoptosis...............................................................................19 
1.5.2 Caspase activity............................................................................................23 
1.5.3 Role of Bcl-2 proteins in the release of cytochrome c release .....................23 
1.5.4 Caspase Assays ............................................................................................24 
1.5.5 Mitochondrial Assays ..................................................................................26 
1.6 Plant extracts used as traditional medicine for treatment of cancer............27 
1.6.1 Momordica charantia ..................................................................................29 
1.6.2 Horticulture of Momordica charantia..........................................................29 
 1.6.3 Origin and geographical distribution of Momordica charantia ...................30 
1.6.4 Description of Momordica charantia fruit and seeds. .................................31 
1.6.4.1 Chinese breed (Yunnan, China) ............................................................33 
1.6.4.2 Indian breed (Maharashtra, India) .........................................................33 
1.6.4.3 African breeds (Kenya, Africa) .............................................................34 
1.6.5 Traditional uses of Momordica charantia....................................................35 
1.7 Phytochemistry of Momordica charantia ........................................................35 
1.7.1 Medical applications of Momordica charantia ...........................................41 
1.7.2 Anti Diabetic Activity of Momordica charantia in animals and humans....41 
1.7.3 Antioxidant Activity of Momordica charantia ............................................42 
1.8 Anti microbial activity of Momordica charantia.............................................42 
1.8.1 Anti cancer activity of Momordica charantia..............................................43 
1.9 Paclitaxel ............................................................................................................45 
1.10 Liposomes ........................................................................................................46 
1.10.1 Architecture of Liposomes .........................................................................47 
1.10.2 Soy lecithin ................................................................................................52 
1.10.2.1 Soy Phosphatidylcholine .....................................................................53 
1.10.2.2 Hydrogenated soy phosphatidylcholine (HSPC) ................................55 
1.10.3 Role of phospholipids present in Soy lecithin ...........................................57 
1.10.3.1 Phosphatidylcholine (PC)....................................................................57 
1.10.3.2 Phosphatidylethanolamine (PE) ..........................................................57 
1.10.3.3 Phosphatidylinositol (PI).....................................................................58 
1.10.4 Liposome morphology and preparation methods.......................................58 
1.10.5 Usage of entrapment of material in liposomes...........................................59 
1.11 Proliposomes ....................................................................................................60 
1.11.1.1 Particulate-based proliposomes...........................................................61 
1.11.2 Solvent-based proliposomes.......................................................................62 
1.12 Liposomes in anticancer therapy ...................................................................63 
1.12.1 Role of liposomes in anti-cancer therapy...................................................65 
1.13 Working hypothesis ........................................................................................67 
1.14 Main Aim .........................................................................................................67 
1.14.1 Specific aims ..............................................................................................67 
 
Chapter 2. General Materials and Methods .............................................................69 
2.1 Materials ............................................................................................................70 
2.1.1 Momordica charantia from China, Africa and India ....................................70 
2.1.2 Phospholipids used in the experiment..........................................................70 
2.1.3 Other materials .............................................................................................70 
2.2 Methods ..............................................................................................................71 
2.2.1 Aqueous extraction of Momordica charantia ..............................................71 
2.2.2 Drying of the aqueous extracts.....................................................................72 
vii 
viii  
2.3 Preparation of liposomes using thin film hydration method ........................73 
2.4 Preparation of liposomes using the solvent-based proliposome method......73 
2.4.1 Momordica charantia Extract ......................................................................73 
2.4.2 Paclitaxel ......................................................................................................74 
2.5 Statistical Analysis ............................................................................................76 
 
Chapter 3. Characteri-sation of Momordica charantia prepared liposomes using 
ethanol-based proliposome ............................................................................................77 
3.1 Introduction .......................................................................................................78 
3.2 Materials ............................................................................................................79 
3.3 Methods for characterisation of liposomes .....................................................79 
3.3.1 Liposome particle size analysis using laser diffraction................................79 
3.3.2 Zeta potential measurements........................................................................80 
3.3.3 Transmission electron microscopy (TEM) ..................................................81 
3.4 Statistical Analysis ............................................................................................82 
3.5 Results and Discussion ......................................................................................82 
3.5.1 Size and size distribution of extract-free liposomes prepared by 
conventional thin film method and proliposome method ........................................82 
3.5.2 Size and size distribution of Momordica charantia liposomes using SPC or 
HSPC 85 
3.5.2.1 Particle size and size distribution of African Momordica charantia 
liposomes .............................................................................................................85 
3.5.2.2 Particle size and size distribution of Chinese Momordica charantia 
liposomes .............................................................................................................90 
3.5.2.3 Particle size and size distribution of Indian Momordica charantia 
liposomes .............................................................................................................94 
3.5.3 Particle size and size distribution of SPC and HSPC liposome formulations 
including PTX ..........................................................................................................97 
3.5.4 Zeta potential of liposomes prepared by conventional thin film method and 
proliposome method...............................................................................................100 
3.5.5 Zeta potential of liposomes made by hydration with the Momordica 
charantia extracts....................................................................................................101 
3.5.5.1 African Momordica charantia extracts ...............................................101 
3.5.5.2 Chinese Momordica charantia extracts ..............................................103 
3.5.5.3 Indian Momordica charantia extracts .................................................105 
3.5.6 Surface charge of the SPC and HSPC liposomal formulations prepared from 
ethanol based proliposome technology on inclusion of PTX.................................107 
3.5.7 Morphology of liposomal vesicle originated by Transmission Electron 
Microscopy.............................................................................................................109 
3.5.7.1 Drug-free liposomes ............................................................................109 
3.5.7.2 Liposomes on inclusion of Momordica charantia extracts ................111 
ix  
3.5.7.3 TEM of liposomes on inclusion of Paclitaxel .....................................113 
3.6 Conclusion........................................................................................................115 
 
Chapter 4. Tissue culture studies to investigating cytotoxicity against glioma cell 
117 
4.1 Introduction .....................................................................................................118 
4.2 Materials ..........................................................................................................118 
4.2.1 Equipment and materials used in cell culture ............................................118 
4.2.2 Glioma cell lines ........................................................................................119 
4.2.3 Liposomes prepared from ethanol-based proliposome ..............................119 
4.2.4 Media and supplements required for cell culture .......................................119 
4.2.5 Chemicals and Reagents ............................................................................120 
4.3 Methods ............................................................................................................120 
4.3.1 Composition of medium for the glioma cell lines used in the study..........120 
4.3.2 Cell culture and passaging of the primary glial cells (1321N1, U87-MG, 
Gos-3 and SVGP12)...............................................................................................120 
4.3.3 Cell Counting Method................................................................................122 
4.3.4 Growth curve..............................................................................................123 
4.3.5 Plating of cell lines .....................................................................................123 
4.3.6 Measurement of MTS assay.......................................................................124 
4.3.7 Statistical analysis ......................................................................................126 
4.4 Results and Discussion ....................................................................................126 
4.4.1 Growth curve study of the four different cell lines; 1321N1, Gos-3, U87- 
MG, and SVGP12 ..................................................................................................126 
4.4.2 Effect of water, 0.002% ETOH and extract free liposomes on the cell lines 
127 
4.4.3 Effect of the treatment of PTX and PTX inclusion in liposomes on the cell 
lines 129 
4.4.4 Effect of Momordica charantia extracts and Momordica charantia 
liposomes on the cell lines .....................................................................................130 
4.4.5 Inclusion of Momordica charantia extracts from different plant origins into 
SPC or HSPC liposomes ........................................................................................134 
4.4.6 Effect of African Momordica charantia extracts on cancerous and non- 
cancerous glial cells ...............................................................................................135 
4.4.7 Effect of African Momordica charantia extracts included in SPC liposomes 
to treat cancerous and non-cancerous glial cell lines. ............................................137 
4.4.8 Effect of African Momordica charantia extracts included in HSPC 
liposomes to treat cancerous and non-cancerous glial cell lines ............................140 
4.4.9 Effect of Chinese Momordica charantia extracts treatment on cancerous and 
non-cancerous glial cell lines. ................................................................................143 
x  
4.4.10 Effect of Chinese Momordica charantia extracts included in SPC 
liposomes to treat cancerous and non-cancerous glial cell lines. ...........................145 
4.4.11 Effect of Chinese Momordica charantia extracts included in HSPC 
liposomes upon addition to cancerous and non-cancerous glial cell lines .............148 
4.4.12 Effect of Indian Momordica charantia extracts on cancerous and non- 
cancerous glial cell lines ........................................................................................150 
4.4.13 Effect of Indian Momordica charantia extracts included in SPC liposomes 
on treatment of cancerous and non-cancerous glial cell lines ................................152 
4.4.14 Effect of Indian Momordica charantia extracts included in HSPC 
liposomes to treat cancerous and non-cancerous glial cell lines ............................155 
4.5 Futher Discussion and Conclusion ................................................................158 
 
Chapter 5. Effect of Momordica charantia extracts and proliferation on activities 
of caspase 3, 7 and 9 and release of cytochrome C in glioma cell lines ...................162 
5.1 Introduction .....................................................................................................163 
5.2 Materials and Methods ...................................................................................163 
5.3 Materials and chemical reagents ...................................................................163 
5.4 Methods ............................................................................................................163 
5.4.1 Plating of cell lines .....................................................................................163 
5.4.2 Measurement of Cytochrome-c release......................................................165 
5.4.3 Statistical analysis ......................................................................................168 
5.5 Results and Discussion ....................................................................................168 
5.5.1 Activity of caspase 3/7 in normal and cancerous glial cells using liposomes 
with or without Momordica charantia (FA extracts) or PTX................................168 
5.5.2 Activity of caspase 9 in normal and cancerous glial cells using liposomes 
with or without Momordica charantia FA extract or PTX ....................................172 
5.5.3 Cytochrome C release in 1321N1, Gos-3, U87-MG and SVGP12 glial cell 
lines, on treatment with SPC and HSPC liposome including Momordica charantia 
extracts or PTX ......................................................................................................174 
5.5.4 Morphological characteristic of cell lines untreated and treated with 
Momordica charantia extract or PTX included in liposomes and drug free liposome 
prepared from proliposome technology .................................................................177 
5.5.5 Conclusion .................................................................................................179 
 
Chapter 6. General Discussion, Conclusion and Future Work ............................181 
6.1 General Discussion ..........................................................................................182 
6.2 Characterization of liposomes generated from proliposomes.....................183 
6.3 Growth curve of cancerous and non-cancerous glial cells ..........................186 
6.4 Cytotoxicity of liposomes generated from proliposomes on tissue culture 187 




6.7 Scope for...........................................................................................................193 
 
Chapter 7.   Reference ................................................................................................194 
7.1 References ........................................................................................................195 
 





List of Figures 
Figure 1.1: Diagrams showing above iilustrate how a normal cell can become tumours 
during the process of mitotic division (Modified from- Henry, 1964). .............................3 
 
Figure 1.2: Diagram showing the origination of glioma from the brain. (a) Supportive 
cells- Oligodendroglioma and Astrocytoma in the cerebrum region and (b) Glioblastoma 
nearby to the cerebellum region. ........................................................................................9 
 
Figure 1.3: Photograph showing grade II astrocytoma: a) fibrillary, b) gemitocytic and 
c) protoplasmic.  (Source: Brat et al. 2003). ....................................................................14 
 
Figure 1.4: A photograph showing grade III Oligodendroglioma: Cells of an anaplastic 
oligodendroglioma demonstrate the classic ‗fried egg‘ appearance: round nuclei with 
clear, peri- nuclear halos (Adapted from – Brat et al. 2003)............................................15 
 
Figure 1.5: A photograph showing grade IV Glioblastoma multiforme: Pseudopalisades 
in glioblastoma are small (a, <100 mm) and medium (b, 200–400 mm). Note the central 
necrosis in the larger pseudopalisade (b) (Adapted from  Brat et al. 2003).....................16 
 
Figure 1.6: Diagram showing the structure of tetrazolium salt and electron transfer 
mechanism for MTS assay. (Adapted from-www.promega.com/automethods/). ...........17 
 
Figure 1.7: Diagrams showing the morphological representation of cell death of viable 
cells via A) Necrosis or Apoptosis B) Apoptosis is characterized by a variety of cellular 
changes including loss of membrane phospholipid symmetry, mitochondrial swelling 
and DNA cleavage. (Adapted form- 
http://www.celldeath.de/encyclo/aporev/revfigs/revfig_2.htm). .....................................19 
 
Figure 1.8: Schematic representations (A-C) of apoptotic events due to the regulation of: 
intrinsic, extrinsic and perforin/granzyme pathway. (Adapted from- Vermes et al. 1995; 
Darzynkiewicz et al. 1992). .............................................................................................22 
 
Figure 1.9: Diagram showing caspase -3/7 and caspase -9, cleavage of the 
proluminogenic substrates containing LEHD and DEVD. Following caspase cleavage, a 
substrate for luciferase (aminoluciferin) is released, resulting in the production of light. 
 (Adapted from- http://www.promega.com/resources/product-guides-and- 
selectors/protocols-and-applications-guide/apoptosis/) ...................................................26 
 
Figure 1.10: Momordica charantia comes in a variety of shapes and sizes: A) Fruit 
diversity (B) Large fusiform fruits (C) Chinese long fruit type (D) Small fruits (E) 
Triangular fruits. (Adapted from- 
http://ddr.nal.usda.gov/bitstream/10113/42264/1/IND44357776.pdf). ...........................32 
 
Figure 1.11: Compounds present in Momordica charantia (Adapted from- 
http://ssjournals.com/index.php/ijbr/article/view/sahu%20et%20al/sahu%20et%20al). 40 
 
Figure 1.12: (A) The bark of the Pacific yew that is used to extract palitaxel. B) The 




Figure 1.13: Arrangement of phospholipid bilayer in the liposomes: A) Phospholipid 
molecule on presence of aqueous phase forms B) phospholipid bilayers having C) polar 
head face outwards and non-polar tail face inwards of the liposome and forms D) 
colloidal and sperical shape vesicle to carry drugs. (Adapted from- http://www.uni- 
magdeburg.de/imos/mea_sen/img/pictures/Lipo.jpg). .....................................................48 
 
Figure    1.14:    Diagram    showing    the    chemical    structure    of    a    phospholipid 
(phosphatidylcholine) molecule. ......................................................................................49 
 
Figure  1.15:  Orientation  of  Cholesterol  in  the  biological  membrane  A)  Chemical 
structure of cholesterol B) Polar and non-polar region in cholesterol molecule and c) 
Orientation of cholesterol molecule inserting itself between the membrane bilayer 
(Adapted from-http://www.cytochemistry.net/cell-biology/membrane_intro.htm). .......50 
 
Figure 1.16: The relationship between packing style of hydrocarbon chains in bilayers 
and the temperature of the hydrating phase. A) shows the fluid state of hydrocarbon 
chain when the temperature is above phase transition (Tc) B) shows the gel phase 
hydrocarbon state when below phase transition C) shows rigid  hydrocarbon state on 
insertion of cholesterol in the formulation above Tc. ......................................................51 
 
Figure 1.17: Pie chart showing the composition of soybean lecithin: Phospholipid 
distribution in dried soy seeds (adapted from Nyberg, 1998). .........................................53 
 
Figure 1.18: Diagrams showing the size and lamellarity of liposomes prepared using 








Figure 1.19: Diagram showing the gaps in the endothelial cells in tumour, allows the 
liposomes to accumulate in the tumour site and stop the proliferation of cancerous cells. 
(Adapted from – Drummond et al. 1999). .......................................................................66 
 
Figure 2.1: The three different species of Momordica charantia. The plant source was 
from A) China (Yunnan), B) India (Maharashtra) and C) Africa (Kenya) and all were 
purchased from the local supplier Kashmir Watan food store (Kashmir Watan Food 
store, Lancashire, Preston PR1 1PJ, United Kingdom). ..................................................70 
 
Figure 2.2: Diagram showing Momordica charantia whole fruits (A) and a fruit after 
being sliced into two halves with the associated seeds (B)..............................................72 
 
Figure 2.3: Schematic presentations for the preparation of liposomes using the solvent- 
based proliposome methods. ............................................................................................75 
 
Figure 3.1: Diagram showin the zeta potential cuvette having electrode for the zeta 
potential analysis of liposomes. .......................................................................................81 
 
Figure 3.2: Bar charts showing A) Particle Size and B) Size distribution of extract-free 
liposomes prepared by thin film or ethanol-based proliposome methods using SPC or 
HSPC. Data are mean ± S.D and n=3. * P < 0.05 for conventional method compared to 
proliposome method.........................................................................................................84 
 
Figure 3.3: Diagrams showing the characterisation of African Momordica charantia 
extracts  (FA,  SA  and  WF)  associated  liposomes-  A)  Particle  size  and  B)  Size 
distribution of SPC liposomes and C) Particle size and D) Size distribution of HSPC 
liposomes. Data are mean ± S.D, n=3 *P < 0.05 for Momordica charantia liposomal 
formulations compared to drug free liposomal formulation. ...........................................89 
 
Figure 3.4: Plots showing the characterisation of Chinese Momordica charantia extracts 
(FA, SA and WF) associated liposomes- A) Particle size and B) Size distribution of SPC 
liposome, C) Particle size and D) Size distribution of HSPC liposomes. Data are mean ± 
S.D, n=3 *P < 0.05 for Momordica charantia liposomal formulations compared to drug 
free liposomal formulation. ..............................................................................................93 
 
Figure 3.5: Plots showing the characterisation of Indian Momordica charantia extracts 
(FA, SA and WF) associated liposomes- A) Particle size and B) Size distribution of SPC 
liposome, C) Particle size and D) Size distribution of HSPC liposomes. Data are mean ± 
S.D, n=3 *P < 0.05 for Momordica charantia liposomal formulations compared to drug 
free liposomal formulation. ..............................................................................................96 
 
Figure 3.6: Bar chart showing characterisation of PTX associated liposomes- A) Particle 
size and B) Size distribution of SPC and HSPC liposomes. Data are mean ± S.D, n=3 *P 
xiv  
< 0.05 for either SPC-PTX liposomal formulations or HSPC-PTX liposomal formulation 
compared to drug free liposome.......................................................................................99 
 
Figure 3.7: Bar charts showing a comparison of surface charges of the drug free 
liposomes prepared by conventional and ethanol-based proliposomes methods. Data are 
mean ± S.D, n=3 *P < 0.05 for zeta-potential of conventional method compared to 
proliposome method.......................................................................................................101 
 
Figure 3.8: Plot showing the zeta-potential of African Momordica charantia extracts 
(FA, SA and WF) associated with liposomes A) SPC and B) HSPC. Data are mean ± 
S.D, n=3 *P < 0.05 for zeta-potential of African FA compared to African SA.............102 
 
Figure 3.9: Plots showing the zeta-potential of Chinese Momordica charantia extracts 
(FA, SA and WF) associated with liposomes A) SPC and B) HSPC. Data are mean ± 
S.D, n=3 *P < 0.05 for Chinese FA compared to the Chinese SA. ...............................104 
 
Figure 3.10: Plots showing the zeta-potential of Indian Momordica charantia extracts 
(FA, SA and WF) associated with liposomes A) SPC and B) HSPC. Data are mean ± 
S.D, n=3 *P < 0.05 for Indian FA compared to Indian SA............................................106 
 
Figure 3.11: Bar charts showing zeta potential of Paclitaxel liposomes prepared from 
SPC and HSPC phospholipids by the ethanol-based proliposome. Data are mean ± S.D, 
n=3 *P < 0.05 for HSPC compared to SPC. ..................................................................108 
 
Figure   3.12:   Electron   micrographs   of   the   drug   free   liposomes   prepared   from 
proliposome showing A) SPC liposomal formulation having oligolamellar structure with 
large aqueous cores b) HSPC liposomal formulation having mixture of oligolamellar and 
multilamellar vesicles. These micrographs are typical of three (n=3) each different 
experiments. ...................................................................................................................110 
 
Figure 3.13: Electron micrographs of the Momordica charantia liposomal formulation 
prepared from proliposome showing A) SPC liposomal formulation and b) HSPC 
liposomal formulation having mixture of oligolamellar and multilamellar vesicles. 
Micrographs are typical of three each different experiments.........................................112 
 
Figure 3.14: Electron micrographs of the PTX liposomal formulation prepared from 
proliposome   showing   A)   SPC   liposomal   formulation   and   b)   HSPC   liposomal 
formulation having mixture of oligolamellar and multilamellar vesicles. Micrographs are 
typical of three each different experiments. ...................................................................114 
 
Figure 4.1: Diagram showing a hemocytometer for cell counting under objective 10X. 
(1,2,3,4 = Major grid line and 5 = Minor grid line of hemocytometer). ........................123 
xv  
Figure 4.2: Flow diagram showing preparation and use of CellTiter 96® AQueous  One 






Figure 4.3: The growth curve of 1321N1, Gos,-3, U87-MG, and SVGP12 cell lines 
using trypan blue cell counting method under inverted microscope at magnification 10X. 
Data are mean ± S D; n=3; *P < 0.05. ...........................................................................127 
 
Figure 4.4: Bar chart showing treatment of glioma cell lines 1321N1, Gos-3 and U87- 
MG and normal glial cell SVGP12 with water +0.002% ETOH, SPC and HSPC 
liposomes. Data are mean ± S D; n=3; *P < 0.05 for treated cells compared to control. 
........................................................................................................................................128 
 
Figure 4.5: Bar charts showing treatment of glioma cell lines 1321N1, Gos-3 and U87- 
MG and normal glial cell SVGP12 with PTX, SPC-PTX and HSPC-PTX liposomes as 
compared to untreated cell lines (100%). Data are mean         ± S D; n=3; *P < 0.05 for 
treated cells compared to untreated cells. ......................................................................130 
 
Figure 4.6: Effect of Momordica charantia extract with and without liposome on A) low 
grade tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal 
cell glial cell line SVGP12 as compared to untreated cell lines. Data are mean ± S D; 
n=3; *P < 0.05. ...............................................................................................................133 
 
Figure 4.7: Dose response curves showing the effect of African Momordica charantia 
extracts (FA, SA and WF) on viability of A) low grade tumours, 1321N1 and Gos-3 and 
B) high grade tumour U87-MG and also normal cell glial cell line SVGP12 as compared 
to untreated cell lines. Data are mean ± S D; n=3; *P < 0.05. .......................................136 
 
Figure 4.8: Dose response curves showing the effect of SPC liposome including African 
Momordica charantia extracts (FA, SA and WF) on the viability of A) low grade 
tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal cell 
glial cell line SVGP12 as compared to untreated cell lines. Data are mean ± S D; n=3; 
*P < 0.05. .......................................................................................................................139 
 
Figure  4.9:  Dose  response  curves  showing  the  effect  of  HSPC  liposome  including 
African Momordica charantia extracts (FA, SA and WF) on the viability of A) low 
grade tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal 
cell glial cell line SVGP12 as compared to untreated cell lines. Data are mean ± S D; 
n=3; *P < 0.05. ...............................................................................................................142 
xvi  
Figure 4.10: Dose response effect of Chinese Momordica charantia extracts (FA, SA 
and WF)  on viability of A) low grade tumours, 1321N1 and Gos-3 and B) high grade 
tumour U87-MG and also normal cell glial cell line SVGP12 as compared to untreated 
cell lines. Data are mean ± S D; n=3; *P < 0.05. ...........................................................145 
 
Figure  4.11:  Dose  response  curves  effect  of  SPC  liposome  including  Chinese 
Momordica charantia extracts (FA, SA and WF) on the viability of A) low grade 
tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal cell 
glial cell line SVGP12 as compared to untreated cell lines. Data are mean ± S D; n=3; 
*P < 0.05. .......................................................................................................................147 
 
Figure 4.12: Dose dependent effect of HSPC liposome including Chinese Momordica 
charantia extracts (FA, SA and WF) on the viability of A) low grade tumours, 1321N1 
and Gos-3 and B) high grade tumour U87-MG and also normal cell glial cell line 
SVGP12 as compared to untreated cell lines. Data are mean ± S D; n=3; *P < 0.05. ...150 
 
Figure 4.13 Dose dependent effect of Indian Momordica charantia extracts (FA, SA and 
WF) on viability of A) low grade tumours, 1321N1 and Gos-3 and B) high grade tumour 
U87-MG and also normal cell glial cell line SVGP12 as compared to untreated cell lines. 
Data are mean ± S D; n=3; *P < 0.05. ...........................................................................152 
 
Figure 4.14: Dose dependent effect of SPC liposome including Indian Momordica 
charantia extracts (FA, SA and WF) on the viability of A) low grade tumours, 1321N1 
and Gos-3 and B) high grade tumour U87-MG and also normal cell glial cell line 
SVGP12 as compared to untreated cell lines. Data are mean ± S D; n=3; *P < 0.05. ...154 
 
Figure 4.15: Dose response effect of HSPC liposome including Indian Momordica 
charantia extracts (FA, SA and WF) on the viability of A) low grade tumours, 1321N1 
and Gos-3 and B) high grade tumour U87-MG and also normal cell glial cell line 
SVGP12 as compared to untreated cell line. Data are mean ± S D; n=3; *P < 0.05. ....157 
 
Figure 5.1: Schematic diagrams showing A) Caspase-Glo® 9 and B) Caspase-Glo® 3/7 




Figure 5.2: Bar charts showing A) SPC and B) HSPC liposomes, encapsulated with and 
without (Drug free liposome) 1.8 mg /ml of Momordica charantia FA from Africa, India 
and China and PTX involves caspase 3/7 activation on the death of 1321N1, GOS-3, 
U87-MG and SVGP12 as compared to untreated cells. Data are mean ± S D; n=3 in 
triplicates *P < 0.05 for fruit extracts liposomal formulation compared to control.......171 
 Figure 5.3: Bar charts showing A) SPC and B) HSPC liposomes, encapsulated with and 
without (Drug free liposome) 1.8 mg / ml of Momordica charantia FA from Africa, 
India and China involves caspase 9 activation on the death of 1321N1, GOS-3, U87-MG 
and SVGP12 as compared to untreated cells. Data are mean ± S D; n=3 in triplicates *P 
< 0.05. ............................................................................................................................173 
 
Figure 5.4: Bar chart showing cytochrome c realease of 13121N1, GOS-3, U87-MG and 
SVGP12 of untreated and 24hr treatment of Drug free liposome, Momordica charantia 
FA extract (African, Chinese and Indian) and PTX loaded within A) SPC ad B) HSPC 
liposomes. Data are mean ± S D; n=3; *P < 0.05 for treated compared to control. ......176 
 
Figure 5.5: Photograph showing untreated cell line 1321N1 (A), GOS-3 (B), U87-MG 
(C) and SVGP12 (D) with no destruction of the chromatins or morphological features. 
Vice versa, treated cell lines; U87-MG with PTX liposome (E) and drug free liposome 
and (F), Gos-3 (G) and SVGP12 (H) treated with Momordica charantia liposome shows 







List of Tables 
Table 1.1: Comparison between cancer cells and normal cells (Adapted from: Yamazaki 
et al. 1995)..........................................................................................................................5 
 
Table 1.2: Nutrient composition per 100 gram of Momordica charantia whole fruit 
(Source: Gopalan et al. 1993)...........................................................................................37 
 
Table 1.3: Major phytochemicals in bitter gourd (Momordica charantia) fruit, and their 
health benefits. .................................................................................................................38 
 
Table 1.4: Composition Lipoid S-100) (Adapted from the supplier: Lipoid GmbH, 
Switzerland) .....................................................................................................................54 
 
Table  1.5:  Composition  of  Phospholipon®90  H  (Adapted  from  the  supplier:  Lipoid 
GmbH, Switzerland) ........................................................................................................56 
 
Table 4.1: Some types of brain cell lines used in the study with grades and companies 
supplying them. ..............................................................................................................119 
 










First and foremost, I would like to express my sincere and deepest gratitude and 
faithfulness to God for his blessing on me, which enabled me to complete my project 
successfully. I am deeply indebted to my respectful supervisor Dr. Abdelbary Elhissi for 
his constant guidance, motivation, enthusiasm, inspiration and support throughout the 
research. He has always acted as a supportive pillar throughout my PhD phase. I could 
not have imagined a better advisor for my PhD study and would always be grateful to 
him. I would also like to give my sincere thanks to my second supervisor Professor 
Waqar Ahmed for his help, support and friendly advice, an also, helping to designing my 
project and arranging workshops for writing papers. Dr. Abdelbary Elhissi and Professor 
Waqar Ahmed both have always encouraged me not only to grow as an experimentalist 
but also to become an independent thinker and consoled me when the things did not go 
in the right direction. 
 
I would also like to give my special thanks to Dr. Leroy Shervington for inculcating 
good lab skills during my MSc by Research phase, which were immensely helpful for 
me during my PhD phase. My big thanks to Professor JaiPaul Singh for supporting my 
research journey as a Research Degree Tutor. I would also like to thank other University 
staff members, Dr Julie Sharrocks, Dr Lisa Shaw and Dr Sarah Dennison for their 
technical support and help to gain experience in tissue culture techniques. I am grateful 
to Lipoid GmbH, Switzerland for providing complementary phospholipids (Lipoid-S- 
100 and Phospholipon®  90 H) to carry out this research. My very special thanks to 
xix  
David McCarthy from London School of Pharmacy for sending me liposome pictures 
produced from transmission electron microscopy. 
 
There are number of friends who provided me their helping hand in my research. I 
would specially like to thank my peer Dr Gunasekar Manoharan for his advice and 
support on tissue culture experiments. My special thanks to Basal Arafat for teaching me 
how to prepare liposomes and being involved in very useful discussions. I appreciate the 
contribution of my research room and lab colleagues, Aisha Ahmed, Banu Abdallah, 
Huner Omer, Iftikhar Khan, Krunal Khamkar, Kanar Hidayat, Maha Nasr, Nozad 
Hussein, Oshadie Korale and Samrudhi Lal for supporting and encouraging me. I also 
thank Sneha Subramanian, Urwashi Naik and Vinod Kumar for maintaining a lively 
environment. I would also love to thank my close friends Abhishek Soni, Adi Mehta, 
Ibrahim Qazi, Khyati Choksi, Mansi Tripathi, Nehala Parkar, Nilu Pandey, Pallavi 
Mahaddalkar, Pooja Barbar, Shardha Aptekar, Shweta Kamble and Zarine Khan for 
immense love, care, support, encouragement and cheering me up with their jokes 
throughout the year. 
 
A special thank to Kashmir Watan food store staff and owner Haji Barkat Mohammad, 
Mohammed Salim and Mohammad Mudasar for treating me as one of their family 
members and for being extremely supportive and encouraging towards my studies. 
 
Finally, I must thank my mother Jaymala Jaiswal and father Rammurat Jaiswal and my 
sister Shristi Jaiswal for their love and support. I am forever indebted to my parents for 
their blessing, trust, care, encouragement and advice for my entire life. 
xx  
List of Abbreviation 
 
 
























































Hexose Monophosphate Pathway 
xxi  
 


















































NADPH Nicotinamide Adenine dinucleotide 
phosphate 
  












































































TC Phase Transition Temperature 
 
 
TEM Transmission Electron Microscopy 
 
 
WF Whole Fruit 
 
 
















































































































Cancer is the Latin word of crab and is an abnormal growth of cells which tend to 
proliferate in an uncontrolled manner and, in some cases, metastasize (i.e. spread to 
other organs) (Bertram, 2000). Cancer may also be referred to as malignancy or a 
malignant tumour or described as a neoplasm (i.e, a new growth). It is not only one 
disease, but also a group of more than 100 different and distinctive diseases. Cancers 
can involve any tissue of the body and have many different forms in each body area 
(Bertram, 2000). Most cancers are named after for the type of cell or organ from 
which they start. For example, a cancer in the breast is called breast cancer. If a 
cancer spreads (metastasizes), the new tumour bears the same name as the original 
(primary) tumour. Normal cells stop dividing at a certain point of time and cancerous 
cells continue to divide, as illustrated in Figure 1.1. These cancerous cells keep on 






Figure 1.1: Diagrams showing above iilustrate how a normal cell can become 




There are three phases are involved in the growth of cancer cells: 
 
Phase 1 – Initiation 
 
This is when either a free radical or a carcinogen changes the genetic makeup of a 
cell, the cell divides more often than it normally does (Troll and Wiesner, 1993; Pitot 
et al. 2004). 
Phase 2 – Promotion 
 
In this phase, the damaged cell multiplies uncontrollably and this phase precedes the 
final progression phase (Yamagiwa and Ichikawa, 1918; Troll and Wiesner, 1993). 
 
Phase 3 – Progression 
 
In this progression phase, cancer grows and invades the surrounding tissues, forming 
new blood vessels. It does so by releasing compounds that go against the natural 
defence of the body and penetrate into the surrounding tissues. Cancer cells also 
build a blood supply network via angiogenesis and invade the surrounding tissues. 
The growth of solid tumour cannot continue without sufficient blood supply, and the 
diameter of the tumour may range between 1-2 cm. Certain natural compounds have 
been shown to retard the spread of cancer cells in any combination of the above three 
phases (Pitot et al. 2004). 
Table 1.1 summarises the difference between normal cells and cancer cells. These 
differences are extremely important because they comprise the basis for designing 




Table 1.1: Comparison between cancer cells and normal cells (Adapted from: 
Yamazaki et al. 1995). 
 
 Cancer cells Normal Cells 
1. Cancer  cells  have  prolonged  life 
 
span by having uncontrolled 
manners of multiplication. 
Normal cells multiply and divides normally. 
2. Cancer  cells  fail  to  perform  the 
 
functions of the relevant organ. 
The   functions   of   the   organ   are   carried   out 
 
successfully. 
3. Cancer  cells  favour  sugar  as  the 
 
main source of energy. 
Normal  cells  multiply  in  presence  of  sufficient 
 
oxygen supply. 
4. Cancer  cells  have  more  insulin 
 
receptors compared to normal 
cells. 
Normal  cells  have  less  insulin  receptors  when 
 
compared to cancer cells. 
5. Cancer  cells  cannot  tolerate  high 
 
temperatures  (i.e.  they  are  more 
heat-sensitive). 
Normal cells have some tolerance with respect to 
 
high temperatures. 
6. Cancer   cells   form   tumour   or 
 
swelling due to abnormal growth 
and spread to the other organs 
through the lymphatic system. 







A glioma is a tumour that grows from glial cells, which are the supportive cells in the 
brain (McPherson, 2013) Astrocytes and oligodendrocytes are the two main types of 
supportive cells in the brain (Figure 1.2). Glioma is the most common type of brain 
tumour and it is typically categorized as primary or secondary. Primary tumours start 
in the brain, whereas secondary tumours spread to the brain from another site such as 
the breast or the lung. A glioma is graded from I to IV based on their nature and 
growth rate. Grade I glioma is often considered a benign tumour, while grades II, III 
and IV are tumours with an increasing likelihood to grow and spread quickly and 




1.2.1    Grading of gliomas 
 
 
The World Health Organization (WHO) defines gliomas according to cell type, 
location and grade, and categorizes them into four classes (Lassman, 2004). These 
are: Grade I tumours (pilocytic astrocytomas), Grade II tumours (low-grade 
astrocytomas), Grade III tumours (anaplastic astrocytomas) and Grade IV tumours, 
which are also known as glioblastoma multiforme (GBM). Grade I tumours do not 
invade  the  surrounding  brain  tissue  and  are  often  curable  with  surgery,  while 
tumours of grades II, III and IV are diffusive and can invade normal brain tissues. 
Grade III and IV tumours are the most aggressive and are referred to as ―high-grade‖ 
or  ―malignant‖  brain  tumours  (Lassman,  2004).  The  incidence  of  glioma  has 
increased since the late 1970s. Despite remarkable advances in surgical techniques 
and treatment options, including chemotherapy and radiotherapy, the prognosis of 
glioma is still very poor (Surawicz et al. 1998). 
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1.2.2    Classification of glioma 
 
 
Gliomas are enormously heterogeneous varying from benign to malignant. Kernohan 
and Sayre introduced a new set and further classified glioma into astrocytomas, 
oligodendromas and glio-blastomas (Collins, 2004). 
I. Astrocytoma 
 
Astrocytomas (Figure 1.2) originate from astrocytes or supporting cells of the brain. 
Astrocytomas are divided into two groups; differentiated neoplasms which are lethal 
and undifferentiated neoplasms which are benign. Well differentiated neoplasms 
occur more in adults than in children. Astrocytic gliomas are graded pathologically 
depending on the most malignant stage recognized (Doolittle, 2004). Astrocytic 
gliomas are divided based on the malignancy into astrocytoma, anaplastic 
astrocytoma, and gliobastoma multiforme. The most common glial tumours are 
anaplastic   astrocytoma   and   glioblastoma   (Doolittle,   2004).   WHO   considers 
astrocytic glioma with nuclear atypia as grade II. Astrocytic tumours that exhibit 
mitotic activity are considered as grade III and tumours that demonstrate atypia, 
mitosis, endothelial cell proliferation and necrosis are categorized under grade IV 
(Hiros, et al. 1995). 
II. Oligodendroglioma 
 
The other common type of glial cells that give rise to tumour is oligodendroglioma 
(Figure 1.2), which is the primary myelinating cell of the central nervous system. 
Low  grade  oligodendroglioma  are  seen  in  children.  WHO  graded 
oligodendrogliomas as grade II or grade III tumours (American Brain Tumour 
Association, 2001). Grade II tumours are well-differentiated, which are irregular 
against normal cells. Grade III tumours are also known as anaplastic tumours as they 
are clear abnormal cells in which pleomorphism, hyperchromatism, hypercellularity, 
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and mitosis are increased (McDonald et al. 2005). Grade III tumours consist of 
numerous blood vessels and rapidly proliferative cells (Miller et al. 2006). Few 
anaplastic oligoastrocytomas consist of glioblastomas that are grade IV destructive 
cells (Reifenberger et al. 1995). 
III. Glioblastoma 
 
Glioblastoma multiforme (Figure 1.2) is the most common malignant brain tumour in 
adults and is uncommon in children. Glioblastoma multiforme is also the most 
malignant and common of all primary brain tumours. Glioblastomas are rapidly 
growing and destructive tumours. Often glioblastoma involves a large portion of the 
cerebral hemisphere. It invades the meninges and by spreading directly across the 
midline it causes a marked distortion of the ventricular system. Glioblastoma 
simulates commonly differentiated astrocytoma, piloid astrocytoma, gemistocystic 
astrocytoma, polar spongioblastoma, oligodendroglioma and medulloblastoma. 
Several tumours are diagnosed as astrocytoma subsequently reveal the appearances 





Figure 1.2: Diagram showing the origination of glioma from the brain. (a) 
Supportive cells- Oligodendroglioma and Astrocytoma in the cerebrum region 




1.2.3    Statistics of Brain tumour 
 
 
The overall incidence rate of brain tumour is around 19 new cases per 100,000 
people every year. The incidence rates are higher in females, and whites, and 
increases with age (CBTRUS, 2011). According to USA statistical report on brain 
tumour, in 2004 more than 612,000 persons were diagnosed with primary brain and 
central nervous system tumours. Also, more than 124,000 persons were suffering 
from malignant tumour and more than 488,000 persons were suffering from non- 




1.2.4    Statistics for tumour-specific glioma (CBTRUS, 2011). 
 
 
1.   Glioma is a term used for all tumours arising from gluey or supportive tissue 
of the brain, representing 31% of all brain tumours and 80% of all malignant 
brain tumours. 
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2.   Glioblasatoma  represents  17%  of  all  primary  tumours,  and  54  %  of  all 
gliomas. 
3.   Astrocytoma represents 7% of all primary brain tumours. 
 
4.   Astrocytoma and glioblastoma combined represents 61% of all glioma. 
 
5.   Oligodendroglioma represents 2% of all primary brain tumours. 
 
The majority of the primary tumours are located within the frontal, temporal, parietal 




1.2.5 Treatment of glioma 
 
 
The treatment of malignant gliomas is performed via surgery, chemotherapy and 
radiotherapy (Lonardi et al. 2005). Depending on the site of lesion and condition of the 
patient, surgery can include gross total excision of the tumour using image guidance or 
may be restricted to biopsy. The treatment remains challenging and recent advances 
have improved both the quality of life and survival (Liu et al. 2008). The main goal of 
surgery is to resect the tumour completely. However, the infiltrating nature of gliomas 
and their imprecise margins make this goal very difficult (Wen and kesari, 2008). 
Surgery usually has positive outcome in patients with low-grade and malignant gliomas 
(Smith et al. 2008). 
 
A study form Eastern co-operative oncology group and radiation therapy group showed 
a positive correlation between survival and extent of resection. A retrospective review 
on three consecutive trials revealed a longer median survival for maximal resection of 
11.3 months as compared to biopsy alone that led to survival for 6.6 months (Chang et 
al. 1983). Many recent technical advances in neuro-imaging like MRI (Magnetic 
Resonance Imaging), MR (Magnetic Resonance) spectroscopy and surgical technology 
like image guided surgery, intra-operative ultrasound and CT surgical techniques have 
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helped to increase the survival time of the glioma patients (Keles and Berger, 2004; 




1.2.5.1   Radiotherapy 
 
 
Radiation therapy, also called radiotherapy, is a non-invasive technique. Also, it 
offers avoidance of adverse effects that are seen with chemotherapy. Radiotherapy is 
performed by applying radiation on glioma. The whole brain is treated with 






1.2.5.2   Chemotherapy to treat cancers 
 
 
Approximately 45% of brain tumour patients benefit when treated with nitrosourea 
drugs (Kornblith et al. 1978). Despite treatment with surgery and radiotherapy, the 
inevitable recurrence makes high-grade gliomas the most devastating neoplasm, with 
eventual death. A number of randomized clinical trials have been conducted to assess 
the role of chemotherapy in improvement of survival for glioma patients (Lonardi et 
al. 2005). Various chemotherapeutic agents have been administrated before, during 
or after radiotherapy (Stewart et al. 2001). A randomized study undertaken by the 
National Cancer Institute of Canada has established the concurrent temozolomide 
and radiation therapy (Stupp et al. 2005). The two major classes of chemotherapeutic 
drugs that are being used currently in the treatment of gliomas include alkylating 
agents and microtubule modulators. 
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1.2.5.3   Alkylating agents 
 
 
Alkylating agents were the first compounds identified for treatment of cancer 
(Espinosa et al. 2003). These compounds react directly with electron rich atoms in 
biological molecules to form covalent bonds. The chemotherapeutic and cytotoxic 
effects are directly related to the alkylation of DNA (Goeffrey et al. 2003). 
Temozolomide (TMZ) is an orally administrated alkylating agent and has excellent 
penetration across the blood brain barrier. TMZ is the current standard treatment for 
anaplastic astrocytomas and has also been tested in combination with other drugs in 
low-grade gliomas (Berger et al. 2007). Nitrosoureas are other commonly used drugs 
in the treatment of gliomas as they are highly lipid soluble, resulting in enhanced 
permeability  across  the  blood  brain  barrier  (Walker  et  al.  1978).  The  main 
nitrosureas employed in treatment of glioma are nimustine, carmustine and lomustine 
(Espinosa et al. 2003). However, changes in the uptake of the drug represent one 
form  of  resistance  that  may  develop  to  anti-neoplastic  therapy. Other  forms  of 
resistance include increases in glutathione production, which may serve as the site of 
drug action, reducing its effect on DNA, increasing efficiency in DNA repair, 
increasing metabolic degradation of the drug and failure to express the p53 gene 
(Jean-Pierre and Michael, 2010). 
 
 
1.3 Study of Tissue culture 
 
 
Tissue culture is the growth of separated tissues or cells in vitro in presence of nutrient 
medium typically facilitated via the use of liquid growth media (ref). The flask or plate 
containing the culture is incubated at 37°C in a sterile condition, in order to prevent 
contamination of the cultured cells (Carrel, 1912). 
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In general, there are two types of tissue culture sterile techniques (Freshney, 2000): 
 
 
a. Primary cell culture – The growth of tissue is derived from the living 
organisms (e.g. biopsy material). The culture consists of mixed population of 
cell types. Frequently, some of the cells may survive without proliferating and 
will therefore be lost in the increasing population of those which are able to 
multiply in the conditions provided in vitro (Maureen, 1997). 
b.  Established Cell lines- These cells are derived from a primary culture and 




1.3.1    Importance of growth media in tissue culture 
 
 
A liquid medium is required to support the growth of the cells in tissue culture. A 
minute sample of tissue is either spread on or added into the culture in biological 
medium (e.g. blood serum or tissue extract). Biological medium might have the 
appropriate nutrients, temperature and pH for the cells to be incubated. The media 
used for glioma cell culture are Dulbecco‘s Modified Eagle Medium (DMEM-500 ml) 
and Eagle‘s Minimal Essential Medium (EMEM-500 ml) (Obara, 1998). However, 
DMEM in comparison to EMEM contains four times higher vitamins, glucose and 
amino acids which are present in the original formula. Additionally, it contains iron 
and phenol red. DMEM is suitable for most types of cells, including human, monkey, 
hamster, rat, mouse, fish and chicken cell lines (Ham et al. 1979). 
14  




Stepwise progression from low to intermediate to high-grade glioma is denoted by 
number of DNA alterations. 
 
1.   Low-grade of astrocytoma- Mutation of the P53 and loss of heterozygosity 
on the large arm of chromosome 22. 
Grade I: Juvenile pilocytic astrocytoma 
 
 
-Low mitotic activity; little nuclear atypia. 
 
 
Grade II: Astrocytoma Variant 
 
 
- Fibrillary, protoplasmic and gemistocytic 
 









Figure   1.3:   Photograph   showing   grade   II   astrocytoma:   a)   fibrillary,   b) 
gemitocytic and   c) protoplasmic.  (Source: Brat et al. 2003). 
 
2.   Intermediate grade of astrocytoma – Appears to be associated with loss or 
inactivation of p16 tumour suppressor gene on chromosome 9 and loss of 
heterozygosity on the long arm of chromosome 9. 
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Grade III: Anaplastic oligodendroglioma 
 
 







Figure 1.4: A photograph showing grade III Oligodendroglioma: Cells of an 
anaplastic oligodendroglioma demonstrate the classic ‘fried egg’ appearance: 
round nuclei with clear, peri- nuclear halos (Adapted from – Brat et al. 2003) 
 
3.   High grade of astrocytoma- Partial or complete loss of chromosome 10. 
 
Most of the high grade astrocytoma also show amplification of the c-erbB1 
oncogene which encodes the epidermal growth factor 
Grade IV: Glioblastoma astrocytoma 
 
 - gaint cell glioblastoma 
 - gliosarcoma 
 - High mitotic activity; high degree of infiltration; cellular and nuclear atypia; 
 




Figure 1.5: A photograph showing grade IV Glioblastoma multiforme: 
Pseudopalisades in glioblastoma are small (a, <100 mm) and medium (b, 200– 
400 mm). Note the central necrosis in the larger pseudopalisade (b) (Adapted 
from Brat et al. 2003). 
 
 




MTS assay is the most popular colorimetric assay in which the compound 3-(4, 5- 
dimethyl thiazol-2yl)-5, (3- carboxymethoxyphenyl)-2 (4 sulfophenyl)-2H 
(tetrazolium) is converted to a coloured insoluble formazan product by mitochondrial 
enzymes (Berridge and Tan, 1993). The end product is solubilised in either alcohol 
or detergent and the absorption is measured at 490 nm (Nikkhah et al. 1992; 
Lewandowicz et al. 2000). The amount of colour produced is directly proportional to 
the number of living cells. MTS assay has been used in several investigations for the 
measurement  of  chemo-sensitivity  testing  in  malignant  gliomas  (Nikkhah  et  al. 
1992). The enzymatic reactions (Figure 1.6) are based on either the oxidase or 
dehydrogenase reactions, which are determined either calorimetrically or 
fluorimetrically using different reagents including oxidative chromogenic dyes or 
reductive chromogenic dyes. Tetrazolium salts are one of the reductive chromogenic 




Figure 1.6: Diagram showing the structure of tetrazolium salt and electron 




1.5 Capase and cytochrome c assay used to identify pathways of cell death. 
 
 
Cell  death  is  typically  discussed  dichotomously  as  either  apoptosis  or  necrosis 
(Majno and Joris, 1995). Apoptosis is described as an active programmed cell death 
regulated in a controlled manner. Apoptosis plays an active role in their own cell 
death,  which  is  known  as  suicidal  cells.  This  mechanism  of  cell  death  makes 
apoptosis distinct from other necrosis, which is another mechanism of cell death. 
Necrosis has been characterised as passive, accidental cell death resulting from 
environmental perturbation with uncontrolled release of inflammatory cellular 
contents (Kerr et al. 1972). Apoptosis is on energy dependent process, while necrosis 
is energy independent process (Rastogi et al. 2009). 
 
Figure 1.7 represents the morphological features of cellular death via apoptotic and 
necrotic pathways. Figure 1.7A shows necrosis and in this process, the cells swell 
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and become leaky and finally disrupt and release their contents into the surrounding 
tissue, resulting in inflammation. 
 
Apoptosis is the process where the cells undergo cellular shrinking, chromatin 
condensation and margination at the nuclear periphery (Van Cruchten, 2002). Cells 
eventually form membrane-bound apoptotic bodies that contain organelles, cytosol 
and nuclear fragments. These apoptotic bodies are phagocytosed by the macrophages 
without  triggering  inflammatory  processes  (Van  Cruchten,  2002).  Figure  1.7  B 
shows apoptotic cells, which have distinctive morphology during the apoptotic 
process, where the cell begins to shrink following the cleavage of lamin and actin 
filaments in the cytoskeleton (Figure 1.7 A). The breakdown of chromatin in the 
nucleus often leads to nuclear condensation and in many cases the nuclei of apoptotic 
cells take on a ―horse-shoe‖ like appearance (Figure 1.7 B). Cells continue to shrink 
(Figure 1.7 C), packaging themselves into a form that allows for their removal by 
macrophages. These phagocytic cells are responsible for clearing the apoptotic cells 
from tissues in a clean and tidy fashion that avoids many of the problems associated 





Figure 1.7: Diagrams showing the morphological representation of cell death of 
viable cells via A) Necrosis or Apoptosis B) Apoptosis is characterized by a 
variety of cellular changes including loss of membrane phospholipid symmetry, 





1.5.1    Mechanism of apoptosis 
 
 
The apoptotic processes are highly complex and sophisticated. Figure 1.8 shows that 
specific  signals  are  given  to  the  cells  to  undergo  apoptosis  and  a  number  of 
distinctive  changes  occur  in  the  cells.  The  pathways  involved  in  apoptosis 
mechanism are : 
Energy Dependent pathway: i) Intrinsic Pathway ii) Extrinsic Intrinsic Pathway and 
iii) perforin/granzyme pathway all of which are activated by granzyme A via single 
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stranded DNA damage (Martinvalet et al. 2005). The Energy Independent pathway is 
perforin/granzyme pathway, which is activated by granzyme B. 
Either extrinsic or death receptor pathway involves death ligands interaction with 
death  receptors  and  inducing  apoptosis.  An  Intrinsic  or  mitochondrial  pathway 
involves   activation   of   mitochondria   macrophages   to   activate   apoptosis   and 
perforin/granzyme  pathway.  In  turn,  the  perforin/granzyme  pathway  activates, 
cytotoxic T-cells to bind to perforin receptor which gives rise to either granzyme A 
(energy dependent) or granzyme B (energy independent) (Figure 5-2). The caspase 
family initiators (caspase-2, -8, -9, -10), effectors or executioners (caspase-3, -6,-7) 
and inflammatory caspases (caspase-1,-4,-5) (Cohen, 1997; Rai et al. 2005) which 
are responsible for regulating the extrinsic, intrinsic and perforin/granzyme pathway 
mediated by granzyme A. The entire three energy dependent pathways converge to 
enexecutive pathway for apoptosis via indication of by caspase- 3 enzymes. This 
enzyme breaks down or cleaves key cellular components that are required for normal 
cellular  function  including  structural  proteins  in  the  cytoskeleton  and  nuclear 
proteins such as DNA repair enzymes. The caspases can also activate other enzymes 
such as DNases, which cleaves the DNA in the nucleus, cross –linkage of protein 
formation of apoptotic bodies, expression of ligands for phagocytic receptors and 
finally uptake of phagocytic cells (Vermes et al. 1995; Darzynkiewicz et al. 1992). 
Figure 1.8 represents apoptosis pathway via extrinsic, intrinsic and 
perforin/granzyme pathway. The entire pathway requires specific triggering signals 
to begin an energy-dependent cascade of molecular events. Each pathway activates 
its own initiator caspase (8, 9, 10), which in turn activates the executioner caspase-3. 
However,  granzyme  A  works  in  a  caspase-independent  fashion.  The  execution 
pathway results in characteristic cytomorphological features including cell shrinkage, 
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chromatin condensation, formation of cytoplasmic blebs and apoptotic bodies and 
finally,  phagocytosis  of  the  apoptotic  bodies  by  adjacent  parenchymal  cells, 






Figure 1.8: Schematic representations (A-C) of apoptotic events due to the 
regulation of: intrinsic, extrinsic and perforin/granzyme pathway. (Adapted 
from- Vermes et al. 1995; Darzynkiewicz et al. 1992). 
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1.5.2    Caspase activity 
 
 
There are a number of caspases in mammalian cells that have been shown to be 
involved in the early stages of apoptosis, e.g. Caspase 2, Caspase 3, Caspase 6, 
caspase 7, caspase 8, caspase 9 and caspase 10. The functions of these enzymes are 
not yet entirely clear, but it appears that after an initial signal to the cell to undergo 
apoptosis, they may be responsible for the activation, amplification and execution of 
the apoptotic cascade such as intrinsic, extrinsic and perforin/granzyme pathway 
activated by granzyme A (Figure 1.8). Apoptosis probably always involves caspase-3 
activated either by caspase-8 or by caspase-9. The upstream mechanisms therefore 
activate either caspase-8 or -9. Caspase-8 is typically activated by death receptors 
(Fas,  TRAIL-receptors,  TNFR).  It  appears that  mitochondrial  apoptosis  is  much 
more common than caspase-8-dependent apoptosis in vivo. Mitochondrial apoptosis 
is regulated through the Bcl-2-family of proteins: within this family, the BH3-only 
proteins (‗triggers‘) often regulate the activation of the effectors Bax and Bak; active 
Bax and Bak cause the release of cytochrome c from the mitochondrial 
intermembrane space into the cytosol, where it binds to Apaf-1, inducing its 




1.5.3    Role of Bcl-2 proteins in the release of cytochrome c release 
 
 
The Bcl-2 proteins are a family of proteins responsible for apoptosis. Proteins Bcl-2 
and  Bcl-XL  are  anti-apoptotic,  while  the  proteins  Bad,  Bax  and  Bid  are  pro- 
apoptotic.  Excessive  concentrations  of  pro-apoptotic  proteins  in  the  cells  cause 
higher  susceptibility  to  apoptosis,  whereas,  excessive  concentrations  of  anti- 
apoptotic proteins may increase the resistance of cells against apoptosis. The pro- 
apoptotic Bcl-2 proteins are often found in the cytosol acting as sensors of cellular 
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damage or stress. Following cellular stress, they relocate to the surface of the 
mitochondria where the anti-apoptotic proteins are located. An excess of pro- 
apoptotic Bcl-2 proteins at the surface of the mitochondria is thought to be important 
for the formation of the pore on the mitochondrial membrane. This interaction 
between pro- and anti-apoptotic proteins disrupts the normal function of the anti- 
apoptotic Bcl-2 proteins leading to the formation of pores in the mitochondria and 
subsequently the release of cytochrome c and other pro-apoptotic molecules from the 
intermembrane  space.  Cytochrome  c  is  a  small  heme  protein  found  loosely 
associated with the inner membrane of the mitochondrion. The release of cytochrome 
c  from  the  mitochondria  is  a  particularly  important  event  in  the  induction  of 
apoptosis. Cytochrome c is a highly soluble protein, unlike other cytochromes, with a 
solubility of about 100 g/L and is an essential component of the electron transport 
chain. Cytochrome-c is capable of undergoing oxidation and reduction (Vidal et al. 
2002). Once cytochrome c has been released into the cytosol, it is able to interact 
with a protein called Apaf-1. These in turn leads to the formation of the apoptosome 
and the activation of the caspase 9 and the induction of apoptosis by activating 
caspase 3. There are different mechanisms via which chemotherapeutic drugs can 




1.5.4     Caspase Assays 
 
 
Caspases consist of a group of aspartic acid-specific cysteine proteases that are 
activated during apoptosis. These unique proteases, which are synthesized as 
zymogens, are involved in the initiation and execution of apoptosis once activated by 
proteolytic cleavage (Nicholson et al. 1995). The activity of caspase- 3 in the cells 
and  the  tissue  of  the  body  is  either  a  marker  or  indication  for  the  cell  death 
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mechanism (Porter et al 1999). Caspase- 3 is a crucial component and central event 
in many cellular apoptosis (Thornyberry et al. 1998; Wolf et al. 1999). Caspase- 9 is 
also known as ICE, Lap6, Mch6 and is an upstream proenzyme in the cascade of 
enzymatic reactions required for cellular apoptosis (Duan et al 1996). Caspase- 9 is a 
key  regulator  of  apoptosis  associated  with  apoptotic  and  anti-apoptotic  proteins 
(Thornberry  et  al  1997;  Petty  et  al.  1995).  The  Caspase-Glo®   9  assay  is  a 
 
homogenous luminescent assay that measures caspase-9 activity. Addition of a single 
Caspase-Glo®-9 reagent in and ‗add-mix measure‘ format resulting in cell lysis. 
Caspase cleavage of the substrate and the generation of a glow type luminescent 
signal produced by the luciferase reaction are obtained from cell lysis. The signal 
generated is proportional to the amount of caspase activity present. Numerous 
commercial kits and reagents are available to assess apoptosis based on caspase 
function. 
 
The Caspase-Glo® Assays use the luminogenic caspase-9 tetrapeptide substrate (Z- 
LEHD-aminoluciferin) and caspase-3/7 substrate (Z-DEVD-aminoluciferin). The 
buffers are optimized for the specific caspase activity, cell lysis and luciferase 
activity. In the absence of active caspase, the caspase substrates do not act as 
substrates for luciferase and thus will produce no light. Upon cleavage of the 
substrates by the respective caspase, aminoluciferin is liberated and can contribute to 
the generation of light in a luminescence reaction (Figure 1.9). The resulting 
luminescent signal is directly proportional to the amount of caspase activity present 






Figure 1.9: Diagram showing caspase -3/7 and caspase -9, cleavage of the 
proluminogenic  substrates  containing  LEHD  and  DEVD. Following  caspase 
cleavage, a substrate for luciferase (aminoluciferin) is released, resulting in the 






1.5.5    Mitochondrial Assays 
 
 
Mitochondrial assays and cytochrome c release allow the detection of changes in the 
early phase of the intrinsic pathway. Cytochrome c is an intermediate compound in 
apoptosis, which is a controlled form of cell death in the process of development or 
in  response  to  infection  or  the  induction  of  DNA  damage  of  any  apoptotic 
programme in cell free extracts (Chandra et al. 2002; Johnstone et al. 2002). 
Cytochrome c is a small heme protein found loosely associated with the inner 
membrane of the mitochondrion. Cytochrome-c is capable of undergoing oxidation 
and reduction (Vidal et al. 2002). Eukaryotic NADPH-Cytochrome c reductase is a 
flavoprotein localized at the endoplasmic reticulum. It is responsible for transferring 
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electrons from NADPH to several oxygenases, the most important of which is the 
cytochrome P450 family of enzymes which are responsible for metabolism of 
xenobiotics (Shen et al. 1993; Plonne et al. 1999). NADPH-cytochrome c reductase 
is widely used as an endoplasmic reticulum marker-3 (Vidal et al. 2002; Hochgraf et 
al. 1997). The proapoptopic stimulus is responsible for the release of cytochrome-c 
and in turn it enhances the activity of caspase-9. Cytochrome-c assay kit is designed 
to measure the NADPH cytochrome-c reductase activity in cell and in purified 
microsomes of the endoplasmic reticulum. The cytochrome-c measurement is based 
on colorimetric assay that monitors the reduction of cytochrome-c by NADPH- 
cytochrome-c reductase in the presence of NADPH, resulting in formation of distinct 
bands in the absorption spectrum, and the increase in absorbance at 550 nm is 
measured with time (Vermillion et al. 1974). 
 
 
1.6 Plant extracts used as traditional medicine for treatment of cancer 
 
 
About 80% of the world population depend on plants for a lot of their basic health care 
 
needs (Sabir and Ahmad, 2007). Fossil records prove that even 60,000 years ago in 
Palaeolithic age plants were also used as medicines (Solecki et al. 1975), clearly 
demonstrating the historic role of nature in provision of medicines that can treat 
various diseases. 
 
The use of natural medicinal agents is recognised by the WHO. Out of 250,000- 
500,000 plant species on the earth, only 1-10% has been studied chemically and 
pharmacologically for their potential medicinal value (Verpoorte, 2000). It has been 
estimated that about 50% of the prescribed medicinal products in Europe and USA are 
 
derived from natural materials (Newman et al. 2003). One approach to control cancer 
could be its prevention by diet, which inhibits one or more neoplastic events and 
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reduces cancer risk (Nerurkar, 2010). Dietary compounds offer a great potential in the 
fight against cancer by inhibiting the carcinogenesis process through the regulation of 
cell homeostasis and cell-death machineries (Nerurkar and Ray, 2010; Talib and 
Mahasneh, 2010). 
 
There are various approaches to using medicinal plant constituents. One approach is to 
isolate bioactive compounds for direct use as drugs (e.g. digoxin, digitoxin, morphine, 
reserpine,  paclitaxel,  vinblastine,  vincristine,  etc).  Alternatively,  semisynthesis  of 
novel anticancer compounds from herbal constituents can be conducted. This aims to 
enhance the anticancer activity and/or lower the toxicity of the extracted compounds. 
Examples of semisynthetic anticancer drugs include met-formin, nabilone, oxycodon, 
taxotere, teniposide, verapamil, and amiodarone. Also, the whole plant or one part of it 
might be used as herbal remedy (Daniel and Norman, 2001). One might expect any 
bioactive compounds obtained from plants to have low human toxicity, but there are 
plants that are toxic to the given endemic culture that has no reported documents 
(Daniel    and    Norman,    2001).    Plants    like    Momordica    charantia,    Zingiber 
offifinale Rosc, Teucrium polium, Phagnalon rupstre, and Inula viscosa are prescribed 
to alleviate diseases including tumour, ulcers, diabetes, renal abnormalities, 
inflammations, rheumatism, and muscle spasms (Talib and Mahasneh, 2010; Sahu et 
al. 2011). Paclitaxel and camptothecin are plant-derived drugs that have improved the 
treatment  of  cancers  (Newman  et  al.  2003).  Numerous  groups  with  antitumor 
properties are plant-derived products such as alkaloids, phenylpropanoids, and 
terpenoids (Kintzios 2006; Park et al. 2008). 
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1.6.1 Momordica charantia 
 
The vegetable Momordica charantia L., (family: Cucurbitaceae) is a scientific name 
of the plant and its fruit. It is also known by other names, for instance in the USA it is 
known as Bitter gourd or balsam pear while its referred to as the African cucumber in 
many African countries. It is also called fukwa in China, kerala in India, nigai uri in 
 
Japan and ampalaya in Philippines (Behera et al. 2010). Momordica charantia is a 
flowering vine in the family of Cucurbitaceae, similar to the cucumber. The 
herbaceous, tendril-bearing vine grows to 5 m. It is a tropical plant vegetable and also 
commonly used in Indian cuisines and food shops. It has been extensively used as folk 
medicine for treatment  of diabetes. The Latin name  Momordica means, ―to  bite‖ 
which refers to the jagged edges of the leaf that appear as if they have been bitten. In 
Ayurveda, the fruit is considered as tonic, emetic, stomachic, stimulant, antibilous and 
laxative. Momordica charantia has been used as Asian traditional medicine for long 
time. Its helps in enhancing the digestion like most of the bitter-tasting food. It also 
helps in dyspepsia, constipation, heartburn and ulcers. Momordica charantia is also a 
mild inflammation modulator, and dermeculent,  and it rarely has negative  effects 




1.6.2 Horticulture of Momordica charantia 
 
 
Momordica charantia is adaptable to various climates (Lim, 1998). It can grow in both 
tropical and subtropical regions (Reyes et al. 1994). In India it is cultivated up to an 
altitude  of  1500  meters.  In  the  sub-tropical  regions,  cultivation  of  Momordica 
charantia can be carried out during rainy, spring and summer seasons (Lim, 1998). 
Temperature suitable for the growth of Momordica charantia is between 25 and 30°C 
whereas very cold climate may kill the plant or retard its growth (Larkcom, 1991; 
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Desai and Musmade, 1998). Furthermore, Momordica charantia grows well in a wide 
range of soil types including peat, light clay and sandy but grows best in a well- 
drained sandy loam soil that is rich in organic matters. It grows well in soils of shallow 
to medium depth (50-150 cm), and like most cucurbits, bitter gourd prefers well- 
drained soils. For bitter gourd, the optimum soil pH is 6.0-6.7, and may tolerate 
alkaline soils up to pH 8.0 (Behera et al. 2010). In India it is cultivated during the 
season of April to July by using 2-3 seeds in a pit. The pits are prepared at a distance 
of 0.5 meter and provided with manure. Only one plant is retained and seedlings are 
watered once or twice per week. The plant begins to flower 30-35 days after sowing 
and fruits are ready to harvest after 15-20 days of flowering. This plant is widely 




1.6.3 Origin and geographical distribution of Momordica charantia 
 
 
Momordica charantia is cultivated in tropical Asia on hundreds to thousands of 
hectares. This plant was domesticated in India and southern part of China. It is found 
naturalized in almost all tropical and subtropical regions. It is an important market 
vegetable in southern and eastern Asia. Local cultivars originally from Asia are 
cultivated on a small scale in tropical America, and the southern part of United States 
(Marr et al. 2004). 
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1.6.4    Description of Momordica charantia fruit and seeds. 
 
 
Seeds are flat and oval. Seeds and pith appears white in unripe fruits and ripens to 
red in mature ripen fruits (Sathish et al.  2010; www.rain.org, 1990). 
 
Fruits  (Figure  1.10)  are  5.0-35.0  cm  long,  ovoid,  ellipsoid,  or  spindle  shaped, 
usually ridged or warty, dehiscent irregularly as a 3 valved fleshy capsule or 
indehiscent. The fruit has a distinct warty looking exterior and an oblong shape. It is 
hollow in cross-section, with a relatively thin layer of flesh surrounding a central 
seed cavity filled with large flat seeds and pith. The surface of the flesh is crunchy 
and watery in texture, similar to cucumber. The green skin is tender and edible. 
However, the fully ripened fruit turns orange and mushy and becomes poisonous, 
very bitter and non-edible (Sathish et al.  2010). Figure 1.10 shows Momordica 
charantia of various shapes and size from different location- (A) Fruit diversity (Dey 
et al. 2006). (B) Large fusiform fruits, pointed at both ends, numerous triangular 
tubercles, giving the appearance of a crocodile's back classified as Momordica 
charantia var. Charantia (Chakravarty 1990). (C) Chinese long fruit type, 30-60 cm, 
smooth ridges, light green in colour, and slightly bitter (Yang and Walters 1992). (D) 
Small  fruits  (Momordica  charantia  muricata;  var.  Chakravarty  1990)  high  in 
 
proteins, carbohydrates, iron, calcium, (Desai and Musmade, 1998) and Vitamin C 
(Behera et al. 2008). (E) Triangular fruit type, cone-shaped, 9-12 cm long, light to 





Figure 1.10: Momordica charantia comes in a variety of shapes and sizes: A) 
Fruit diversity (B) Large fusiform fruits (C) Chinese long fruit type (D) Small 
fruits (E) Triangular fruits. (Adapted from- 
http://ddr.nal.usda.gov/bitstream/10113/42264/1/IND44357776.pdf). 
 
The three different species of Momordica charantia are explained, depending on the 
phonetype, climatic condition and soil type as stated below: 
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1.6.4.1 Chinese breed (Yunnan, China) 
 
 
Phenotype-  Chinese  phenotype  is  20–30 cm  long,  oblong  with  bluntly  tapering 
 
round ends. It has uneven pebble like longitudinally arranged smooth ridges. It is 
light green in colour. Momordica charantia of Chinese phenotype is slight bitter 
(Yang and Walters, 1992) . 
Climatic conditions- Yunnan has a humid monsoon climate typical of subtropical 
 
and tropical plateau zone, with distinctive dry and rainy seasons and drastic changes 
in climatic conditions. However the average temperature of the Yunnan is between 4 
and 24 °C (Adapted from- http://www.chinatoday.com/city/yunnan.htm). 
Soil  type-  Yunnanis  covered  by  red  soil.  Red  soils  lack  nitrogenous  material, 
 
phosphoric  acid  and  organic  matter  and  are  rich  in  iron.  It  is  formed  by  the 
breakdown of the igneous rocks and metamorphic rocks. The pH of the red soil is 




1.6.4.2   Indian breed (Maharashtra, India) 
 
 
Phenotype-  Indian phenotype is 6–10 cm in length with a narrower shape and 
 
pointed ends. The surface of the plant is covered with jagged, triangular "teeth" and 
ridges and the colour is whitish green. Momordica charantia of Indian breed is 
strongly bitter in taste (Chakravarty, 1990). 
Climatic  conditions-  The  climate  of  Maharashtra  is  semi-dry.  The  temperature 
 
ranges from 10°C to 47°C. Rainfall starts in the first week of June. July is the wettest 
month in Maharashtra and August is also rainy. Monsoon starts its retreat with the 
beginning of September (Subramaniam and Roa, 1987). 
Soil condition- Extensive deposits of black soil are found in the Deccan Plateau of 
 
Maharashtra. The pH of the soil is 6 - 8.5. The soil is black, thick and relatively 
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impermeable. The fruits of Momordica Charantia swell and become sticky when 
they are wet and they shrink when they are dried during the dry season when the soil 
develop wide cracks. The soil becomes rich in iron, magnesia and alumina and also 
contains potash and lacks phosphorus and nitrogen. Colour of the soil ranges from 




1.6.4.3   African breeds (Kenya, Africa) 
 
 
Phenotype- Fruit is ovoid or oblong-cylindric, 10 cm to 20 cm long, coarsely ridged 
 
and tapered at the end and covered with bumpy and blunt skin. It is dark-green in 
colour. Momordica charantia From Africa is moderately bitter (Chakravarty, 1990). 
Climatic condition- Nairobi the capital city of Kenya has tropical climate that is hot 
 
and humid. There is plenty of sunshine throughout the year, which is appropriate for 
growing Momordica charantia. The temperature ranges from 13°C to 32°C and the 
long rain season occurs from April to June and a short rain season occurs from 
October to December. The hottest period of the year is during February and March 
and coldest is during July and August (UNON, 2012). 
Soil condition of Kenya- Nairobi, Kenya has dry land condition. The soil is saline 
 
and sodic (Rich in sodium). It is also rich in calcium and magnesium. The pH of the 
soil ranges from 5.1-7.6. Nitrates may be present in appreciable quantities only rarely 
(Awiti et al. 2007). 
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1.6.5    Traditional uses of Momordica charantia 
 
 
In the United States, bitter melon is grown for its immature fruits, which are used in 
Asian cooking. In other countries, the young leaves are harvested and used as a 
potherb (Susan, 1998). The fruit and leaves have a bitter taste because they contain 
the alkaloid momordicine. Alkaloid content can be reduced by parboiling or soaking 
the  fruit  and  leaves  in  saltwater.  The  fruit  is  considered  as  tonic,  stomachic, 
stimulant, emetic and laxative. The fruit may be useful in gout, rheumatoid and sub 
acute cases of spleen and liver diseases (Trivedi et al. 2011). Momordica charantia 
fruit is also, useful for detoxification process (Trivedi et al. 2011). Fruit also has 
hypoglycaemic  (anti  diabetic)  properties  as  demonstrated  in  animal  and  human 
studies (Agarwal and Beohar, 2010). 
The fruit juice and the tea made from the leaf are being used for diabetes, malaria, 
colic, wounds and sores. It is also being used for measles, hepatitis and fevers. Fruit 
pulp, leaf juice and seeds are antithelimintic, while leaves act as galactogogue and 
root may be used as astringent. 
 
 
1.7 Phytochemistry of Momordica charantia 
 
 
Momordica  charantia   fruits   consist   of   a  number  of  coumpounds   including 
glycosides, saponins, alkaloids, reducing sugars, resins, phenolic constituents, fixed 
oil and free acids (Miniraj et al. 1993; Desai and Musmade, 1998). The leaves of this 
plant are nutritious sources of calcium, magnesium, potassium, phosphorus and iron. 
The edible fruit are great sources of the B vitamins (Sathish et al.  2010). Tables 1.2 
and Table 1.3 show the main phytochemical constituents of the plant. The leaf and 
fruit are the good source of carbohydrate and protein, which serves as medicinal 
properties  against  some  diseases,  and  also  a  good  source  of  energy  for  body 
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metabolic activities. Other coumpounds such as α and β momorcharins and MAP30 
(Momordica Anti-HIV Protein) isolated from seeds of Momordica charantia have 
been reported to exhibit antitumor and ribosome inactivating properties (Bakare et al. 
2010). Charantin is the cucurbitane, which generally tastes bitter and has been found 
to be toxic to cancer cells. Charantin consists of stigmasterol functional group 
attached to glucose as shown in the Figure 1.5. Charantin is a mixture of two 
glucosides such as sitosteryl glucoside (Figure 1.5 G) and stigmasteryl glucoside 
(Figure 1.5 H). Charantin has potential activity against diabetes as well as toxic 
effects against tumour cells (Paul, 2010). 




Table 1.2: Nutrient composition per 100 gram of Momordica charantia whole 




 Nutrients Proximate Quantity (mg /100g) 
 




































β Carotene 0.126 
 
 




Table 1.3 summarises the active phytochemical present in the Momordica charantia 
 
whole fruit useful for the treatment of cancer and other diseases. 
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Table 1.3: Major phytochemicals in bitter gourd (Momordica charantia) fruit, 




Phytochemicals Plant parts Applications References 
β  - momorcharin Seeds Glycoproteins that 
acts as midterm 
abortifacient 
Leung et al. (1987) 





Dutta et al. (1981) 
Phenols Seeds Antioxidants       that 
reduce 
 
blood pressure and 




Horax et al. (2005) 
Momordicosides 
 







Okabe et al. (1980) 











Phytochemical Plant part Application Reference 
Polypeptide-p Seeds and fruits Hypoglycemic 
peptide 
 




Carotenoids Seeds and fruits Antiojddants that 
lower 
 







at al. (1975); (1976) 
Charantin (Figure 
1.11 C) 








Figure  1.11  shows  the  structural  formulae  of  the  active  phytochemical  and 







































































1.7.1    Medical applications of Momordica charantia 
 
 
Momordica charantia has been used for centuries as medicine in India, China, Africa 
and  Latin  America.  Momordica  charantia  extracts  possess  antioxidant, 
antimicrobial, antiviral, anti-cancer, antiulcerogenic and antidiabetic properties 
(Raman  and  Lau,  1996).  A  report  also  has  shown  that  this  plant  has  anti- 
tumour activity (Nagasawa, 2002). Ethno-medical reports of Momordica charantia 
indicate that it has been used in folkloric medicine for treatment of various ulcers, 
diabetes, and infections (Gurbuz et al. 2000; Scartezzini and Speroni, 2000; Beloin et 
al. 2005). The root of Momordica charantia has abortifacient property and the leaf 
and stem decoctions are also used in treatment of dysentery and gout (Subratty et al. 
2005).  The  extracted  juice  from  leaf,  fruit  and  whole  plant  has  been  used  for 
treatment of wounds and against infections, parasites (e.g., worms), measles, 




1.7.2    Anti Diabetic Activity of Momordica charantia in animals and humans 
 
 
Enormous  research  studies  have  demonstrated  the  hypoglycaemic  activity  of 
 
Momordica charantia on animals including humans (Sarkar et al. 1996; Ahmed et al. 
 
1998; Raza et al. 2000; Ahmed et al. 2001; Grover et al. 2001; Miura et al. 2001; 
Grover et al. 2002; Rathi et al. 2002 a, b; Kar et al. 2003; Ahmed et al. 2004; 
Chaturvedi et al. 2004; Miura et al. 2004; Sathishsekar and  Subramanian 2005; 
Shetty et al. 2005) and humans (Baldwa et al. 1977; Leatherdale et al. 1981; 
Welihindal et al. 1986; Srivastava et al. 1993). Momordica charantia extracts and 
isolated components may exert their hypoglycaemic effects via a range of 
mechanisms including stimulation of insulin secretion and glucose utilization by 
cells and inhibition of intestinal glucose uptake (Singh et al. 2011). 
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1.7.3    Antioxidant Activity of Momordica charantia 
 
 
Momordica   charantia   shows   antioxidant   properties   due   to   the   presence   of 
carotenoids that protect plants during photosynthesis. Momordica charantia fruit 
contains as many as 14 carotenoids, depending on stage of maturity of the fruit. 
Other natural antioxidants present in the plant are phenolics and polyphenolic 
compounds. Other antioxidants present in this plant are vitamin C, vitamin B, 
phenolic acids, and organosulfur compounds (Simon, 1997). Bitter gourd is also a 
rich source of phenolic compounds, such as gallic acid, gentisic acid, catechin, 
chlorogenic acid and epicatechin. The concentration of phenolics varies with plant 
organ (fruit, leaf or root) (Jayasooriya et al. 2000; Ahmed et al. 2001). 
 
 
1.8 Anti microbial activity of Momordica charantia 
 
 
It has been demonstrated that the consumption of the fruit extract of Momordica 
charantia may increase the human and animal resistance against viral infections via 
the promoted production of natural killer cells (Sahu et al. 2011). Ribosome 
inactivating  protein  α-momorcharin  stimulates  the  production  of  MAP30 
(Momordica anti-HIV protein) and simultaneously suppresses HIV activity (Lee et 
al. 1990; Lee et al. 1995). 
The fruit extracts of the Momordica charantia have shown antimicrobial activity 
against Escherichia coli, Staphylococcus, Pseudomonas, Salmonella, Streptobacillus, 
and Streptococcus bacteria (Omoregbe et al. 1996). Moreover, whole plant extract 
has shown antiprotozoal activity against Entamoeba histolytica. Also, fresh fruit 
extracts may exhibit antimicrobial activity against tuberculosis and helicobacteria 
pylori (Hussain and Deeni, 1991; Omoregbe et al. 1996; Yesilada et al. 1999). 
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1.8.1    Anti cancer activity of Momordica charantia 
 
 
Chemical constituents of Momordica charantia include glycosides, saponins, 
alkaloids, fixed oils, triterpenes, proteins and steroids (Grover, 2004). Nutritional 
value of Momordica charantia is attributed to its high mineral and vitamin contents, 
while bitterness is attributed to the non-toxic alkaloids, momordicosides and 
momordicines. α- and β- momorcharins, momordins, and cucurbitacin B are a group 
of ribosomes inactivating proteins that are present in Momordica charantia and can 
be useful for inhibition of tumour cells (Okabe et al. 1980). Research in the last few 
decades has proved that Momordica charantia itself and its extract are useful for 
suppressing cancers and tumour growth. It has been reported that leukaemia 
lymphocyctes  can  be  inhibited  by the  aqueous  extract  of  Momordica  charantia 
(Semiz and Sen, 2007). Momordica charantia contains charantin that is a steroidal 
saponin with insulin-like properties (Singh et al. 2011). Since 1928, insulin has been 
used to treat diabetes. Cancer cells thrive on sugar and they have more insulin 
receptors compared to normal cells. Depriving the cancer cells from sugar may hence 
be fatal to them. During insulin therapy, the blood sugar level is reduced to 50 mg/dl 
causing the patient to feel drowsy and weak for a short period when the cancer cells 
are also desperate for sugar. The cancer cells will take up sugar rapidly after being 
starved.   Any   chemotherapeutic   agents,   when   infused   with   sugar,   might   be 
excessively taken up by the starving cancer cells. This is an effective approach to 
deliver chemotherapeutic agents to target cancer cells with less negative effects on 
normal cells (Jiao 2003). Among the various ribosome-inactivating proteins (RIPs) 
isolated from Momordica charantia, MAP30 (Momordica protein of 30 kDa) has 
displayed anti-tumour activity (Lee-Huang, 2000). The efficacy of MAP30 has been 
tested in estrogen-independent and highly metastatic human breast tumour MDA- 
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MB-231 cell lines, resulting in inhibition of cancer cell proliferation by inhibiting the 
expression of HER2 gene (Lee-Huang 2000). When MDA-MB-231 human breast 
cancer cells were transplanted into SCID mice, the mice developed extensive 
metastases, and all mice succumbed to tumours by day 46. Treatment of the mice 
with MAP30 resulted in significant increases in survival, with 20–25% of the mice 
remaining tumour-free for 96 days. The effect of MAP30, isolated from Momordica 
charantia  seeds,  was  examined  in  premalignant  and  malignant  human  prostate 
cancer cell lines and caused an induction of cell cycle arrest and apoptosis (Xiong, 
2009). Administration of MAP30 decreased PC3 human prostate cancer cell growth 
in nude mice, and this effect was primarily due to the induction of apoptosis. The 
Momordica charantia seed or fruit extracts have been shown to display anti-cancer 
activity in a rat colonic aberrant crypt foci model (Kohno, 2002) and a mouse 
mammary  tumor  model  (Nagasawa,  2002).  Akihisa  et  al.  (2007)  have  isolated 
thirteen cucurbitane-type triterpene glycosides, including eight new compounds 
named charantosides I -VIII, and five known compounds, 8, 9, 14, 15, and 18, from a 
methanol extract of the fruits of Japanese Momordica charantia . Charantosides I 
and II exhibited marked inhibitory effects in both 7,12 dimethylbenz[a]anthracene- 
and peroxynitrite-induced mouse skin cancers. Seed oil of bitter melon contains more 
than 50–60% alpha-eleostearic acid (α-ESA) which also may suppress the growth of 
DLD-1 human colon cancer cells by inducing apoptosis via lipid peroxidation 
(Tsuzuki, 2004). α-ESA is converted to conjugated linoleic acid in vivo, causing a 
stronger  suppressive  effect  on  cancer  than  the  non-conjugated  linoleic  acid. 
Treatment with α-ESA may also induce apoptosis in HL60 human promyelocytic 
leukemia cells (Kobori, 2008). Grossmann et al. (2009) have shown that that α-ESA 










strongly induced apoptosis in HL60 cells, the acetone extract of bitter melon seed, 
which is probably rich in α-eleostearic acid, did not induce apoptosis in the cells. 
Lipophilic components of pericarp and placenta in the acetone extract may slow 
down the apoptosis process in HL60 cells. In fact, the acetone extract also did not 
suppress the colon cancer growth in xenograft model (Tsuzuki, 2004). Therefore, 







Paclitaxel is a natural product with antitumor activity. Paclitaxel is a diterpene 
alkaloid derived from the dried bark of Pacific yew tree Taxus brevifolia (Figure 
1.12  A)  (Spencer,  1994). The  chemical  name  for  paclitaxel  is  5β,20-Epoxy- 
 
l,2α,4,7β,10β,13α-hexahydroxytax-l l-en-9-one  4,10-diacetate  2-benzoate  13-ester 
 






















Figure 1.12: (A) The bark of the Pacific yew that is used to extract palitaxel. B) 




Paclitaxel is a white to off-white crystalline powder with the empirical formula 
C47H51NO14 and a molecular weight of 853.9 g/mol. Paclitaxel is highly lipophilic, 
and melts at around 216-217°C (Singla, 2002) and is used in treatment of various 
advanced carcinomas such as ovarian cancer, lung cancer, breast cancer, acute 
leukemias, head and neck cancers and Kaposi‘s sarcoma. Paclitaxel is a mitotic 
inhibitor  that  blocks  the  proliferation  of  cancer  cell   (Schiff,  1979)  and  is 
commercially   available   as   Taxol®    that   consists   of   Paclitaxel   solubilised   in 
Cremophor EL (polyethoxylated castor oil) and dehydrated alcohol (1:1 v/v) (Weiss, 
1990). Unfortunately, severe adverse reactions like hypersensitivity reactions are 
caused by Cremophor EL (Yang, 2007). To exclude the solvent Cremophor EL and 
maximize the therapeutic index of the drug, different delivery systems of paclitaxel 
have been developed such as Abraxane®  which has been approved for clinical use. 
Abraxne®      (Abraxis    Bioscience)    is    albumin    bound    paclitaxel,    which    is 
 







1.10  Liposomes 
 
 
Liposomes   have  been   used  as   a  delivery  system   for  treatment   of  tumour 
(Gregoriadis, 1973; Gregoriadis, 1977; Gregoriadis, 1978; Sofou, 2007). Many 
phytochemical constituents are poorly bioavailable due to their large molecular size 
or low water solubility. Thus, nanotechnology has infused new dimensions into the 
targeted drug delivery systems through self-assembling supramolecules based 
nanostructures (Mohanraj and Chen, 2006). Amongst many types of nanocarriers, 
liposomes have been investigated intensively during the last few decades to explore 
and exploit their intrinsic targeting potential (Mohanraj and Chen, 2006). Ajazuddin 
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(2010) has reported that the active ingredient of the herb curcurmin was loaded into 




1.10.1  Architecture of Liposomes 
 
 
The name liposome is derived from two Greek words: 'Lipos' meaning fat and 'soma' 
meaning body. It has been over 35 years since their discovery while being studied as 
model biological membranes (Bangham, 1961; Bangham, 1968). Liposomes are self- 
assembled,  self-closed  colloidal  nanocarriers  having  phospholipid  bilayer 
membranes. Phospholipids are part of all cell membranes of living organisms and 
play an important role in signal transduction mechanism and are arranged according 
to fluid mosaic pattern in biological membranes. Phospholipids are heterogeneous 
molecules containing phosphoric residues, polar head groups and non-polar alkyl 































Figure 1.13: Arrangement of phospholipid bilayer in the liposomes: A) 
Phospholipid molecule on presence of aqueous phase forms B) phospholipid 
bilayers having C) polar head face outwards and non-polar tail face inwards of 
the liposome and forms D) colloidal and sperical shape vesicle to carry drugs. 
(Adapted from- http://www.uni- 
magdeburg.de/imos/mea_sen/img/pictures/Lipo.jpg). 
 
Vigorous dispersion of purified phospholipid in water, by adding ‗process energy‘ in 
the form of mixing or sonication, above the phase transition temperature (Tm) of the 
lipid results in formation of liposomes. Phase transition temperature (Tm) of a given 
phospholipid is the temperature at which the bilayer transfers from the gel state to the 
liquid crystalline state at which the molecules are more mobile and the bilayers are 
more permeable. Thus, liposomes above the Tm have more flexibility and 
permeability.  Hydrophilic  molecules  are  entrapped  in  the  aqueous  spaces  of 
liposomes while hydrophobic materials are entrapped in the bilayers (Ueno et al. 
1991). Because of their unique size and surface properties, liposomes can enhance 
the   performance   of   drugs   by   increasing   their   solubility,   improving   their 
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bioavailability, enhancing their cellular uptake and altering their pharmacokinetic 
properties (Mizuno et al. 2003; Haag and Kratz, 2006). 
 





A phospholipid molecule is amphipathic consisting of one polar head goup and two 
non-polar alkyl chains (Figure 1.14). When phospholipid molecules are hydrated 
with water, the polar heads tend to face the aqueous phase and the non-polar tails 
stick  together  and  shield  away  from  the  aqueous  compartments,  resulting  in 
formation of bilayers. 
 
 
Figure  1.14:  Diagram  showing  the  chemical  structure  of  a  phospholipid 
(phosphatidylcholine) molecule. 
 
i) Polar head groups of phospholipids 
 
Most phospholipid head groups belong to the phosphoglycerides family such as 
phosphatidylcholine (PC) (Figure 1.14), phosphatidylserine (PS), 
phosphatidylethanolamine (PE) and phosphatidylinositol (PI). The polar headgroups 
are respectively choline, serine, ethanolamine and inositol attached to phosphate 
groups and glycerol backbone (Wehrmüller, 2008). 
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ii) Non-polar tails of phospholipids 
 
The non-polar tail contains two fatty-acyl chains. The fatty-acyl chains are 
hydrophobic in nature. The fatty-acyl chains in biological membranes usually 
consist of an even number of carbon atoms and are saturated or unsaturated. 
B) Cholesterol 
 
Cholestrol is a lipid that is abundant in biological membranes. The amount of 
cholesterol may vary depending on the type of membrane. However, membranes 
have nearly one cholesterol molecule per phospholipid molecule. The following 
figure shows the steroid structure of cholesterol with an illustration of the non-polar 






Figure 1.15: Orientation of Cholesterol in the biological membrane A) Chemical 
structure of cholesterol B) Polar and non-polar region in cholesterol molecule 
and c) Orientation of cholesterol molecule inserting itself between the membrane 
bilayer (Adapted from-http://www.cytochemistry.net/cell- 
biology/membrane_intro.htm). 
 
During phase transition temperature the gel phase is converted into liquid crystalline 
phase and both of the hydrophobic tails of the phospholipid are freely moving as 
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shown in Figure 1.16.  At temperatures above the Tc, the bilayer ―melts‖ and the 
interior is fluid allowing the lipid molecules to move around, rotate and exchange 
places. At temperatures below the phase transition (Tc) of a given phospholipid, the 
bilayer is in the gel state and tightly packed.  Cholesterol molecules insert themselves 
into  the  phospholipid  bilayers  with  the  same  orientation  of  the  phospholipid 




Figure 1.16: The relationship between packing style of hydrocarbon chains in 
bilayers and the temperature of the hydrating phase. A) shows the fluid state of 
hydrocarbon  chain  when  the  temperature  is  above  phase  transition  (Tc)  B) 
shows the gel phase hydrocarbon state when below phase transition C) shows 
rigid  hydrocarbon state on insertion of cholesterol in the formulation above Tc. 
(Source- http://www.cytochemistry.net/cell-biology/membrane_intro.htm). 
Functions of cholesterol functions in the membrane of liposome: 
 
 
1.         The  cholesterol  embed  themselves  between  the  bilayer.  The  hyrophilic 
portion of cholesterol molecule face towards the membrane surface. Cholesterol 
increases the fluidity of the membrane by interfering the tight packing of the 
phospholipid molecule. Cholesterol prevents crystallization of hydrocarbons and 
phase shifts in the membrane (Yeagle, 1985). 
2.        Cholesterol retards the movements of the hydrocarbon alkyl chains in the 
phospholipid molecules. This makes the lipid bilayer less deformable and decreases 
its permeability to small water-soluble molecules. Without cholesterol such as in 
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bacterial cells  cell walls are needed to maintain the function of the cells and prevent 




1.10.2  Soy lecithin 
 
 
Soy lecithin is the most commercially important lecithin derived from plant. Soy is a 
subtropical plant native to South Eastern Asia and is mainly consumed in the Eastern 
style diet. Soyabeans are the richest vegetarian source of phospholipids. Because of 
the high content of phospholipid in soybeans, they are often used as raw materials for 
dietary supplementation as well as emulsification in many food products 
(Wehrmuller, 2008). Importantly, soy products contain putative protective 
components such as oligosaccharides and protease inhibitors, which are responsible 
for protection against some cancers (Davies et al 1999). Soy lecithin is a combination 
of naturally occurring phospholipids, which are extracted during the processing of 
soybean oil. The main phospholipids in soy lecithin are lysophospholipid, 
phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine and 
phosphatidic  acid  (Figure  1.17).  However,  soy  lecithin  is  sometimes  used  as 
synonym for pure soy phosphatidylcholine. There is epidemiological evidence that 
soy phosphatidylcholine has protective effects against colon cancer (Adlercreutz, 
1998;  Messina,  1994).  Using  soy  products,  anti-proliferative  effects  have  been 
shown on a wide range of cell types in vitro including cells of the gastrointestinal 
tract (Yanagihara et al. 1991). Soy lecithin is an excellent source of choline, which is 
essential to the integrity of cellular membranes. Without choline, the cell membranes 
would harden, prohibiting important nutrients from entering and leaving the cell. The 
importance of soy lecithin is not confined to its dietary supplement of choline but 
also   extends   to   include   methyl   metabolism,   cholinergic   neurotransmission, 
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Figure 1.17: Pie chart showing the composition of soybean lecithin: Phospholipid 




1.10.2.1 Soy Phosphatidylcholine 
 
 
Lipoid S100 is a relatively pure form of soy phosphatidylcholine (SPC), which is 
derived from soybean (Lipoid GmbH, Switzerland). Lipoid S-100 soy lecithin is 
comprised mainly of soya phosphatidylcholine (94% of the dry weight) in addition to 
a mixture of phospholipids including N-Acyl-phosphatidylethanolamine, 
Phosphatidylethanolamine, Phosphatidylinositol and Lysophosphatidylcholine. The 
composition of Lipoid S-100 is shown in Table 1.4 and phosphatidylcholine 
comprises 94% of the weight of the product according to the manufacturer sheet. 
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 Composition of soy lecithin, Lipoid S-100 
Phospholipids fraction 
Phosphatidylcholine(by anhydrous weight) 94.0% 
N-Acyl-phosphatidyl ethanolamine 0.5% 
Phosphatidyl ethanolamine 0.1% 
Phosphatidyl inositol 0.1% 
Lysophosphatidyl choline 3.0% 
Typical fatty acid composition in % to total fatty acids 
Fatty acid % Of fat composition 
Palmitic acid 12-17 
Stearic acid 2-5 
Oleic acid 11-15 
Linoleic acid 59-70 
Linolenic acid 3-7 
Approximate Molecular Weight: 790 
 
Storage: -20 ºC 
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1.10.2.2 Hydrogenated soy phosphatidylcholine (HSPC) 
 
 
Phospholipon® 90H is hydrogenated soy lecithin product and is simply referred to as 
hydrogenated soy phosphatidylcholine (HSPC) and was supplied by Lipoid GmbH, 
Switzerland). Phospholipon® 90H contains soybean-derived phospholipids with fully 
saturated alkyl chains such as hydrogenated phosphatidylcholine and hydrogenated 
lysophosphatidylcholine. As shown in Table 1.5, hydrogenated phosphatidylcholine 
comprises 90% of the Phospholipon®90H. The composition of saturated fatty acids 
(palmitic acid and stearic acid) is higher in comparison to unsaturated fatty acids 
(oleic acid, linoliec acid and linolenic acid) (Table 1.5). 
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Table  1.5:  Composition  of  Phospholipon®90  H  (Adapted  from  the  supplier: 





Hydrogenated Phosphatidylcholine min. 90% 
Hydrogenated Lysophosphatidylcholine max. 4% 
Oil/ triglycerides max. 2% 
Typical fatty acid composition in % to total fatty acids 
Fatty acid % Of fat composition 
Palmitic acid 15 
Stearic acid 85 
Sum of stearic acid and palmitic acid min. 98% 
Sum of unsaturated fatty acids 
 
(oleic, linoleic, linolenic acids) 
max   2% 
Approximate Molecular Weight: 784 
 
Storage : 0 ºC 
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1.10.3.1  Phosphatidylcholine (PC) 
 
 
Phosphatidylcholine (PC) is the major phospholipid constituent of cell membranes, 
comprising 40-50% of total phospholipids (Vance, 2008). PC is also known as 1,2- 
diacyl-sn-glycero-3-phosphocholine, or is simply referred to as lecithin. PC plays an 
important biochemical role in the maintenance and integrity of the cell membrane 
and is an important signalling molecule (Exton, 1994; Billah, 1990; Kiss, 1990; 
Kester, 1989). Recently, it has been suggested that PC by its own may have a 
therapeutic role in some cancers (Semalty et al. 2009 ). Animal studies have indicated 
that deficiencies in choline and PC may disrupt cell membrane signal transduction in 
ways that could lead to various cancers. There is evidence suggesting that liver 
cancer is promoted in various animals by choline-deficient diets, and it has been 





1.10.3.2  Phosphatidylethanolamine (PE) 
 
 
Phosphatidylethanolamine (also sometimes called ‗cephalin‘) is the second most 
abundant phospholipid in animal and plant lipids. It comprises 20 - 50% of the total 
phospholipid content of the mammalian membranes. It can make up to about 20% of 
liver phospholipids and as much as 45% of phospholipids of the brain. Higher 
proportions of PE are found in the mitochondria than in other organelles of the cell 
(Vance, 2008). 
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1.10.3.3  Phosphatidylinositol (PI) 
 
 
Phosphatidylinositol (PI) is an acidic (anionic) phospholipid that consists of a 
phosphatidic acid backbone linked via the phosphate group to inositol. Inositol is 
phosphorylated to form phosphatidylinositol phosphate (PIP), phosphatidylinositol 
bisphosphate  (PIP2) and  phosphatidylinositol  trisphosphate  (PIP3). PIP,  PIP2   and 
PIP3, which are collectively called phosphoinositides. Two phospholipid derivatives 
of PI are PI phosphate and PI biphosphate have been found to be important in the 
signal transduction pathway located in the inner half of the plasma membrane. 
Inhibition of phospholipid inositol metabolism may induce cancer (Ana et al. 2001). 
PI may comprise up to 10% of the phospholipids of the brain. There is usually less PI 




1.10.4  Liposome morphology and preparation methods 
 
 
According to their morphology, liposomes are classified into either oligolamellar, 
unilamellar or multilamellar. Multilamellar liposomes (MLVs) have a size range 
from 500 to 10,000 nm. Unilamellar liposomes can be small unilamellar vesicles 
(SUVs) or large unilamellar vesicles (LUVs). SUVs are usually smaller than 100 nm 
whilst LUVs are larger than 100 nm. Liposomes of very large size are commonly 
referred to as giant liposomes and have a size larger than 10,000 nm and are either 
unilamellar  or  multilamellar.  Some  large  liposomes  may  encapsulate  smaller 
liposome vesicles and these are called multi-vesicular liposomes which have a size 
range of 2,000 - 40,000 nm. Morphology of liposomes is highly determined by the 




Figure 1.18: Diagrams showing the size and lamellarity of liposomes prepared 
using different methods (Adapted from- Jesorka, 2008) 
 
Liposomes prepared by the conventional thin film hydration method are MLVs. This 
method is unsuitable for manufacturing liposomes on a large scale and because 
liposomes are dispersed in aqueous phase (i.e. no drying is applied) they are 
chemically and physically unstable during storage. Stability of liposomes depends 
upon the method of preparation, nature of the constituent lipids and properties and 




1.10.5  Usage of entrapment of material in liposomes 
 
 
• Lipoosme   is   used   to   deliver   hydrophilic   lipohilic   and   amphiphatic 
compounds. Their location in the liposome will be dependent on 
physiochemical of the loaded agents. They can either be located in the 
liposome membrane or in the intra-liposome aqueous phase. 
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• Liposomes   as a drug delivery system can improve the therapeutic activity 
and safety of drugs, mainly by delivering them to their site of action (i.e. 
targeting) and by maintaining therapeutic drug levels for prolonged periods of 
time (Abou et al. 2003; Ajazuddin and Saraf, 2010). 
• Liposomes can protect a drug against degradation 
 
• Liposomes can protect the patient against side effect of the encapsulated 
drug. 
• Liposomes are used for the delivery of drug, protein or nucleic acid, si RNA, 
plasmid,  DNA,  peptides,  proteins,  viruses  and  bacteria  (Schroeder  et  al. 





1.11  Proliposomes 
 
 
Proliposome methods are based on the conversion of the initial proliposome 
preparation into liposome dispersions by addition of an aqueous phase (Maitani et al. 
2001). This method is suitable for encapsulation of a wide range of drugs with 
varying solubility in water and alcohol and can provide high encapsulation 
efficiencies when compared with other methods of manufacturing liposomes. 
Proliposomes are easy to scale up, potentially providing an alternative approach for 
the production of liposomes for clinical applications (Turanek et al. 1997; Wagner 
and Karola, 2011). Liposomes prepared from proliposome are safe, biodegradable 
and may enhance the chemical stability of the formulation since aqueous phase 
addition takes place immediately before administration. Proliposomes are potentially 
applicable for preparation of tumour targeting liposomes for anticancer drug delivery 
(Crommelin and Sindelar, 2002). For solid tumours, liposomes are of particular 
interest  because of their easy manipulation  and  optimum  size.  It  is  known that 
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tumour has leaky vasculature and poor lymphatic drainage. Liposomes can be used 
as a targeting tool by exploiting what has been described as ―Enhanced Permeation 
and Retention effect‖ (EPR). Proliposome formulations are either Particulate-based 
or Solvent-based. Solvent-based proliposomes are referred to as alcohol-based or 




1.11.1.1 Particulate-based proliposomes 
 
 
Particulate-based proliposomes are dry, free-flowing carrier particles coated with 
phospholipids in order to generate liposomes upon addition of aqueous phase (Payne 
et al 1986). Particulate-based proliposomes comprise soluble carrier particles (e.g. 
carbohydrate) coated with phospholipids to generate MLVs by the addition of 
aqueous phase above the phase transition temperature (Tc) of the lipid used (Payne et 
al. 1986). Particulate-based proliposomes are made by attaching a flask containing 
the soluble carrier particles to a rotary evaporator followed by portion-wise addition 
of organic solution of the lipid via a feed line under reduce pressure to coat the 
carrier particles. Evaporation of the organic solvent results in the production of 
particulate-based proliposomes (Payne et al., 1986, Elhissi and Taylor, 2005). 
Proliposomes can then be stored below 0°C. Once the liposomes are required for 
administration, an aqueous phase is added to the proliposome powder. This approach 
offers phospholipid formulations that are free of aqueous phase during storage and 
hence chemical and physical instabilities of liposomes are minimised. The 
manufacturing procedures however is tedious and may be difficult to control, since 
the operation requires: (a) addition of organic solution of the lipid and subsequent 
solvent evaporation; (b) close monitoring to ensure that the powder is not overly wet 
and the unit is properly operating under vacuum; and (c) overnight drying of the 
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proliposomes in a desiccators under reduced pressure may also be required (Chen et 
al. 1987). Also, the involvement of an organic solvent is an environmental hazard. 
 
Liposomes generated from particulate proliposomes may offer high entrapment 
efficiency of hydrophobic drugs as compared to hydrophilic drugs. Nicotine is 
amphiphilic in nature and has 45-58% entrapment efficiency in liposomes generated 
from particulate-based proliposomes (Chung, 1999), 
 
The entrapment efficiency of hydrophilic drugs in proliposome-generated liposomes 
was much lower, for instance the entrapment efficiency of propranolol hydrochloride 
was approximately 4 to 10% and high phospholipid concentrations were used in 
order to maximise the entrapment of this drug (Ahn et al. 1995). In another study, a 
value of about 45 % of salbutamol sulphate was entrapped in liposomes using a 






1.11.2  Solvent-based proliposomes 
 
 
Solvent-based proliposoms are concentrated solutions of phospholipid, which 
generate liposomes upon addition of aqueous phase above the Tc of the lipid (Perrett 
et al. 1991). Typically, the solvent used is ethanol; hence they are commonly referred 
to as alcohol-based or ethanol-based proliposomes. This method offers a simple 
means  of  generating  liposomes  with  high  entrapment  of  hydrophilic  materials 
(Perrett et al. 1991; Turanek et al., 1997; Elhissi et al., 2006). The spontaneous 
generation of liposomes from proliposomes has been demonstrated to produce large 
vesicles under static condition (approximately 11-13 μm), when compared to the 
agitated proliposome samples (approximately 1 μm) (Deo et al. 1997). 
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Liposomes generated by from alcohol-based proliposomes provide high entrapment 
of  hydrophilic  materials,  which  ranged  between  approximately  65  and  80% 
depending on phospholipid composition (Perrett et al. 1991). The ethanol-based 
proliposome   approach   may   provide   a   means   for   cost-effective   large   scale 
manufacture of liposomes containing hydrophilic drugs (Perrett et al. 1991; Turanek 
et al. 1997). 
 
 
1.12  Liposomes in anticancer therapy 
 
 
Many liposome formulations of various anticancer agents have been shown to have 
less toxic effects than the drug itself (Gabizon, 1989). It has been reported that small 
liposomes are passively targeted to different tumours because they can circulate in 
the blood compartment for longer period of time and perfuse better into cancerous 
tissues.  Doxil®   is  an  intravenous  liposome  formulation  of  doxorubicin  and  is 
prepared by using the Stealth technology. Stealth liposomes are liposomes coated 
with polyethylene glycol, resulting in better capability to escape clearance via the 
reticuloendothelial system and hence they are long circulating liposomes. Caclyx® 
and Myocet® are liposomal formulation of doxorubicin used for treatment of ovarian 
 
cancer and recently for treatment of metastic brain cancer (Samad et al. 2007). 
Antibody-conjugated liposomes or immunoliposomes are liposomes bearing specific 
antibodies on their surfaces to target the encapsulated drug molecules to particular 
diseased tissues or organs. The pharmacological effect on brain cancer cells in vivo 
supports the viewpoint that macromolecules such as plasmid DNA can be delivered 
across biological barriers including the blood-brain barrier, the plasma membrane of 
the target cells within the brain tissue and the nuclear membrane (Zhang et al. 2003). 
 
 
In some cases, sustained release of the liposomal formulations showed enhanced 
64  
efficacy and longer presence of therapeutic concentrations of the anticancer drug in 
lymphoma cells (Storm et al. 1987). 
 
 
Table 1.6 shows the examples of the liposome product available in the market for the 





Table 1.6: Some commercially available anticancer liposome formulations that 
have been investigated clinically (Adapted from: Samad et al. 2007) 
 
Liposome product Drug Targeted sites 
Doxil® Doxorubicin Kaposi‘ sarcoma 
EVACTTM Doxorubicin Refractory tumour 
 
 
Metastatic breast cancer 
DaunoXome® Daunosome Advanced kaposi‘s 
 
sarcoma, breast cancer, 
small cell lung cancer, 
leukemia and solid 
tumours 
VincaXome® Vincristine Solid tumour 
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1.12.1  Role of liposomes in anti-cancer therapy 
 
 
Liposomes are biocompatible and ideal non-toxic biodegradable carriers. The 
phospholipid bilayer of the liposome protects the drug from degradation in the body 
while being targeted to the tumour site. It also prevents the exposure of active drug to 
the healthy tissues, while the drug is in blood circulation. The negative side effect of 
the drug is also reduced while in liposomes as compared to non-encapsulated drug 
(Brown and Khan, 2012). The principal pathway for the movement of liposomes into 
the tumour interstitium is via extravasation through the discontinuous endothelium of 
the tumour microvasculature. However, the tumour vasculature is discontinuous with 
gaps, allowing liposomes to extravasate and reach the tumour interstitium by 
transcytosis process. Non-targeted liposomes are localized in the interstitium 
surrounding the tumor cells and eventually they leak the drug out of the liposome. 
Non-targeted liposomes are not seen within tumour cells, although they are observed 
by the tumour macrophages, resulting in a special mode of accumulation that is 
different from targeted liposomes. Targeted liposomes accumulate in tumours, but on 
entering the tumour area are endocytosed by the tumour cells. This process results in 
breakdown of the liposomes by lysosomes and an increased delivery of the drug to 
the nucleus, resulting in cytotoxic effects in the tumour area. Large tumors are more 
difficult  to  treat  than  small  ones,  in  part  because  of  the  resulting  increase  in 
interstitial pressure, which prevents access of drugs to the necrotic core (Drummond 
et al. 1999). The extravasation and accumulation of liposomes into tumors are 





Figure 1.19: Diagram showing the gaps in the endothelial cells in tumour, allows 
the liposomes to accumulate in the tumour site and stop the proliferation of 
cancerous cells. (Adapted from – Drummond et al. 1999). 
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1.13  Working hypothesis 
 
 
Liposomes generated from proliposomes can be used to encorporate and deliver 
plant-derived drugs for the treatment of gliomas. 
 
 
1.14  Main Aim 
 
 
The main aim of the project was to prepare liposome formulations of Momordica 
charantia extracts and to apply the extracts on glioma cell lines. Solvent-based 
proliposome method was used to generate liposomes. The phospholipid used in the 
experiment was soy phosphatidylcholine (SPC) or hydrogenated soy 




1.14.1  Specific aims 
 
 




2.  To prepare liposomes from proliposomes using solvent-based proliposome 
technology. 
3.  To study the physical and chemical properties of liposomes by size, size 
distribution, surface charge and surface morphology. 
4.   To prepare extracts of Momordica charantia using three different species of 
 
Momordica charantia from Africa, China and India. 
 
5.   To segregated Momordica charantia fruit into flesh of the fruit (fruit alone; 
FA), seeds (seeds alone; SA) or whole fruit including the seeds (WF) and 
produce water-soluble extracts for incorporation into liposomes generated 
from proliposomes. 
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6.   Similarly, prepare Paclitaxel (PTX) liposomal formulations and compare with 
 
Momordica charantia extracts liposomal formulations in the experiment. 
 
7.   To deliver drug loaded liposomes on three different glioma cell lines and a 
normal glail cell. 
8.   To culture the three glioma cell lines and study their morphology before and 
after treatment by measuring cell viability. 
9. To investigate the mechanism of extracts of Paclitaxel and Momordica 
charantia  in  the  cell  death  measuring  the  activities  of  caspase  and 
cytochrome c release. 















































2.1.1    Momordica charantia from China, Africa and India 
 
 
Three species African, Chinese and Indian of Momordica Charantia fruits was 
purchased from a local food store (Kashmir Watan Food store, Lancashire, Preston 
PR1 1PJ, United Kingdom). 
 
 
Figure 2.1: The three different species of Momordica charantia. The plant source 
was from A) China (Yunnan), B) India (Maharashtra) and C) Africa (Kenya) 
and all were purchased from the local supplier Kashmir Watan food store 




2.1.2    Phospholipids used in the experiment 
 
 
The soy lecithin used in the experiments was Lipoid S-100 (Soy 
phosphatdidylcholine) and Phospholipon® 90H (Hydrogenated soy 




2.1.3    Other materials 
 
 
HPLC grade Methanol and Ethanol was purchased from Sigma Aldrich, UK. 
Cholesterol (99%) was also supplied by Sigma Aldrich, UK and Paclitaxel was 







2.2.1    Aqueous extraction of Momordica charantia 
 
 
The unripe fruit of Momordica charantia was washed thoroughly in deionised water 
and then was cut into small pieces. The various parts of the plant were studied for 
their anticancer activity. These parts were: 
 
• Whole fruits (1000 g). These included the fruit and the associated seeds. 
 
• The fruits alone (1000 g). These were the fruits without the seeds. 
 
• The seeds (500 g). These were only the seeds present inside the fruits. These 
plant sections are shown in Figure 2.2. 
Whole Fruit (WF; 1000 g) or Fruit Alone (FA; 1000 g) of Momordica charantia was 
sliced into small pieces. The sliced pieces were grinded in a blender model no- 
3402E19 (Thomas Scientific, UK) in presence of 900 ml of deionised water and than 
added 100 ml of methanol. The resultant aqueous dispersions were mixed well 
manually for 10 minutes and then squeezed using muslin cloth and sterile filtered 
using 0.45 μm Cellulose Nitrate membrane filter (Fisher Scientific, UK) in glass 
bottles followed by storage at 4ºC. The solid insoluble materials were discarded. 
 
The seeds (500 g; Figure 2.1) collected from Momordica charantia fruits were 
grinded with 450 ml of distilled water and methanol (50 ml) was added to the extract, 
later. The dispersion was mixed well for 10 minutes and squeezed using muslin 


















Figure 2.2: Diagram showing Momordica charantia whole fruits (A) and a fruit 




2.2.2    Drying of the aqueous extracts 
 
 
Empty round-bottomed flasks were weighed and 20 ml of each extract (WF, FA or 
SA) were added and evaporated under vacuum to remove water and methanol using 
an R210 rotary evaporator (Buchi, Switzerland) for 2 hours. The flask was removed 
and kept for drying in the oven at 40 ° C for 1 hour. The flasks with the extract were 
weighed in order to find out the amount of the extract present. 
 
After rotary evaporation was completed and dried in the oven for an hour at 40 ° C. 
The amount of WF, FA, and SA extracts from the three different species of the plant 
(i.e.  Indian,  Chinese  and  African)  was  calculated  afer  rotary  evaporation  and 
complete drying. The weight of the WF, FA and SA was found to be 737.6 mg, 
541.2 mg and 373.4 mg, respectively for the Indian plant, 750.45 mg, 620 mg and 
 
410.22 mg, respectively for the Chinese plant, and 720 mg, 420 mg and 340 mg, 
respectively for the African plant. The solid material was dissolved in deionised 
water (5 ml) to have the following range of concentrations: 0, 1.75, 3.50, 5.25, 7.00 
and 8.75 mg. 
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2.3 Preparation of liposomes using thin film hydration method 
 
 
Phospholipid (SPC or HSPC) was dissolved in ethanol (40 mg / ml) in 100 ml pear 
shaped flask and attached to the rotary evaporator. Vacuum was applied, rotation 
speed was set at maximum, and the water bath was set at 35C. After one hour, the 
vacuum pump was turned off in order to detach the flask. The pear shaped flask 
containing thin layer of phospholipid was immersed in water bath and hydrated with 
5 ml deionised water (60 C) and shaken in order to form liposomes. The liposomes 
were kept immersed in the water bath at 60  C for 10 min followed by vigorous hand 
shaking in order to ensure the film is completely hydrated. The SPC and HSPC 
liposomes were allowed to cool at room temperature for 2-3 hours before performing 
further investigations or experiments. 
 
 
2.4 Preparation of liposomes using the solvent-based proliposome method 
 
 
Volumetric flasks (5 ml) were washed with methanol and dried in the oven at 80 C in 
order to avoid microbial contamination. SPC or HSPC (40 mg) and cholesterol (10 




2.4.1    Momordica charantia Extract 
 
 
Ethanol (100 μl) was added to the flask containing the SPC or HSPC (40 mg) at 
room temperature with gentle mixing to produce a clear solution of phospholipid. 
Cholesterol (10 mg) was added while keeping the flask containing the phospholipid 
partially immersed in a water bath (60°C) until the cholesterol was completely 
dissolved and a clear concentrated proliposome solution was obtained. This step was 
referred to as the proliposome preparation step. Increasing quantities of WF, FA or 
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SA of Momordica charantia extracts were added to a set of proliposome solutions. 
This was performed by dissolving the solid matter (0, 1.75, 3.50, 5.25, 7.00 and 8.75 
mg) in 5ml of deionised water as previously described. The aqueous extract (2.5 ml) 
was added to the proliposome solutions at room temperature followed by vortex 
mixing for two minutes to generate liposomes. This step was referred to as the 
primary hydration step. The secondary hydration step involved addition of another 
2.5 ml of the aqueous phase followed by vortex (A2754 - Fisons whirlimixer, Fisons 
scientific equipment, UK) mixing for two minutes so that the liposome solution is 
mixed homogenously. The preparation was allowed to settle for one hour at room 





2.4.2    Paclitaxel 
 
 
The SPC and HSPC phospholipid (40 mg) was dissolved in 500 μl ethanol solution 
containing paclitaxel (0, 1.75, 3.50, 5.25, 7.00 and 8.75 mg) at 60°C. The solution 
was transferred to a flask containing cholesterol (10 mg) at 60°C in order to obtain a 
clear proliposome solution of Paclitaxel. Deionised water (2.5 ml) was added at 60°C 
followed by gentle mixing and vortexing (A2754 - Fisons whirlimixer, Fisons 
scientific equipment, UK) for two minutes to perform the primary hydration. This 
was followed by dilution with another 2.5 ml of deionised water and vortex mixing 
for two minutes. Liposomes were allowed to settle for one hour at 60° C for SPC and 
HSPC before conducting further experiments in order to avoid re-precipitation of 
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Figure  2.3: Schematic presentations for  the  preparation of liposomes using  the 
solvent-based proliposome methods. 
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2.5 Statistical Analysis 
 
 
All data generated in the study were processed using SPSS program. Control and test 
data were compared using student t-test and ANOVA test. Moreover, all the data 
were  expressed  as  ±  either  Standard  Error  of  the  Mean  (S.E.M)  or  Standard 
Deviation (S.D). Control (untreated) and treated data were compared and a value of 



































Chapter 3. Characteri 
 










The conventional thin film hydration method for preparation of liposomes is difficult 
to scale up, and phospholipids in liquid dispersions are liable to hydrolysis (Kensil 
and Dennis, 1881; Grit et al. 1989) and oxidation (Hunt and Tsang, 1981). Moreover, 
liposomes may aggregate or fuse during storage and leak the entrapped material. As 
an alternative approach to the thin film hydration method, proliposomes are stable 
phospholipid  formulations  that  generate  liposomes  prior  to  administration  by 
addition of aqueous phase (Payne et al. 1986; Perrett et al. 1991). One type of 
proliposomes is ethanol-based proliposomes that are concentrated alcoholic solutions 
of phospholipid (with or without cholesterol). The addition of aqueous phase to the 
proliposome formulation with shaking generates oligolamellar liposomes (Perrett et 
al. 1991). Liposomes generated from ethanol-based proliposomes have demonstrated 
different thermal profile, size and drug entrapment compared to conventional 
liposomes (Elhissi et al. 2006a).  Recently, a study by Epstein- Barash et al. (2010) 
has compared the effect of liposome size and charge on the bioactivity of liposomal 
bisphosphonates using a wide range of cell types in vitro and in vivo. There are many 
potential barriers that affect the delivery of drug in its active form to the tumour site. 
Most of the small-molecule chemotherapeutic agents have large volume of 
distribution on administration. This results in narrow therapeutic index and high level 
of toxicity to the healthy tissues. Therefore, encapsulation of drug in macromolecules 
called liposomes reduces the volume of distribution of the active agent due to sustain 
release pattern. The drug encapsulated in macromolecules becomes very effective at 
the tumour site (Drummond et al. 1999). Also,  the stable encapsulation of drug 
within the large liposome, likely prevents filtration and removal of the drug by the 
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kidneys (Drummond et al. 1999). Modifying and control physicochemical properties 
such as size and surface charge can achieve targeting of liposomes to monocytes and 
macrophages (Kelly et al. 2011). 
 
Thus, many studies have shown that the biological properties of liposomes and 
subsequent fate of the entrapped / associated material are highly dependent on 
liposome characteristics including size and zeta potential. In this chapter, liposomes 
incorporating Momordica charantia extracts was prepared and characterised in terms 
of size, size distribution, zeta potential (i.e. surface charge) and vesicle morphology 






The dye used for transmission electron microscopy (TEM) was 1% Uyral Acetate 
dye and supplied by Sigma-aldrich, UK. Lipoid, Switzerland supplied all 
phospholipids used as indicated in Chapter 2. 
 
 




3.3.1    Liposome particle size analysis using laser diffraction 
 
 
The size of liposomes was analysed via laser diffraction by using the Malvern 
Mastersizer 2000 (Malvern Instruments Ltd., UK). Large particles scatter the light at 
narrow angles with high intensity whereas smaller particles scatter the light at wider 
angles and with low intensity (Koch et al. 2003). The instrument was switched on 30 
min before starting the size measurements. The dispersion unit was washed several 
times with deionised water, by increasing the stirring speed to 3,500 rpm and 
subsequently reducing the speed  of the dispersion  unit  controller to  1,360  rpm. 
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Deionised water (100 ml) was added in the dispersion unit for liposome size analysis. 
After alignment of the background, the sample was added to the dispersion unit to 
get the obscuration in the green range and analyse the size and size distribution of 
liposomes. Size and size distribution were presented by the volume median diameter 
(VMD,  50%  undersize)  and  Span,  respectively.  Span  is  a  term  introduced  by 
Malvern Instruments Ltd to express the size distribution of particles. Span = (90% 




3.3.2    Zeta potential measurements 
 
 
Zeta potential of liposomes was important because surface charge of particles could 
give information about formulation stability. It also specified the intensity of 
repulsion among similarly charged dispersed particles and attraction between 
oppositely charged particles. Zeta potential was measured by applying an electrical 
field  to  the  suspension,  which  was  also  known  as  electrophoresis  (Naderkhani, 
2011). Using the DTS1060C Malvern‘s ZetaSizer, Liposome sample was injected 
through the plugs of a disposable zeta potential cell and voltage was applied through 
two gold plated electrodes (Figure 3.1). Particles movement under the influence of an 
applied electric field was exploited to determine the zeta potential of the liposome 





Figure 3.1: Diagram showin the zeta potential cuvette having electrode for the 
zeta potential analysis of liposomes. 
 





3.3.3    Transmission electron microscopy (TEM) 
 
 
Morphological and size examinations of freshly prepared blank liposomes, extract- 
containing liposomes were done using negative staining transmission electron 
microscopy. A droplet of the spontaneously formed liposomal samples was placed 
onto a carbon-coated copper grid (400 mesh) for about 3 minutes to permit proper 
absorption of the sample. The droplet was then dried using pieces of filter paper 
before leaving the grid for another 1 minute. A droplet of the negative stain solution 
(1% uranyl acetate) was added to the surface of the grid. After 1 minute, the copper 
mesh grid was dried using pieces of filter paper and kept in a filter paper lined petri 
dish. The size, morphology and lamellarity of liposomes were then viewed using a 
Philips CM12 transmission electron microscope and photographed at an accelerating 
voltage of 80 kV. 
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3.4 Statistical Analysis 
 
 








3.5.1 Size  and   size  distribution   of   extract-free   liposomes   prepared   by 
conventional thin film method and proliposome method 
 
 
The study investigated the characteristics of extract-free liposomes prepared from 
SPC and cholesterol (4:1) or HSPC and cholesterol (4:1). Hydrogenated PC or 
partially hydrogenated PC instead of unsaturated egg PC in liposome preparation 
affects the stability of liposomes. Phospholipids with unsaturated acyl chains are 
subject to oxidation, which may affect the permeability of the bilayers and the in vivo 
performance of the liposomes (Smolen and Shohet, 1974; Konings, 1984). Thus, it is 
important to compare the characteristics of HSPC and SPC before performing the 
tissue culture studies on glioma cell lines. Moreover, liposomes generated from 
proliposomes were compared to liposomes generated using the thin film hydration 
method. The comparison was conducted in terms of size, size distribution and zeta 
potential. The effect of lipid composition using SPC and HSPC was also studied. 
 
As  shown  in  Figure  3.2  A,  using  blank  liposomes  (i.e.,  containing  no  drug  or 
extract), vesicles generated from proliposomes had significantly (P < 0.05) smaller 
size than liposomes prepared by the conventional method for both SPC and HSPC. 
Moreover, student t-test analysis of particle size by conventional and proliposome 
method confirmed that HSPC produced significantly (P < 0.05) larger liposomes as 
compared to SPC (Figure 3.2A). Laser diffraction studies conducted by Elhissi et al. 
(2006a) have shown that ethanol-based proliposome method produces smaller size 
liposomes than thin-film conventional method (Elhissi et al. 2006a), which agrees 
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with the findings in the present study. The reason for the reduced size may be due to 
the presence of fewer bilayers as a result of ethanol inclusion in liposomes generated 
from   proliposomes.   The   presence   of   ethanol   causes   interdigitation   of   the 
phospholipid  bilayers  by  converting  the  gel  phase  into  liquid  crystalline  phase 
(Elhissi et al. 2006a). 
 
Figure 3.2B represents the span (i.e. polydispersity) of liposomes. When SPC was 
used to prepare liposomes, there was no significant difference in the span regardless 
of the method of preparation. However, liposomes made from HSPC phospholipid 
showed significantly (P < 0.05) higher span values when liposomes were prepared by 
the conventional method (Figure 3.2 B), indicating that when high Tm lipids are used, 
proliposomes could generate liposomes with lower polydispersity. Moreover, for 
both methods, the span was significantly higher by using HSPC phospholipid to 
manufacture liposomes. Higher span values indicate possible aggregation of the 
vesicles. This study has overall demonstrated that proliposomes-generated liposomes 






Figure 3.2: Bar charts showing A) Particle Size and B) Size distribution of 
extract-free liposomes prepared by thin film or ethanol-based proliposome 
methods using SPC or HSPC. Data are mean ± S.D and n=3. * P < 0.05 for 
conventional method compared to proliposome method. 
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The median size and size distribution of SPC and HSPC liposomes including 
Momordica charantia were analysed in this study. The effect of extract type in terms 
of plant organ (WF, FA or SA) and source (Africa, China or India) was investigated 
for comparision. Similarly, the study also investigated the effect of extract 









When SPC was employed, the size of liposomes using the African Momordica 
charantia (FA and WF) was significantly (P < 0.05) increased as the concentration of 
the dried extract increased (Figure. 3.3 A). By contrast, for the SA extract, the 
particle size did not significantly change (P > 0.05) by increasing the extract 
concentration (Figure 3.3 A). Similarly, particle size using the FA component of the 
plant was the largest compared to the size of vesicles prepared by hydration with the 
SA or WF extracts (Figure 3.3 A) but this was not significant. This might be 
attributed to the difference in the extracted compounds from various plant organs, 
leading to differences in the bilayer packing and vesicle size. It has been previously 
shown that materials that interact with the liposome bilayers are capable of affecting 




Using SPC phospholipid, liposomes containing the African Momordica charantia 
(FA, SA or WF) showed a slight, but a significant (P < 0.05) increase in the span 
value, indicating some aggregation of the liposomes upon the inclusion of higher 
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extract  concentrations  (1.05  -  1.75  mg  /  ml)  as  compared  to  the  extract-free 
liposomes (Figure 3.3 B). This again confirms the influence of the biochemical 
compounds extracted from the plant on the bilayer characteristics and liposome size. 
 
As a large number of natural product modulators have been discovered over the 
years, natural products such as curcumin flavonoids (natural products) can modulate 
ABC drug transporters (Bakare et al. 2010). 
 
Similar to the results obtained using SPC, the size of HSPC-made liposomes with the 
African  Momordica  charantia  (FA,  SA  or  WF)  was  significantly  (P  <  0.05) 
increased at high extract concentrations as compared to the extract-free liposomes 
(Figure 3.3 C). Size measurements of the African Momordica charantia was the 
largest when using the SA extract followed by the extracts of the FA and WF. Bakare 
et al. (2010) have conducted a nutritional and chemical evaluation of Momordica 
charantia showing that the crude fat content in the seeds is higher than that in the 
fruit and leaf organs of Momordica charantia. This possibly indicates that the crude 
fat content of the seed of Momordica charantia may be the reason behind liposome 
aggregation or fusion. Previous studies have demonstrated that the increased 
hydrophobicity of liposome surfaces can  cause fusion between adjacent vesicles 
(Ohki and Arnold, 1990). 
 
When the size distribution (i.e. span) of the HSPC liposomes was studied using only 
the FA and WF, and when used at highest concentration (1.75 mg /ml) caused an 
increase in the span value compared to the extract-free liposomes. By contrast, the 
SA extract caused inconsistency of the span measurements and showed no clear 
trend upon increasing the extract concentration (Figure 3.3D). 
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Thus,  in  general,  both  SPC  and  HSPC  using  all  African  Momordica  charantia 
extracts caused an increase in size and span of liposomes, suggesting that the 
extracted constituents have influenced the packing of the liposome bilayers with a 
subsequent increase in liposome size. 
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Figure 3.3: Diagrams showing the characterisation of African Momordica 
charantia extracts (FA, SA and WF) associated liposomes- A) Particle size and B) 
Size distribution of SPC liposomes and C) Particle size and D) Size distribution 
of  HSPC  liposomes.  Data  are  mean  ±  S.D,  n=3  *P  <  0.05  for  Momordica 
charantia liposomal formulations compared to drug free liposomal formulation. 
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SPC liposomal formulations of Chinese Momordica charantia (FA or WF) showed 
no significant (P > 0.05) change in the measured particle size and size distribution at 
all concentrations (Figure 3.4A and Figure 3.4B). However, FA SPC formulation 
demonstrated a marked and significant increase (P < 0.05) in the span value at the 
concentration of 0.7 mg / ml, indicating aggregation of liposomes.  This finding is 
difficult to justify based on the present data, suggesting that further studies are 
needed in the future to explore the effect of these extracts on the liposome bilayers. 
This  investigation  can  be  conducted  using  sophisticated  and  robust  thermal 
techniques  such  as  differential  scanning  calorimetry  or  solution  calorimetry. 
However, for the SA extract formulation, although it did not show any change in the 
size at the low concentrations (from 0.35 mg / ml to 1.4 mg / ml), a significant (P < 
0.05) size increase at the highest extract concentration (1.75 mg / ml) was observed 
when compared to the extract-free SPC liposomes (Figure 3.4 A). Seed extract of 
Momordica charantia has high contents of crude fat (Bakare et al. 2010), which 
might be the causative of vesicle aggregation. Thus, liposomes at the highest SA 
extract concentration were much larger than the extract-free liposomes for both 
phospholipids  (Figure  3.4  A  and  C).  When  using  SPC,  Chinese  Momordica 
charantia SA showed a significant (P < 0.05) and drastic increase in the span with 
uneven size distribution when the extract concentration was higher than 0.7 mg/ml 
(Figure   3.4B).   These   results   support   the   finding   of   Hussain   (2010),   who 
demonstrated that size of liposomes increased with increasing the cucurmin 
concentration. Cucurmin is a hydrophobic phytochemical compound that is also 
present in Momordica charantia and has a great tendency to associate with the 
91  
hydrophobic regions of liposome bilayers. Also, there might be many other 
compounds present in the extract having affinity towards the hydrophobic region and 
making the size of liposomes larger and the size distribution wider. 
 
HSPC liposomal formulations of Chinese Momordica charantia FA and WF did not 
show  any  significant  (P  >  0.05)  change  in  the  particle  size  at  the  lower 
concentrations (0.35 mg / ml and 0.7 mg /ml). In contrast, a significant (P > 0.05) 
increase of the particle size at the higher concentrations (1.4 - 1.75 mg / ml) was 
demonstrated as compared to the drug free liposomes (Figure 3.4 C). By contrast, SA 
of the Chinese Momordica charantia liposome formulation showed a significant (P < 
0.05) increase as a result of extract inclusion (0.35 – 1.75 mg / ml) as compared to 
the extract-free liposomes (Figure 3.4 C). The Chinese Momordica charantia seed 
contains 90% eleostearic and 2–3% stearic acid (Chang et al. 1996). Eleostearic is 
unsaturated fatty acid.  Unsaturated fatty acid causes oxidation of liposome at high 
temperature. The reason for instability of liposomes is oxidation of unsaturated fatty 
acid, which causes the phospholipid to aggregate and make the liposome unstable 
(Lee et al. 1998). Momordica charantia seed extract contains 90% eleostearic 
(unsaturated fatty acid) and this can also be the reason for increased the size and size 
distribution of the liposomes prepared from SPC and HSPC phospholipid containing. 
 
HSPC liposomal formulations of Chinese Momordica charantia (FA, WF and SA) 
had a significantly (P < 0.05) lower span values as compared to the extract-free 
HSPC liposome (Figure 3.4D), again confirming the need for conducting highly 
sensitive thermal studies on the liposome bilayers. 
92  
i 
. • • 
A)   8 + orugfree • chi nese FA A Chi nese SA X chinese WF 
 













0  0.35  0.7 1.05  1.4  1.75 
















* I I i 
* 










:R: ' I 
0  0.35  0.7 1.05  1.4  1.75 








Figure 3.4: Plots showing the characterisation of Chinese Momordica charantia 
extracts (FA, SA and WF) associated liposomes- A) Particle size and B) Size 
distribution of SPC liposome, C) Particle size and D) Size distribution of HSPC 
liposomes. Data are mean ± S.D, n=3 *P < 0.05 for Momordica charantia 
liposomal formulations compared to drug free liposomal formulation. 
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The SPC liposomes of Indian Momordica charantia (FA, SA and WF) had either 
similar or slightly different particle size as compared to the extract free liposomes 
(Figure 3-4A). Also, the size distribution of SPC liposomes (FA or WF) and extract- 
free liposomes were similar. In contrast, SPC liposomes on inclusion of SA extract 
of Indian Momordica charantia had slightly larger span values and inconsistent size 
distribution with increasing concentrations of the extract liposomes (Figure 3-5B). 
 
The  HSPC  liposomal  formulations  of  Indian  Momordica  charantia  (SA) 
demonstrated a significantly (P < 0.05) larger size with the increasing the extract 
concentration (0.35 – 1.75 mg / ml) (Figure 3.5 C). The same observation was seen 
for the FA extract but up to 1.4 mg/ml (1 -1.75 mg / ml). 
 
When using HSPC liposomes, the range of concentrations of FA and SA extracts had 
only minor but not significant differences (P > 0.05) in the span with all values being 
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Figure 3.5: Plots showing the characterisation of Indian Momordica charantia 
extracts (FA, SA and WF) associated liposomes- A) Particle size and B) Size 
distribution of SPC liposome, C) Particle size and D) Size distribution of HSPC 
liposomes. Data are mean ± S.D, n=3 *P < 0.05 for Momordica charantia 
liposomal formulations compared to drug free liposomal formulation. 
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3.5.3 Particle   size   and   size   distribution   of   SPC   and   HSPC   liposome 
formulations including PTX 
 
 
Figure 3.6 (A) illustrates the relationship between paclitaxel concentration in 
formulation and the particle size of SPC and HSPC liposomes. The concentrations of 
Paclitaxel used were 0, 0.35 mg, 0.7 mg, 1.05 mg, 1.4 mg and 1.75 mg / ml. The size 
of Paclitaxel liposomes using SPC phospholipid was in the range of 3 – 8.9 μm, and 
HSPC phospholipid was in the range of 5.81 – 11.21 μm (Figure 3.6B). Moreover, 
the increase in paclitaxel concentration resulted in an increase in liposome size 
regardless of the phospholipid type. Previous study by Balasubramanian et al. (1994) 
also agrees with the present findings. Paclitaxel has a tendency to undergo 
concentration-dependent aggregation in the hydrophobic environment causing 
intermolecular hydrogen bonding (Balasubramanian et al. 1994; Wenck et al. 1996). 
Van der Waal‘s force interaction between lipid bilayer and Paclitaxel causes 
condensation and causes closer packing of the lipid bilayer decreasing the 
permeability and fluidization of the bilayers and increase aggregations of liposomes 
(Kan et al. 2011). For each paclitaxel concentration, the size of HSPC liposomes was 
significantly (P < 0.05) larger than that of SPC vesicles (Figure 3-6 A), possibly 
because HSPC has much higher phase transition temperature than SPC. It has been 
previously reported that saturated lipids cause rigidity of the liposome membranes 
(Maurer et al. 2001). It is well known that HSPC contains high proportions of 
saturated lipids, possibly this made PTX liposomes more rigid and the disaggregation 
of liposomes during hydration less efficient. 
 
In this study, the influence of phospholipid type and paclitaxel concentration on 
liposome  size  distribution  was  also  investigated  by  measuring  the  span  of  the 
different formulations (Figure 3.7 B). The span value of Paclitaxel formulation using 
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SPC was relatively and significantly (P < 0.05) higher than that of the drug-free 
formulation (P < 0.05). When paclitaxel was incorporated in the formulations, for 
each drug concentration, SPC liposomes had significantly higher span values than 
HSPC liposomes (P < 0.05) (Figure 3.7B). This finding was unexpected since the 
larger size measurements of HSPC liposomes (Figure 3.6 A) may initially suggest 
that HSPC liposomes are more liable to aggregation and subsequently may have 
higher span values. It seems likely that HSPC liposomes have aggregated but that 
was followed by fusion of the small vesicles with the larger ones. Hence this resulted 
in an upward shift in the size but the size distribution became narrower (i.e. span 
decreased). It has been reported that lipids may precipitate by cooling which might 
lead to larger size or heterogeneity of the final liposomes (Kumar and Spandana, 
2011). It is possible that slight decreases in the temperature of HSPC liposomes 
during size measurement have caused some aggregation and subsequent fusion of the 
vesicles, which was enhanced in the presence of the hydrophobic drug Paclitaxel. 
This explains the increase in size and decrease in span when paclitaxel concentration 
is increased. 
 
These findings also indicate that paclitaxel has interacted with the liposome bilayers 
causing them to become more hydrophobic with a subsequent change in both size 
and size distribution of the vesicles. Changes of vesicle size and size distribution due 
to incorporation of paclitaxel in liposome formulations has, already been reported by 
Bernsdroff et al. (1999). They stated that paclitaxel incorporated into saturated 
phospholipids causes changes in the thermotropic phase behaviour of liposomes by 
reducing the fluidity of the gel phase. On the contrary, incorporation of paclitaxel in 
liposomes made from unsaturated phospholipids causes a decrease in the fluidity of 
the liposome bilayers (i.e. an increase in bilayer rigidity). The aqueous core of the 
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unsaturated phospholipid liposomes is larger than that of saturated phospholipid 
vesicles. Inclusion of hydrophobic drug such as paclitaxel to SPC (unsaturated 
phospholipid) liposomes may cause aggregation and rigidification of liposomes and 
might also cause paclitaxel to precipitate out and widen the size distribution of the 
formulation (Feng and Huang, 2000; Bernsdorff et al. 1999). On the contrary, HSPC 
has larger hydrophobic domain that easily incorporates paclitaxel without causing 







Figure 3.6: Bar chart showing characterisation of PTX associated liposomes- A) 
Particle size and B) Size distribution of SPC and HSPC liposomes. Data are 
mean ± S.D, n=3 *P < 0.05 for either SPC-PTX liposomal formulations or HSPC- 
PTX liposomal formulation compared to drug free liposome. 
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3.5.4 Zeta potential of liposomes prepared by conventional thin film method 
and proliposome method 
 
 
In this section of the study the zeta potential of SPC and HSPC liposomes was 
investigated. Using no drug, the thin film hydration method was compared with the 
ethanol-based proliposome technology (Figure 3.7).   Regardless of liposome 
preparation method and type of phospholipid, all formulations had negative zeta 
potential (Figure 3.7). However, there was a slight but significant (P < 0.05) 
difference was detected between different formulations (Figure 3.7).  According to 
Shenoy et al. (2011), PC liposomes prepared by the conventional method generated 
neutrally charged liposomes since PC and cholesterol are neutral lipids. By contrast, 
liposomes prepared in this study (Figure 3.7) were slightly negative with zeta 
potential values being in the range of approximately -3.5 to – 6.5 mV. The slightly 
negative surface charge of liposomes (Figure 3.7) might be attributed to the presence 
of traces of negatively charge lipids in Lipod S-100 and Phospholipon® 90 H. When 
SPC was used to prepare liposomes, both methods produced vesicles having similar 
zeta potential values (P > 0.05). By contrast, when HSPC was used, significantly but 
slightly higher negative zeta-potential measurements (P < 0.05) were demonstrated 
for the liposomes generated from ethanol-based proliposomes (Figure 3.7). The 
presence of a charge on liposomes may reduce their aggregation when compared to 
neutral liposomes. Smaller particles with higher zeta potential may exhibit higher 
stability by prevention of aggregation but can also form larger and irregular shape 
particles  (Jong  and  Keun,  1999).  This  overall  indicates  that  HSPC  liposomes 
prepared by using the proliposome method might be a bit more stable than thin-film 
hydrated vesicles in terms of stability upon storage. Further studies are required in 




Figure 3.7: Bar charts showing a comparison of surface charges of the drug free 
liposomes prepared by conventional and ethanol-based proliposomes methods. 
Data are mean ± S.D, n=3 *P < 0.05 for zeta-potential of conventional method 









3.5.5.1   African Momordica charantia extracts 
 
 
When no extract was used for hydrating the phospholipids the zeta potential was 
around -6 mV and -7.5 mV for SPC and HSPC respectively (Figure 3.8). For SPC 
liposomes, upon using ascending extract concentrations, the negative zeta potential 
tended to neutralize by using the WF extract and become positive when using SA (+6 
mV) or FA extracts (+4 mV) (Figure 3.8A). Regardless of plant organ, increasing 
extract concentrations (0.35 - 1.75 mg / ml) HSPC liposome formulations caused the 
negative surface charge of vesicle to convert from negative to positive. Thus, when 
using HSPC liposomes, positively charged liposomes with zeta potential 






extract-free liposomes having a negative zeta potential (-7.5 mV) (Figure 3.8B). This 
overall   indicates   that   the   African   extracts   may   contain   positively   charged 
constituents that could interact with SPC and HSPC liposome bilayers, causing the 
















































Figure 3.8: Plot showing the zeta-potential of African Momordica charantia 
extracts (FA, SA and WF) associated with liposomes A) SPC and B) HSPC. Data 
are mean ± S.D, n=3 *P < 0.05 for zeta-potential of African FA compared to 
African SA. 
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3.5.5.2   Chinese Momordica charantia extracts 
 
 
The zeta potential of the increasing concentrations of Chinese extract in SPC 
liposomal formulations was dependent on both phospholipid type and extract 
concentration, (Figure 3.9). For SPC liposomes, slightly negative or neutral surface 
charge of liposomes ranging between -3.86 mV to +0.26 mV were measured, as 
compared to extract free liposomes which had a negative zeta potential (-6 mV) 
(Figure 3.9A).  This indicates that Chinese Momordica charantia extracts has some 
positively charged constituents which is consistent with the findings for the African 
extract of the fruit. 
 
However,  with  HSPC  liposomes,  inclusion  of  the  extract  resulted  in  higher 
variability in the measurements. WF extract generated neural liposomes and SA 
extract generated positively charged liposomes ranging between +0.36 mV and +4.5 
mV. In contrast, the zeta potential measurements for the FA extract formulations 
were negative and in the range from -0.13 mV to -8 mV as compared to the extract- 
free liposomes (-7.5 mV) (Figure 3.9B). Overall, surface charge reversion from the 
negative range to positive range was more apparent and highly consistent for the 
African extracts compared with the Chinese extracts of the fruit (Figure 3.8; Figure 
3.9). These findings suggest that the proportion or types of fruit constituents are 
different when the fruit origin is different, indicating a significant role of climatic 








Figure 3.9: Plots showing the zeta-potential of Chinese Momordica charantia 
extracts (FA, SA and WF) associated with liposomes A) SPC and B) HSPC. Data 
are mean ± S.D, n=3 *P < 0.05 for Chinese FA compared to the Chinese SA. 
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3.5.5.3    Indian Momordica charantia extracts 
 
 
The influence of extract concentration on the zeta potential of liposomes using 
Chinese Momordica charantia (Figure 3.10) was highly similar to that produced by 
the African extract (Figure 3.8) especially when the phospholipid employed was 
HSPC. This indicates that the trend shown by the Chinese extract was different from 
the African and Indian extracts of Momordica charantia. For SPC liposomes, the 
increasing concentration of Indian Momordica charantia extract (FA), from lower to 
higher concentrations (0.35- 1.4 mg /ml) showed significant (P  < 0.05) gradual 
change  from  slightly  negative  towards  almost  neutral  surface  charge  (-1.5  mV 
towards 0.5 mV) and at the highest concentration (1.75 mg/ ml) the liposomes 
suddenly had negative zeta potential measurement (-3 mV). The negative charge was 
less intense when compared to that of extract-free liposomes (-6 mV) (Figure 3.10 
A). By contrast, the SA and WF extract liposomes continued towards having a 




The trend by using HSPC liposomes was more predictable and similar for all fruit 
organs.  The dispersion of Indian Momordica charantia extracts produces cationic 
liposomes with increasing the extract concentration (0.35 – 1.75 mg / ml). The 
positive surface charge of the liposomes was ranging from 2 – 6.7 mV compared to 
approximately -8 mV for the extract free formulation (Figure 3.10B). This may 
indicate that the Indian extracts of Momordica charantia contain positively charged 
constituents that can interact with HSPC liposomes, rendering vesicle surfaces 
positively charged. This is very interesting since the presented trend suggest that 
these liposomes are cationic and hence future investigations may involve these 









Figure 3.10: Plots showing the zeta-potential of Indian Momordica charantia 
extracts (FA, SA and WF) associated with liposomes A) SPC and B) HSPC. Data 
are mean ± S.D, n=3 *P < 0.05 for Indian FA compared to Indian SA. 
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3.5.6 Surface charge of the SPC and HSPC liposomal formulations prepared 
from ethanol based proliposome technology on inclusion of PTX. 
 
 
In Figure 3-11 the surface charge of PTX liposomes incorporated with SPC 
phospholipid showed a neutral surface charge at the lower extract concentration (0.3 
mg / ml) and a gradual increase in the negative charge of the particles from lower to 
higher concentrations (0.7- 1.75 mg / ml) ranging between -1.5 mV to 5 mV. 
Similarly, the surface charge of PTX liposomes encapsulated with SPC phospholipid 
showed significant (P < 0.05) neutral charged particle at the lower concentration (0.3 
mg / ml). The other concentrations from 0.7-1.75 mg / ml showed slightly less 
negatively charged particle in the range of – 3.6 mV to -7 mV. The results showed no 
consistency in either increase or decrease of the surface charge and it was still less 
negatively charged as compare to drug free HSPC liposomes.   PTX liposomes 
generated from SPC phospholipid produced slight less negatively charged particle as 
compared to PTX liposomes generated from HSPC phospholipid. Paclitaxel itself is 
not a pH sensitive cancer chemotherapeutic agent. The negative charge of the 
liposomes might be attributed due to the presence of the carboxylic group. The 
negatively charged liposomes are not affected by the pH difference and causes 
negligible zeta-potential changes (Yanga et al. 2009). Therefore, on inclusion of PTX 
in the negatively charged liposomes, regardless of the phospholipid does not affect 
the zeta-potential due to changes of the pH environment. The role of liposome 
membrane composition in the stability of paclitaxel-containing formulations is 




Figure 3.11: Bar charts showing zeta potential of Paclitaxel liposomes prepared 
from SPC and HSPC phospholipids by the ethanol-based proliposome. Data are 
mean    ±    S.D,    n=3    *P    <    0.05    for     HSPC    compared    to    SPC. 
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3.5.7.1   Drug-free liposomes 
 
 
TEM as shown in Figure 3.12 represents the morphology of drug-free liposomes 
prepared from SPC and HSPC phospholipids (phospholipid: cholesterol; 4:1). Figure 
3.12A represents SPC drug free liposome having large oligolamellar vesicles with 
large aqueous core. By contrast, HSPC liposomes seemed to be of smaller aqueous 
cores and having higher polydispersity as a group of small vesicles were seen to 










Figure 3.12: Electron micrographs of the drug free liposomes prepared from proliposome showing A) SPC liposomal formulation 
having oligolamellar structure with large aqueous cores b) HSPC liposomal formulation having mixture of oligolamellar and 











3.5.7.2   Liposomes on inclusion of Momordica charantia extracts 
 
 
TEM  as  shown  in  Figure  3.13  represents  the  morphology  of  SPC  and  HSPC 
liposome upon using concentrations (0.35 mg / ml to 1.75 mg / ml) of Momordica 
charantia extracts (FA, SA and WF) from Africa, India and China. On the 
incorporation of Momordica charantia extracts from different countries in SPC or 
HSPC liposomes were oligo-lamellar and multilamellar (Figure 3.13A and Figure 
3.13B). TEM also shows that HSPC vesicles have tendency to aggregate and fuse as 
 
























































Figure 3.13: Electron micrographs of the Momordica charantia liposomal formulation prepared from proliposome showing A) 
SPC liposomal formulation and b) HSPC liposomal formulation having mixture of oligolamellar and multilamellar vesicles. 










3.5.7.3   TEM of liposomes on inclusion of Paclitaxel 
 
 
TEM  as  shown  in  Figure  3-14  represents  the  morphology  of  SPC  and  HSPC 
liposome upon using concentrations (0.35 mg / ml to 1.75 mg / ml) of PTX. On the 
incorporation of PTX extracts in SPC or HSPC liposomes were Oligo-lamellar and 
multilamellar (Figure 3.14A and Figure 3.14B). TEM also shows that SPC vesicles 
have tendency to aggregate and fuse as huge vesicles were observed as compared to 




























































Figure 3.14: Electron micrographs of the PTX liposomal formulation prepared from proliposome showing A) SPC liposomal 
formulation and b) HSPC liposomal formulation having mixture of oligolamellar and multilamellar vesicles. Micrographs are 

















SPC and HSPC liposomes prepared by conventional method produce large size 
negatively charged drug free liposome as compared to liposomes prepared by 
proliposome method. On the inclusion of Momordica charantia extracts (FA, SA and 
WF) from Africa, China and India, HSPC phospholipid generated large size vesicles 
as compared to SPC. The change of size of the particle might be due to the difference 
in   the   phase   transition   temperature   (Tm)   of   both   the   phospholipids.   SPC 
phospholipid has low phase transition temperature, whereas, HSPC phospholipid has 
high  phase  transition  temperature.  Therefore,  during  cooling  process  of  the 
liposomes formulation might be causing the phospholipid to form aggregates. SPC 
liposome generates large size distribution as compare to HSPC liposome may be due 
to larger entrapment of the hydrophilic material and formation of aggregation of SPC 
liposome. The surface charge of SPC and HSPC liposome were less negative, neutral 
or positive as compared to the drug free liposomes.  The surface charge of the 
liposome reverts back to positive direction on the inclusion of increasing 
concentration of the Momordica charantia extract. This result indicates that the 
extract contains some positive constituents. On inclusion, of paclitaxel hydrophobic 
molecule in the HSPC phospholipid produces large size liposome as compare to SPC 
phospholipid.  While,  both  the  phospholipid  generated  large  size  liposome  as 
compare to the drug free liposome. SPC produce higher span value on inclusion of 
PTX. As SPC has less hydrophobic domain to accommodate hydrophobic drug PTX 
and might be causing the drug to precipitate out. HSPC gave less span value on 
inclusion of PTX drug as compared to drug free HSPC liposomes. Regardless of the 
phospholipids, both the formulation produces anionic liposomes on the inclusion of 
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PTX drug. But, the surface charge of both the phospholipid was slightly less as 




































Chapter 4. Tissue 
 









The aim of this chapter was to use phospholipids derived from soy to manufacture 
solvent-based proliposomes, which could be used to generate phospholipid vesicles 
(liposomes) when aqueous phase (e.g. water) is added. Water-soluble materials were 
extracted from the fruit Momordica charantia and the soluble extracts were used to 
hydrate the proliposomes and convert them into liposomes. The efficacy of the 
resultant liposome formulations on the viability of glioma cells by MTS cytoxic 







4.2.1    Equipment and materials used in cell culture 
 
 
New Brunswick Scientific (CO281R) - water jacketed CO2 incubator, water bath, 
laminar flow hood, inverted phase contrast microscopes (Zeiss Axiovert, Germany), 
weighing balance, Tecan plate reader (Tecan Austria GmbH, 2004 model), 
refrigerator, freezer (- 20°C), deep freezer (-80°C), centrifuge machine, electrical 
aspirator, vortex mixer, 2, 20, 200 and 1000 μl pipettes, motorized pipette controller, 
75 cm2/25 cm2 culture flasks, sterile forceps, aluminium foil, 5 and 10 ml disposable 
 
plastic pipettes, 15 ml and 50 ml centrifuge tubes (Fisher Scientific, UK), Cryovials, 
 
―Mr.  Frosty‖  freezing container and liquid nitrogen, DMSO (Sigma Aldrich, UK), 
 
0.22  μm  and  0.44  μm  sterile  filters  (Fisher  Scientific,  UK),  syringes  (Fisher 
Scientific, UK), pasteur pipettes (Fisher Scientific, UK), universal bottles, 5 ml 




4.2.2    Glioma cell lines 
 
 
Table 4.1 represents various grades of cancerous and non-cancerous glial cells on the 
basis of their clinical pathological condition and origins. They are bought from 
different companies for the tissue culture experiments. 
 
Table 4.1: Some types of brain cell lines used in the study with grades and 
companies supplying them. 
 
Cell lines Diagnosis Grade Company 
1.   1321N1 Astrocytoma II ECACC,UK 
2.   U87-MG Glioblastoma 
 
astrocytoma 
IV ECACC, UK 










4.2.3    Liposomes prepared from ethanol-based proliposome 
 
 
The preparation of empty liposomes or liposomes including Momordica charantia 
extracts (FA, SA and WF) from different countries or by using PTX drug were 




4.2.4     Media and supplements required for cell culture 
 
 
DMEM (Dulbeco‘s Modified Eagle‘s Medium), MEM (Minimal Essential Medium), 
Foetal  bovine  serum  (FBS),  trypsin,  L-Glutamine,  non-Essential  Amino  Acid 
(NEAA) and sodium pyruvate were all bought from Lonza, UK. 
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4.2.5    Chemicals and Reagents 
 
 
• Ethanol and Methanol (Fisher Scientific, UK) 
 
 
• Phosphate Buffered Saline (PBS) tablets (Sigma, Aldrich, UK) –2 tablets were 
dissolved in 400 ml of water and stored the solution at 4 °C 
 











4.3.1    Composition of medium for the glioma cell lines used in the study 
 
 
(i)   GOS-3- Dulbecco‘s Modified Eagle Medium (DMEM-500 ml), 10% Foetal 
bovine serum (FBS-50 ml) and 4 mM L-glutamine (10 ml). 
(ii)  1321N1  -  Dulbecco‘s  Modified  Eagle  Medium  (DMEM-500  ml),  10% 
Foetal bovine serum (FBS-50 ml) and 2 mM L-glutamine (5 ml). 
(iii) U87-MG  and  SVGP12  –  Eagle‘s  Minimal  Essential  Medium  (EMEM- 
 
500ml), 10% Foetal bovine serum (FBS-50 ml), 2 mM L-glutamine (5 ml), 
 







4.3.2 Cell culture and passaging of the primary glial cells (1321N1, U87-MG, 
Gos-3 and SVGP12) 
 
 
Culture medium, PBS and trypsin (sterile) were removed from the 4°C fridge and 
subsequently placed in a water bath at 37°C for 30 min in order to equilibrate. The 
laminar  flow  hood  was  turned  on  for  10  min  prior  to  commencement  of  the 
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experiment in order to purge the air inside the cabinet. The cells were incubated at 
 
37°C in an atmosphere of 5% CO2 in air. Thereafter, the cells were examined under 
an inverted contrast microscope to note confluence and their general health. The 
flask was passaged when the cells had reached 70-80% confluence. 
 
The medium was aspirated from the cultured flask and washed with sterile PBS (5 ml 
if 75 cm2 flask and 2 ml if 25 cm2 flask were used) in order to remove any traces of 
serum from the cells, thus preventing the possible inactivation of the trypsin by the 
serum components. Trypsin solution (2 ml if 75 cm2 flask and 1 ml if 25 cm2 flask) 
was pipetted in the flask and incubated at 37°C in an atmosphere of 5% CO2  in air 
for 3-5 min until the cells started to detach. This was confirmed by microscopic 
investigation at intervals. The cells were left in trypsin for an appropriate length of 
time to avoid damage. Complete Growth Medium (2 ml) was then added to the flask 
to inactivate the trypsin and the cells were pipetted up and down to break down any 
large cell aggregates. The cell suspension was removed from the flask and placed 
into a 15 ml centrifuge tube followed by centrifugation at 1000 r.p.m for 5 min. After 
centrifugation, the supernatant was aspirated leaving the cells pellet at the bottom of 
the centrifuge tube. Depending upon the cell pellet density, a volume of 1 ml to 2 ml 
of fresh medium was suspended in the centrifuge tube. The pellet cells were mixed 
properly in the medium. A volume of 20 μl of trypsinised cell suspension and 80 μl 
of tryphan blue (1:5) were mixed together and counted using the haemocytometer 
employing 1 ml of cell suspension. The total volume of the cell suspension present in 
the centrifuge tube was required to make 1 or 2 flasks. The cell suspension was 
divided in one or more flasks (depending on the cell density) and fresh growth 
medium (10 ml to 12 ml if 75 cm2 flask and 5 ml if 25 cm2 flask) was added to the 
 
flasks, which was then placed in a 5% CO 
2 
incubator to continue cell growth. In 
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addition, the same cells were seeded in 96 well plates and approximately more than 1 
million cells were frozen down in liquid nitrogen depending on the number of cells 




4.3.3    Cell Counting Method 
 
 
A volume of 20 μl of cell suspension and 80 μl of tryphan blue were pipetted into a 
micro-centrifuge tube and mixed together. A cover slip was gently placed over the 
chambers of the haemocytometer, and a volume of 20 μl of the cell suspension was 
slowly pipetted against each short side of the cover slip so that the suspension could 
spread into each chamber. The haemocytometer was placed onto the stage of an 
inverted phase contrast microscope (10X) and focused on the centre 25 squares of 
one chamber. The numbers of cells in these squares were then counted. These steps 
were repeated for the other chambers. The average number of cells in the centre grid 
 
2 4 
(1 mm ) of each chamber was calculated. This number was multiplied by 10  to 
 
obtain the number of cells per 1 ml of suspension. The total number of cells was 
calculated by multiplying the number of cells per 1 ml by the total volume of the cell 






Figure 4.1: Diagram showing a hemocytometer for cell counting under objective 







4.3.4    Growth curve 
 
 
In this study, the standard growth curve of glioma cells was constructed. The master 
flask was passaged and cell count was noted. Approximately 0.23 x 106 (day-0) cells 
were taken and seeded in five sub-flasks. The sub-flasks were incubated at 37ºC in 
5% of CO2  incubator. Each sub-flask was passaged on regular basis from day-1 till 




4.3.5    Plating of cell lines 
 
 
Cell suspensions of 13121N1, Gos-3, U87-MG, and SVGP12 were acquired during 
passaging and were diluted in 1:10 ratio of cell suspension in the media. The required 
volumes of cell suspension and fresh medium volumes were calculated based on the 
cell count. The dilutions were made till 200 μl suspensions consisted of 2000 cells. A 
96 well plate was taken and 200μl of suspension was added in each well. After the 
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4.3.6    Measurement of MTS assay 
 
 
The plate was removed after 24 hrs of incubation in the 5% CO2 incubator at 37ºC. 
The media in the plates were removed on sterile tissue paper. Another 150 μl of 
media and 50 μl of Momordica charantia (whole fruit, fruit or seed) extracts, 
Paclitaxel or liposomal dispersions of Momordica charantia  or liposomal Paclitaxel 
were added to the wells and incubated in 5% CO2  incubator at 37ºC for another 12 
hours. The suspension from the plates was again removed and all the plates were 
washed with PBS. Again 200 μl of respective medium was added to all the plates and 
20 μl of MTS reagent was added to all the plates in the absence of light. These plates 
were  incubated  at  37ºC  in  5%  CO2   incubator  for  two  hours.  Absorbance  was 
measured using the Tecan plate reader. The software used for absorbance assay was 
XFLUOR4GENIOSPRO Version: V 4.53 (Year, 2004). The measurements were set 
up by adjusting the absorbance at 492 nm, type of the plate was GRE 96ft pdf, 
temperature was set at 22.5ºC, and the shaking and settling time was conducted for 2 
minutes. The cell viability was measured using cellTitier 96 aqueous absorbance 





Figure 4.2: Flow diagram showing preparation and use of CellTiter 96® AQueous 







4.3.7    Statistical analysis 
 
 
MTS cell viability assay experiments were performed in triplicate. Plotted the graph 
of cell viability absorbance in percentage measured at 492 nm and apoptosis 
luminescence on Y-axis and concentration of drug in percentage on X-axis. The 
results were expressed as mean ±Standard Deviation (SD) from three independent 
experiments. Statistical analysis was performed using SPSS. All the data were 
evaluated for unpaired variables to compare two or more groups by paired Student‘s 











4.4.1 Growth curve study of the four different cell lines; 1321N1, Gos-3, U87- 
MG, and SVGP12 
 
 
Figure 4.3 shows tryphan blue cell counting method revealing the growth pattern of 
the glioma cell lines 1321N1, GOS-3, U87-MG and the normal glial cells line 
SVGP12 in the culture for 10 days. The results observed in the graph show gradual 
proliferation of all the four cell lines from day 0 to day 6 and sudden decrease in the 
proliferation from day 7 to day 10. The proliferation of 1321N1 and Gos-3 is 
comparatively higher compared to SVGP12 and U87-MG cells at the initial stage. 
However, in a later stage, a sudden drop in the viability at a greater rate, as compared 
to, SVGP12 and U87-MG cells was observed. The drop in the viability of 1321N1 
might be due to lack in the nutrition, in the media. Since most of the nutrients were 
utilized at the early stage of the growth period. Where as, U87-MG (i.e. the grade IV 
aggressive  cells)  and  SVGP12  normal  glial  cells,  initially  grew  slowly,  so  less 
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nutrients were utilized and the extra component used in the U87-MG and SVGP12 
media provided extra nutrition. This extra nutrition helps the cells to keep 
proliferating for longer period of time. Low-grade glioma may appear to contain a 
high density of normal cells and a growth rate of less than 2%. Anaplastic glioma 
exhibits more atypical cells with pleomorphic nuclei, growth rate in 5-10% range but 
no evidence of necrosis. In contrast, U87-MG proliferated slowly at the initials days 
but seemed to show an increase in the proliferation rate after a few days. Gliomas 




Figure 4.3: The growth curve of 1321N1, Gos,-3, U87-MG, and SVGP12 cell lines 
using trypan blue cell counting method under inverted microscope at 








The  glioma  cell  lines  1321N1,  Gos-3  and  U87-MG  and  normal  glial  cell  line 
 
SVGP12  were  treated  with  water  +  0.002%  ethanol  (ETOH),  drug  free  HSPC 
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liposomes or drug free SPC liposomes as shown in the Figure 4.4. Water + 0.002% 
ETOH did not show any marked effect on the inhibition or growth of the normal or 
glioma cell lines. SPC phospholipid contains linoleic acid as the fatty acid. It has 
been reported that linoleic acid is toxic to tumour cells with little or no cytotoxic 
action on normal cells (Lu et al. 2010). The results shown in Figure 4.4 did not agree 
with the findings of Lu and co-workers (2010) since no marked effect of SPC on any 
of the cell lines was observed. In contrast, HSPC drug free liposome showed an 
increase in the viability of the normal glial cells and U87-MG high-grade glioma 
cells. HSPC liposomes contains high amount of palmitic and stearic acid. Saturated 
fatty acids such as palmitic acid and stearic acid show little or no tumour promoting 





Figure 4.4: Bar chart showing treatment of glioma cell lines 1321N1, Gos-3 and 
U87-MG and normal glial cell SVGP12 with water +0.002% ETOH, SPC and 
HSPC  liposomes.  Data  are  mean  ±  S  D;  n=3;  *P  <  0.05  for  treated  cells 
compared to control. 
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PTX drug has a unique mechanism of action by suppressing microtubules that leads 
to mitotic arrest. However, PTX has a very low solubility in conventional aqueous 
vehicles (e.g. water). Liposomes were found to be a practicable approach for the 
therapeutic and effective use of PTX because they may improve its toxicological and 
pharmacological characteristics (Koshkina et al. 2001). Figure 4.5 shows that 0.35 
mg / ml of PTX with and without liposomes, elicits inhibition of the cancerous 
(1321N1,  Gos-3,  U87-MG)  and  non-cancerous  glial  cell  lines  (SVGP12)  as 
compared to the untreated cells. Low-grade glioma 1321N1, showed significant (P < 
0.05) decrease in their growth as compared to the other cell lines investigated (Gos-3, 
U87-MG and SVGP12). The results have also indicated that the inclusion of PTX 
within either SPC or HSPC liposomes causes higher toxicity to the glioma cells as 
compared  to  PTX  alone.    On  the  other  hand,  either  PTX  with  SPC  or  HSPC 
liposomes was less toxic to the glial cells as compared to PTX alone. Thus, result 
proved the advantage of using liposomes, which might be helpful to improve the 
therapeutic index of PTX (Figure 4.5). PTX was used as a positive control in the 
experiments. The PTX with and without liposomes showed maximum inhibition of 
cell as compared to Momordica charantia extracts from Africa, China or India as 





Figure 4.5: Bar charts showing treatment of glioma cell lines 1321N1, Gos-3 and 
U87-MG and normal glial cell SVGP12 with PTX, SPC-PTX and HSPC-PTX 
liposomes as compared to untreated cell lines (100%). Data are mean        ± S D; 




4.4.4    Effect  of  Momordica  charantia  extracts  and  Momordica  charantia 
 
liposomes on the cell lines 
 
 
Cancer prevention by the use of naturally occurring dietary substances is considered 
a practical approach to reduce the ever-increasing incidence of cancer (Baker, 2010). 
A vegetable commonly eaten in India, China and Africa called bitter melon (also 
known by the botanical name as Momordica charantia) has been shown in several 
previous studies to have a beneficial effect by reducing the levels of blood sugar and 
cholesterol (Anila et al. 2000; Raj et al. 2005; Islam et al. 2011). Momordica 
charantia contains glycosides such as mormordin, anti-oxidants, vitamin C, 
carotenoids, flavanoids, and polyphenols (Anila et al. 2000; Raj et al. 2005). It also 
contains terpenoids, isoflavones, anthocyanins, amino acids, minerals, and other 
antioxidants that might protect against cancer, cardiovascular diseases, diabetes and 
hypertension (Islam et al. 2011). Momordica charantia extract contains both chemo- 
preventive  and  suppressing  agents  (Wattenberg,  1992;  Chiampanichayakul  et  al. 
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2001). In 1992, Wattenberg discussed chemo preventive agents as blocking agents 
that prevent carcinogens from either reaching or reacting with critical target sites, 
and as suppressing agents that prevent evolution of the neoplastic process in cells 
that otherwise would become malignant. Other phytochemicals that have been 
documented with cytotoxic activity are a group of ribosome-inactivating proteins 
named alpha- and beta-momorcharin, momordin, and cucurbitacin B. A chemical 
analog of bitter melon proteins was extracted and named MAP-30 and its discoverers 
reported that this compound is able to inhibit prostate tumor growth. Studies involves 
the antitumor activity of the entire plant of bitter melon studies reported that a water 
extract can block the growth of rat prostate carcinoma. Hot water extract of the entire 
plant can inhibit the development of mammary tumours in mice (Cunnick et al. 1990; 
About herb, 2007). A study by Saint Louis University Scientists has provided 
evidence that this plant triggers a chain of events on a cellular level that stops breast 
cancer cells from multiplying and also kills them (Garau, 2003). Figure 4.6 A and B 
shows the effect of Momordica charantia extract and Momordica charantia extract 
included within the liposome, on low grade 1321N1 and Gos-3 cell line, high grade 
glioma U87-MG and normal glial cell SVGP12. The extract was  obtained from 
whole fruit of Momordica charantia of African origin and applied on the cell lines. 
The results illustrated the significant (P < 0.05) steady decrease in the proliferation of 
cells with increasing concentrations (0.35 -1.75 mg / ml) as compared to untreated 
cells. Inclusion of the extract within liposomes showed less proliferation of the glial 
non-cancerous cells as compared to the cancerous cells treated with the extract alone. 
Therefore, the results demonstrated that liposomes could be associated with large 
proportions of active components, facilitate their interaction with the cancerous cells 
and help to combat the cancer. Bisht et al. (2007) performed and experiment on 
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curcumin which is a yellow polyphenol extracted from turmeric. They showed that 
curcurmin is much less soluble in water. Thus, they increased the solubility of 
cucurmin by using liposomes, resulting in anti-cancer properties against pancreatic 
cancer (Bisht et al. 2007). Similarly, in the present study, liposomes may have 
improved the solubility of Momordica charantia components similar to cucurmin, 
flavonoid and large proteins etc. These active components in the liposomes have 










Figure 4.6: Effect of Momordica charantia extract with and without liposome on 
A) low grade tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG 
and also normal cell glial cell line SVGP12 as compared to untreated cell lines. 
Data are mean ± S D; n=3; *P < 0.05. 
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4.4.5 Inclusion of Momordica charantia extracts from different plant origins 
into SPC or HSPC liposomes 
 
 
Anti-oxidants, like α- tocopherol in the formulation, were shown to reduce auto- 
oxidation of lipid components and others and prolong the shelf lives of liposomes 
(Hunt and Tsang 1981). Similarly, anti-oxidants from Momordica charantia fruit 
might also be assumed to prolong the shelf life of liposomes. PC represents a far 
more pleasant means for dietary choline repletion than choline itself. Also, PC is an 
excellent  emulsifier  that  enhances  the  bioavailability  of  the  co-administered 
nutrients. Antioxidant nutrients and especially the flavonoids are likely to be better 
absorbed in combination with PC (Buzzelli et al. 1993), for instance, the B vitamins, 
minerals, and numerous other nutrients. In The present study, Momordica charantia 
containing cancer inhibiting components were included in saturated and unsaturated 
soy-derived phospholipid PCs, namely HSPC and SPC, respectively. These 
phospholipids are known to be non-toxic. The treated and untreated cells were 
incubated for 24 hours with and without the African, Indian and Chinese Momordica 
charantia extracts (FA, SA and WF). The results were obtained by MTS assay 
absorbance at 492 nm. 
 
Sections 4.4.6 - 4.6.14 showed the effect of different concentrations (0.3 - 1.75 mg / 
ml) of the African, Chinese and Indian Momordica charantia extracts (FA, SA and 
WF) on viability of three glioma cell lines 1321N1, Gos-3, U87-MG and the normal 
glial cell line SVGP12, as compared to the untreated cell lines. The results obtained 
for the four different cell lines were as follows: 
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4.4.6 Effect of African Momordica charantia extracts on cancerous and non- 
cancerous glial cells 
 
 
Figure 4.7 A shows that cell viability depends on the concentration of the extract (P 
 
< 0.05) with a continuous steady decrease (cell death) in the cell viability of 1321N1 
(grade II) and Gos-3 (grade II/III), upon treatment with increasing concentrations of 
African Momordica charantia (AMC) extracts, fruit alone (FA), seed alone (SA) or 
whole fruit (WF) (0.7 – 1.75 mg / ml) as compared to the untreated cells. At the low 
concentration (0.35 mg / ml) of the extracts (FA, SA and WF), 1321N1 and Gos-3 
were not able to demonstrate marked decrease in the cell viability. Therefore, the 
viability of the cells was more or less around 100%, but the next concentrations (0.7 
mg / ml to 1.75) showed a gradual decrease as compared to the untreated cells 
(Figure 4.7 A). 
 
Figure 4-7 B showed no significant (P > 0.05) changes in the viability of U87-MG 
(grade IV) and SVGP12 (normal glial cells) on the treatment with AMC extracts 
(FA, SA and WF). Using the U87-MG cells, except for the concentration 1.75 mg / 
ml of the AMC- FA extracts their was a, slight but not significant (P > 0.05) decrease 
in the cell viability of U87-MG. Figure 4.7 A, B shows FA extract to exhibit 
maximum inhibition of 1321N1, Gos-3 and U87- MG cell line compared to other SA 
and WF extracts. AMC-FA extract evokes more effect on cell viability of 1321N1 
cell line followed by Gos-3, U87-MG and SVGP12 (Figure 4.7 A, B). AMC extracts 
were more effective on low-grade glioma 1321N1 and Gos-3 than on the high-grade 
glioma U87-MG but there was no significant (P > 0.05) changes in the viability of 
the SVGP12 normal glial cells. Garau et al. (2003) reported that fruit extracts are 
found  to  significantly activate  the  liver  enzymes  glutathione-S-transferase, 
glutathione peroxidase and catalase. These enzymes showed a depression following 
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exposure to the anti-cancerous constituents of Momordica charantia fruit during 
carcinogenesis mediated their modulatory effect on enzymes of the biotransformation 






Figure 4.7: Dose response curves showing the effect of African Momordica 
charantia  extracts  (FA,  SA  and  WF)  on  viability  of  A)  low  grade  tumours, 
1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal cell glial 
cell line SVGP12 as compared to untreated cell lines. Data are mean ± S D; n=3; 
*P < 0.05. 
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4.4.7    Effect  of  African  Momordica  charantia  extracts  included  in  SPC 
 
liposomes to treat cancerous and non-cancerous glial cell lines. 
 
 
Figure 4.8 A illustrated SPC formulation on the inclusion of AMC extracts (FA, SA 
 
and WF) showing significant (P < 0.05) gradual decrease in the viability of treated 
 
1321N1 and Gos-3 with increasing concentrations (0.35 – 1.75 mg / ml). AMC – SA 
extract on inclusion with SPC liposomes demonstrates less inhibition of 1321N1 and 
GOS-3  on  comparison  with  AMC  –  FA  and  WF  extract.  WF  and  FA  extracts 
contains active constituents such as antioxidants, Momordicine, Map 30, Cucurmin 
(Raman and Lau, 1996) which might be responsible for retarding the growth of 
astrocytoma cells. The retardation of low-grade glioma was increased due to the 
incorporation of AMC extracts in the SPC phospholipid which is rapidly taken as 
nutrition by the astrocytomas. 
 
Similarly,  Figure  4.8  B  shows  U87-MG  gradual  decrease  in  cell  viability  as 
compared to untreated U87-MG on the treatment with AMC extracts (FA, SA and 
WF) included in SPC liposomes. By contrast, AMC SA extracts showed significant 
(P < 0.05) steady state increases in the cell viability of SVGP12, whereas, SPC 
liposomal  formulation  of  AMC  FA  and  WF  showed  no  significant  (P  >  0.05) 
changes in the cell viability at concentrations (0.3 - 1.75 mg / ml) (Figure 4.8 B). 
AMC –FA extract was more potent than SA and WF extract to kill the cancerous 
cells 1321N1, GOS-3 and U87-MG (Figure 4.8 A, B). SPC phospholipid liposomes 
with AMC extracts (FA and WF), except for SA, showed more inhibition as compare 
to the individual extract alone. This result indicates that SPC liposomes enhanced the 
permeation of Momordica charantia active constituents. The inhibition of the growth 
of glioma cells (1321N1, GOS-3 and U87- MG) was higher upon inclusion of AMC 
extracts with SPC liposome as compared to the AMC extract alone. This might be 
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because cancer cells are more aggressive at trying to utilize the surrounding nutrition 
(e.g. SPC) more rapidly. The anticancer effect of the active constituents of the AMC 
extract was enhanced by the facilitated penetration through the cancer cells due to the 
presence of SPC phospholipid. SPC phospholipid liposomes have possibly entrapped 
appreciable proportions of the active constituents in the water-soluble AMC extracts. 
AMC extracts within the SPC liposome formulation served as extra nutrition and was 
more supportive to the growth of the normal glial cell line SVGP12 as compared to 









Figure 4.8: Dose response curves showing the effect of SPC liposome including 
African Momordica charantia extracts (FA, SA and WF) on the viability of A) 
low grade tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and 
also normal cell glial cell line SVGP12 as compared to untreated cell lines. Data 
are mean ± S D; n=3; *P < 0.05. 
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4.4.8    Effect  of  African  Momordica  charantia  extracts  included  in  HSPC 
 
liposomes to treat cancerous and non-cancerous glial cell lines 
 
 
Figure  4.9  A  shows  the  findings  when  AMC  extracts  (FA,  SA  and  WF)  were 
included in liposomes prepared from HSPC phospholipid. These liposomes were 
used for the treatment of 1321N1 and Gos-3. Similarly, Figure 4.9 B also exhibited 
AMC extracts (FA, SA and WF) included in HSPC liposomes. They were used for 
the treatment of U87-MG and GOS-3 cell lines. Both graphs (Figure 4.9 A, B) 
demonstrated that AMC- FA extract on inclusion within HSPC liposomes showed (P 
< 0.05) maximum inhibition of 1321N1 and U87-MG at the concentrations 0.35 – 
 
1.75 mg / ml. Similarly, WF extract in HSPC liposome also showed significant (P < 
 
0.05) decrease in the viability of glioma cells. But, the effect of WF extract was less 
than that  of the FA extract.  By contrast,  AMC-SA extract  in HSPC liposomes, 
showed no significant (P > 0.05) changes in the viability of 1321N1, Gos-3 and U87- 
MG glioma cell line and SVGP12 normal glial cells. Similarly, AMC extracts (FA 
and WF) in HSPC liposomes did not show significant (P > 0.05) changes in the cell 
viability of SVGP12 (Figure 4.9 B). AMC extracts included in HSPC liposomes and 
liposome free AMC extract showed almost similar inhibition of glioma cancer cells, 
indicating that the saturated phospholipid (i.e. HSPC) has no effect or significant 
action in the permeation of Momordica charantia extract through the cancerous glial 
cells. 
 
Extracts combined with the HSPC liposomes were less effective as compared to 
extract combined with the SPC liposomes. This might be because the HSPC 
liposomes were larger due to aggregation, or possibly they did not offer sufficient 
entrapment of the active water-soluble constituents. These materials in Momordica 
Charantia extracts might be amphipathic. This means that they might interact with 
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the liposome bilayers; hence their association with the liposome structures may 
facilitate its permeation through the target cells. Hence, it is possible that interaction 
of these medicinal extracts with the unsaturated phospholipid (i.e. SPC) was better 
than their interaction with the saturated phospholipid (i.e. HSPC). This is possibly 
the reason behind the enhanced anticancer effect of the extracts with the SPC 
liposomes compared to that using the HSPC vesicles.  Unlike SPC phospholipid 
liposomes  with  AMC  extracts  (FA,  SA  and  WF),  HSPC  liposomes  with  AMC 
extracts were slightly more effective than AMC extract alone. However, the effect of 
AMC extracts with SPC liposomes was higher than that of HSPC liposomes 
containing AMC extracts. This indicates that HSPC phospholipid also serves as 
nutrition for the cancer cells to thrive and shows inhibitory effect on cancer cells, 
when mixed with AMC extracts. HSPC phospholipid also serves as nutrition for the 
normal glial cell to grow and reduces the toxic effect as compared to AMC extract 













Figure 4.9: Dose response curves showing the effect of HSPC liposome including 
African Momordica charantia extracts (FA, SA and WF) on the viability of A) 
low grade tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and 
also normal cell glial cell line SVGP12 as compared to untreated cell lines. Data 
are mean ± S D; n=3; *P < 0.05. 
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4.4.9 Effect of Chinese Momordica charantia extracts treatment on cancerous 
and non-cancerous glial cell lines. 
 
 
Figure 4.10 A represents the treatment of 1321N1 and Gos-3 cell lines with Chinese 
 
Momordica charantia (CMC) extracts (FA, SA and WF) as compared to untreated 
 
1321N1 and Gos-3 cell lines. Application of the extract of CMC-FA on 1321N1 and 
Gos-3 caused significant (P < 0.05) gradual decrease in cell viability. Similarly, 
CMC SA extract had significant (P < 0.05) decrease in the viability of 1321N1 and 
GOS-3 at the highest concentrations (1.4 -1.75 mg / ml) and no changes at the other 
concentrations. Similarly, CMC –WF caused a decrease of 1321N1 viability at the 
highest concentrations (1.4 -1.75 mg / ml). By contrast, Gos-3 cell line exhibited 
significant (P < 0.05) steady decrease at the concentration 0.7 -1.75 mg / ml of CMC- 
WF extract, when compared to untreated GOS-3 cell line. Thus, CMC-FA, SA and 
WF extract seemed to have high concentrations of potent and active antitumor 
ingredients like antioxidants, phenols and ribosome inactivating proteins. These 
compounds were possibly responsible for inhibition of the growth of the low-grade 
glioma. 
 
Figure 4.10 B shows that the CMC-FA extract can exhibit significant (P < 0.05) and 
gradual decrease in the viability of the malignant cell line U87-MG. In contrast, there 
was no significant changes in the viability of SVGP12 as compared to untreated 
U87-MG and SVGP12. By contrast, CMC- SA and WF extracts also did not show 
any significant changes in the viability of U87-MG and SVGP12 as compared to 
untreated cells. 
 
Figure 4.10 B shows the viability of 1321N1, Gos-3 and U87-MG cell lines. The 
results show that there was less proliferation following treatment with CMC –FA 
144 
 
extract alone as compared to CMC-WF and CMC-SA. A study by Zulbadli et al. in 
 
2011 used GC-MS to analyze the structure of valuable compounds present in the 
Momordica charantia fruit extract. These researchers have identified few medicinal 
active compounds like vitamin E, ascorbic acid, cucurbitacin B and gentisic acid in 
Momordica charantia fruit extract. Gentisic acid and vitamin E are known for their 
antioxidant activity. These medicinal compounds were known for their antioxidant 
activity, anti-proliferative activity and hypoglycemic effect (Jayini, 2012). CMC 










Figure 4.10: Dose response effect of Chinese Momordica charantia extracts (FA, 
SA and WF)  on viability of A) low grade tumours, 1321N1 and Gos-3 and B) 
high grade tumour U87-MG and also normal cell glial cell line SVGP12 as 




4.4.10  Effect  of  Chinese  Momordica  charantia  extracts  included  in  SPC 
 
liposomes to treat cancerous and non-cancerous glial cell lines. 
 
 
Figure 4.11 A illustrates the effect of Chinese Momordica charantia (CMC) extracts 
on cell viability when they were incorporated in liposome prepared from SPC 
phospholipids. The SPC liposomes containing CMC extracts (FA, SA and WF) were 
used to treat the low-grade glioma cell line 1321N1 and Gos-3 and compared to 
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untreated cells. SPC liposome containing CMC extracts (FA, SA and WF) 
demonstrated significant (P < 0.05) but gradual decrease in the viability of 1321N1 
and GOS-3 at all concentration (0.35 – 1.75 mg / ml). In contrast,1321N1 and Gos-3 
cell lines on treatment with SPC liposome containing CMC-FA extract displayed 
maximum inhibition in followed by CMC- WF and CMC-SA. 
 
Figure 4.11 B shows significant (P < 0.05) and maximum inhibition of U87-MG as 
compared to untreated cells, following treatment with CMC-FA and WF extract 
included in SPC liposome. In contrast, U87-MG treated with CMC-SA extract on 
inclusion with SPC phospholipid liposome did not show any significant (P > 0.05) 
changes in the viability as compared to untreated U87-MG. This might be due to the 
fact that the SA extract dosage was not sufficient to kill the high-grade cancer cells. 
Similarly, SVGP12 treated with SPC liposomes containing FA, SA and WF extracts 
did not show any significant (P > 0.05) change in the viability as compared to 
untreated SVGP12. But it showed significant (P < 0.05) increase in the growth of 
SVGP12 cells when treated with extract included in SPC liposome as compared to 
the extract alone. This observation indicates that the cancerous cells may metabolize 
more extract when SPC liposomes were used to entrap the extract. Another possible 
explanation is that it may supports the growth or it is less toxic for the normal glial 
cell line. 
 
Figure  4.11  A  and  B  illustrates  the  effect  of  CMC  extracts  in  SPC  liposomes 
enhanced   the   penetration   of   active   constituents   in   the   CMC   extracts.   The 
proliferation rate of glioma cell line (1321N1, Gos-3 and U87-MG) was inhibited, 
when treated with SPC liposome-containing CMC extracts. CMC extract within the 
SPC liposomes seemed to show more promising effect for the treatment of glioma. 
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This  result  indicates  that  the  active  constituent  of  CMC  extracts  with  SPC 
 









Figure 4.11: Dose response curves effect of SPC liposome including Chinese 
Momordica charantia extracts (FA, SA and WF) on the viability of A) low grade 
tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal 
cell glial cell line SVGP12 as compared to untreated cell lines. Data are mean ± S 
D; n=3; *P < 0.05. 
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4.4.11  Effect  of  Chinese  Momordica  charantia  extracts  included  in  HSPC 
 
liposomes upon addition to cancerous and non-cancerous glial cell lines 
 
 
Figure 4.12 A demonstrates cell viability of 1321N1 and Gos-3 following treatment 
with increasing concentrations (0.35 - 1.75 mg / ml) of CMC extracts (FA, SA and 
WF) included with HSPC liposomes. On the treatment of 1321N1 and Gos-3 with 
CMC extracts (FA, SA and WF) entrapped in HSPC liposomes, a significant (P < 
0.05) and gradual decrease in the viability of each cell line was observed. However, 
the CMC-SA extract in HSPC liposomes did not inhibit Gos-3 at the lower 
concentrations (0.35 – 0.7 mg /ml) as compared to untreated cells. Similarly, CMC- 
WF extract shows no significant (P > 0.05) decrease in the 1321N1 viability at 0.3 
mg / ml as compared to untreated cells. Likewise, the extract free from liposome 
show inhibition of 1321N1 and Gos-3 cells (Figure 4.10). But, on inclusion of extract 
within the liposome facilitated slightly more than ±5 % inhibition of 1321N1 and 
Gos-3 cells at the highest concentrations 1.4 mg /ml and 1.75 mg /ml (Figure 4.12). 
 
Figure 4.12 B shows the effect of CMC extracts (FA, SA and WF) included in HSPC 
liposomes on the viability of U87-MG and SVGP12 cell lines as compared to 
untreated cells. The normal glial cells SVGP12 showed significant (P < 0.05) 
proliferations when treated with 0.35 mg / ml and 0.7 mg / ml but with no effect 
when higher concentrations (1.05 – 1.75 mg / m) were used. In contrast, treatment of 
U87-MG with CMC-FA extract in HSPC liposomes demonstrated significant (P < 
0.05) and gradual decrease in cell viability. SVGP12, when treated with HSPC 
liposomes containing CMC-SA extract showed no significant change in the viability. 
Whereas,  CMC-WF extract  in  HSPC  liposome displayed  slightly less  inhibitory 
effect  but  this  was  significant  (P  <  0.05)  on  SVGP12  cells  at  the  higher 
concentrations (1.05 – 1.75 mg /ml) compared to untreated. Similarly, U87-MG 
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HSPC  liposomes  containing  CMC-WF  and  SA  extracts  evoked  a  small  but 
significant (P < 0.05) inhibition at the higher concentrations (1.05 – 1.75 mg /ml). 
 
Figure 4.12 A, B show that the CMC extracts (FA, SA and WF) in HSPC liposomes 
had more potential to inhibit the glioma (1321N1, Gos-3 and U87-MG) cells. The 
result reveal a slight inhibition of normal glial cells (SVGP12) compared to untreated 
cells. The CMC extracts, when combined with HSPC liposomes showed more 
inhibition of glioma compared to CMC extract alone and CMC extracts along with 
SPC phospholipid liposomes. Except, the normal SVGP12 glial cells did not show 










Figure 4.12: Dose dependent effect of HSPC liposome including Chinese 
Momordica charantia extracts (FA, SA and WF) on the viability of A) low grade 
tumours, 1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal 
cell glial cell line SVGP12 as compared to untreated cell lines. Data are mean ± S 




4.4.12  Effect of Indian Momordica charantia extracts on cancerous and non- 
cancerous glial cell lines 
 
 
Figure 4.13 A and B shows the viability of 1321N1, Gos-3 and U87-MG glioma cell 
lines and SVGP12 normal glial cells when treated with Indian Momordica charantia 
(IMC)  extracts  FA,  SA  and  WF.  The  results  reveal  no  significant  (P  >  0.05) 
cytotoxic effect to the cells at the lower concentrations (0.35 mg / ml and 0.7 mg / 
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ml) of the extracts. Whereas, on the treatment with the higher concentrations of 
extract (1.4 mg / ml and 1.75 mg / ml) there was a significant (P < 0.05) decrease in 
the glioma cell viability. Except, Gos-3 on treatment with IMC-SA extract showed 
no decrease in the viability of cells at all the concentrations (0.35 -1.75 mg / ml). 
This clearly shows that Gos-3 cell line might need to be treated with higher 
concentrations of IMC-SA extract. The concentration of the SA extract should be 
more than 1.75 mg / ml to show a gradual decrease in the viability of Gos-3 cells. In 
contrast, IMC extracts WF and SA used on SVGP12 normal glial cells did not show 
any cytotoxic effect. In fact, these extracts supported the growth of the SVGP12 
normal glial cells. FA extract derived from IMC shows a small cytotoxic effect on 
the normal glial cells SVGP12 at the higher concentrations 1.4 mg / ml and 1.75 mg / 
ml. FA extract contains active component as antioxidants, Momordicine, Map 30, 
Cucurmin  (Raman and Lau, 1996). These components are toxic because they tend to 









Figure 4.13 Dose dependent effect of Indian Momordica charantia extracts (FA, 
SA and WF) on viability of A) low grade tumours, 1321N1 and Gos-3 and B) 
high grade tumour U87-MG and also normal cell glial cell line SVGP12 as 




4.4.13  Effect   of   Indian   Momordica   charantia   extracts   included   in   SPC 
 
liposomes on treatment of cancerous and non-cancerous glial cell lines 
 
 
Figure 4.14 A represented 1321N1 and GOS-3 treated with IMC extracts (FA, SA 
and WF) in SPC liposomes. The formulations had no significantly (P > 0.05) 
inhibitory effect on the cell growth at the lowest extract concentration (0.35 mg /ml) 
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of the extract. However, increasing the concentration (0.7 - 1.75 mg / m l) of IMC 
extracts in SPC liposomes caused a gradual decrease in the viability of low-grade 
glioma (1321N1 and Gos-3). 
 
Figure 4.14 B represents the viability of U87-MG and SVGP12 cells treated with 
IMC extracts (FA, SA and WF) in SPC liposomes. The results show that U87-MG on 
the treatment with FA or WF extracts demonstrated a gradual decrease in viability, 
whereas  the  SA  extract  did  not  cause  any  change  in  viability  at  the  low 
concentrations (0.35 – 1.05 mg / ml) but only a slight inhibitory effect on the cell 
viability at the higher concentrations (1.4 mg / ml and 1.75 mg / ml). Similarly, the 
viability of SVGP12 cells was not affected by treatment with the extracts 
formulations. FA extract with this liposome is found to be more potent in inhibiting 
glioma as compared to SA or WF extract with liposomes. This might be due to the 
fact that higher concentration of active constituents is present in the FA extract 
compared with the WF and SA extracts. However, Figure 4.14 B shows that IMC 
extract on inclusion within the liposome facilitated more cytotoxic effect on the 
glioma  cells  as  compared  to  the  cells  treated  with  extracts  without  liposomes. 
Extracts along with liposomes are more effective on the tumour cells. Higher 
concentrations of FA extracts on inclusion within the liposome showed no toxic 
effect on SVGP12 normal glial cells. It seemed to support the growth of normal glial 
cells. Similarly, SA and WF extracts with liposome evoked no significant (P > 0.05) 
changes in the viability of SVGP12 cell as compared to non- treated SVGP12. Thus, 
seed extract might have components which act as nutrients to support the growth of 










Figure 4.14: Dose dependent effect of SPC liposome including Indian Momordica 
charantia extracts (FA, SA and WF) on the viability of A) low grade tumours, 
1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal cell glial 
cell line SVGP12 as compared to untreated cell lines. Data are mean ± S D; n=3; 
*P < 0.05. 
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4.4.14  Effect  of  Indian  Momordica  charantia  extracts  included  in  HSPC 
 
liposomes to treat cancerous and non-cancerous glial cell lines 
 
 
Figure 4.15 A shows the viability of 1321N1 and Gos-3 treated with increasing 
concentrations (0.35 – 1.75 mg / ml) of IMC extracts (FA, SA and WF) in HSPC 
liposomes. The results shows that 1321N1and Gos-3 cell lines when treated with FA 
and WF included in HSPC liposomes show both a significant (P < 0.05) and a 
gradual decrease in viability by increasing the extract concentration (0.35 -1.75 mg / 
ml). In contrast, IMC-SA included in HSPC liposomes had very slight effect on the 
viability of 1321N1and Gos-3 cells. 
 
Figure 4.15 B reveal a small but a significant (P < 0.05) decrease in the viability of 
U87-MG cells upon treatment with the HSPC liposome formulations of IMC extracts 
(FA and WF). However, no effect (P > 0.05) on the U87-MG cell viability was 
observed upon treatment with HSPC SA extract. Similarly, the treatment of SVGP12 
with IMC-SA extract in HSPC liposomes resulted in inhibition of cells, but also 
caused a non-consistent growth pattern. It seems that combination of both SA extract 
along with HSPC liposome turns to be poisonous for the healthy SVGP12 cells. 
 
Similarly, Figure 4.15 A, B also shows that when IMC extracts included in HSPC 
liposomes, there was a small tendency to inhibit glioma, when compared to IMC 
extracts in SPC liposomes. In contrast, the extract shows more potent inhibition of 
cells, when compared to IMC extract without liposomes. The SA extracts in 
combination with HSPC liposomes were slightly toxic to both the cancerous and 
normal cells. The toxicity might be due to the presence of fatty acid or some other 
components in the Momordica charantia SA extract. Momordica charantia seeds 
contain around 60% eleostearic acid (α-ESA), which is a conjugated linolenic acid 
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(Zang et al. 2012). One of the studies published in 2012 by Zang et al. suggested that 
α-ESA may exhibit a potential cytotoxicity and cause apoptosis induction on human 
breast cancer cells, with little effect on normal cells at certain concentrations (Zang 










Figure 4.15: Dose response effect of HSPC liposome including Indian Momordica 
charantia extracts (FA, SA and WF) on the viability of A) low grade tumours, 
1321N1 and Gos-3 and B) high grade tumour U87-MG and also normal cell glial 
cell line SVGP12 as compared to untreated cell line. Data are mean ± S D; n=3; 







4.5 Futher Discussion and Conclusion 
 
 
The growth curve of low-grade glioma 1321N1 and Gos-3 proliferates faster, and die 
sooner as compared to the high-grade glioma U87-MG. The low-grade glioma cells 
1321N1 are not very aggressive to utilize the nutrition so they grow faster and die 
faster. The SVGP12 normal glail cells proliferate at normal rate utilizing sufficient 
nutrition to grow. Whereas, U87-MG high-grade glioma cells may utilize all the 
nutrition present in the media and turning the media from dark pink to light pink. 
U87-MG cells grow in very aggressive pattern overlapping on one another. The 
glioma cells treated with ETOH+water, HSPC and SPC liposomes showed no 
significant (P > 0.05) increase or decrease in the cell viability. U87-MG cells, 
treatment with HSPC liposome seemed to support the cellular growth, suggesting 
that HSPC phospholipid may serve as nutrition to the high-grade glioma. SPC and 
ETOH+water, did not show any effect on U87-MG. Similarly, SPC and HSPC 
liposome have helped the normal glial cells SVGP12 to proliferate. The normal glial 
cells showed a slight decrease in the cell viability on treatment with ETOH+water, 
indicating that ethanol is slightly toxic to the normal glial cells. On evaluation of 
Momordica charantia extract and PTX with SPC or HSPC liposomes, PTX was very 
toxic and killed both cancerous and non-cancerous cells. PTX therapeutic index was 
improved   when   included   in   liposome   formulations.   However,   inclusion   of 
Momordica charantia extract within liposomes was not as effective as PTX on 
cancerous cells. The really good result was exhibited by the promoted growth of the 
normal glial cells SVGP12 when the extract was combined with liposomes. 
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Momordica charantia is an excellent source of phenolic compounds, antioxidants, 
and antimutagens that are useful for inhibition of cancer. The results in this chapter 
represented the effect of Momordica charantia extracts (FA, SA and WF) with or 
without liposomes on the viability of cancerous and non-cancerous cells of the brain. 
Momordica charantia was bought from India, Africa and China and divided as FA, 
SA and WF. Momordica charantia liposomes were prepared by using SPC or HSPC 
phospholipids. Extract without liposomes, showed an inhibiting effect on the growth 
of glioma cells (1321N1, Gos-3 and U87-MG) and supported the growth of normal 
cells (SVGP12). On inclusion of extracts within SPC liposomes, a significant (P < 
0.05) decrease of the glioma cells was observed. In contrast, no significant decrease 
in normal SVGP12 cell line was seen. Similarly, the effect of Momordica charantia 
HSPC liposomes was less effective compared to SPC liposomes. Whereas, the effect 
of the Momordica charantia HSPC liposomes was a little bit higher compared to the 
extract alone, but, lower compared to the SPC formulations. It was proved that FA 
extract and WF extract of Momordica charantia along with SPC or HSPC liposomes 
was able to show maximal inhibition effect on the glioma cell line (1321N1, Gos-3 
and U87-MG) on comparison with the FA and WF extract without liposome. It also, 
showed that the FA and WF extract from all the countries in combination with 
liposome did not show any toxic effect on the normal glial cell SVGP12. Whereas, 
Momordica charantia SA extracts from Africa and China along with SPC and HSPC 
liposome supports the growth of the normal glial cells and did not show any changes 
in the growth of the glioma (1321N1, Gos-3 and U87-mg) cell line. Momordica 
charantia  SA  extracts  from  India  along  with  HSPC  showed  equal  amount  of 
decrease in the viability of SVGP12. The Momordica charantia FA extracts from 
India, Africa and China, with or without liposome was more potent to inhibit the 
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growth  of  glioma  (1321N1,  Gos-3  and  U87-Mg)  cell  lines  as  compared  to 
Momordica charantia SA and WF extracts. The FA extract of Momordica charantia 
with SPC and HSPC liposome seem to be more permeable in cancer cells because it 
could inhibit several more cells as compared to FA extract of Momordica charantia 
without any liposome associated. The AMC and IMC FA extract showed more 
inhibition when in corporate within SPC liposome, rather than HSPC liposome. But, 
CMC FA extract showed reversed effect. The AMC and IMC FA, SA and WF 
extracts were able to show inhibition at the highest concentration. In contrast, there 
extracts were, not able to show any significant decrease of growth at the lower 
concentration.  CMC  FA  extract  along  with  HSPC  phospholipid  showed  the 
maximum inhibition rate, compared to all other FA, SA and WF Momordica 
charantia extracts from India, China and Africa with or without any SPC and HSPC 
phospholipid liposome. This indicates that HSPC liposome could entrap maximum 
active constituents derived from CMC-FA extract that is useful for the inhibition of 
glioma (1321N1, Gos-3 and U87-MG) cell lines. It did not show any toxic effect on 
the normal glial cell. The AMC, CMC and IMC extracts (FA, SA and WF) either 
with or without liposome, killed low-grade (1321N1 and Gos-3) glioma cells and 
they had very little effect on high-grade (U87-MG) glioma cells but no significant 
effect on normal glial (SVGP12) cells. In contrast, IMC-SA on inclusion within 
HSPC liposome showed slight toxic effect to the normal glail cells. It is known that 
the seed extract contains 60% α-ESA, which at times is toxic to the normal cells at 
various concentrations. The combination of α-ESA with HSPC liposome enhanced 
the cytotoxic effect on the normal cells.  The effect of AMC, CMC and IMC extracts 
(FA, SA and WF) either with or without liposome was not as effective as PTX with 






In summary, Momordica charantia extracts inclusion in HSPC and SPC liposome 
prepared from solvent-based proliposome method, facilitated more permeation of the 
active constituents. These active constituents of Momordica charantia retard the 
growth of glioma cell lines and do not affect the growth of normal glial cells. The 
same part of Momordica charantia plant extracts obtained from different countries 
showed different rate of inhibition of glioma cells. This might be dur to the fruit lack 
the amount of active ingredient varies. The variation of active ingredient might be 
due to climatic condition including temperate, hot or humid, soil condition; red soil, 
alkaline soil, amount of nutrients and many other factors might be responsible to 
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The chapter 4 of this study describes the efficacy of the resultant liposome 
formulations on the viability of glioma cells by MTS cytoxic assay. This chapter was 
specifically designed to investigate the molecular mechanism of apoptosis induced 
by Momordica charantia fruit extracts and Paclitaxel included in the liposome. 
Apoptosis involves permanent damage to the mitochondria leading to the release of 
caspase-3, caspase-9 and cytochrome-c (Kerr et al. 1972). Caspase assay and 
mitochondrial assay are important to identify the apoptotic-signalling pathway for 
death of the tumour cells. 
 
 
5.2 Materials and Methods 
 
 
5.3 Materials and chemical reagents 
 
 
Caspase-Glo® 3/7 and Caspase-Glo® 9 activity (Promega, UK) (Figure 5-4). 
Cytochrome-c (Sigma-Aldrich, UK). 
Other  materials  used  in  the  studies  presented  in  this  chapter  were  previously 







5.4.1    Plating of cell lines 
 
 
Plating of the cell lines was performed as described in chapter 4 (section 4.4.5). 
Measurement of Caspase-Glo® 3/7 and Caspase-Glo® 9 activity 
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The 1321N1, Gos -3, U87- MG and SVGP12 cell lines were incubated for 24 hrs in 
5% CO2  incubator at 37ºC. The media in the plates were removed on sterile tissue 
paper. Another 75 μl of media and 25 μl of liposomal solutions of Momordica 
charantia and Paclitaxel were added to the wells and incubated in 5% CO2 incubator 
at 37ºC for another 12 hours. The treated and non-treated cells were incubated for 12 
hrs at 37°C in 5 % CO2. Prior to starting the assay the prepared sample of Caspase- 
Glo® 3/7 and Caspase-Glo® 9 reagents was equilibrated to room temperature. After 
 
24 hr, each plate (96 well plate GRE 96 fb) was removed from the incubator for 30 
min to equilibrate to room temperature. A volume of 100 μl of Caspase-Glo® 3/7 and 
Caspase-Glo® 9 assay reagent was added to each well of a white walled 96 well plate 
containing 100 μl of blank and treated cells in the culture medium (Figure 5.4). The 
plate was then covered with aluminium foil and mixed gently by using a plate shaker 
at 300-500 rpm for 2 min, followed by incubation at room temperature for 30 min. 
The Caspase-Glo®  3/7 and Caspase-Glo®  9 assay was performed in the absence of 
light. The Luminescence was measured using a Teccan Plate reader. The software 
used for the Luminescence assay was XFLUORHGENIOSPRO version V 4.53 
(Version 2004). The plate type used from the software was specified as GRE 96 fb 







Figure 5.1: Schematic diagrams showing A) Caspase-Glo® 9 and B) Caspase- 






5.4.2    Measurement of Cytochrome-c release 
 
 
The  1321N1,  Gos  -3,  U87-  MG  and  SVGP12  cell  lines  were  incubated  with 
liposomal  solutions  of Momordica charantia  or Paclitaxel.  The induced  (treated 
cells)  apoptosis  cell  suspension  contained  roughly  107   cells.  A  sample  of  non- 
induced (untreated cells) cells was denoted as control. For a zero-time control also 
contained 107 cells. The induced and non-induced cells were incubated for 24 hours 
at 37°C in 5 % CO2. The induced cells and the non-induced cells were transferred to 
15 ml centrifuge tube and centrifugation at 1000 r.p.m for 5 min at 4 °C. The 
supernatant was removed by gentle aspiration of both induced and non-induced cells. 
166 
 
The cell pellets were then washed once with 1 ml of PBS. The microsomal pellet was 
subsequently  obtained  by  centrifuging  at  12,000  rpm  for  1  hour  at  and  the 
supernatant  was  removed  completely  by  gentle  aspiration.  The  centrifuged  cell 
pellets  were  then  treated  with  1  X  lysis  buffer  (Sigma-Aldrich,  UK)  at  a 
concentration of 100 μl per 107 cells, and the cells were placed on ice bath for 15-20 
min. The lysed cells were centrifuged at 16,000 to 20,000 x rpm for 10 to 15 min at 
4°C and the supernatants were transferred to new 1 ml tubes and subsequently frozen 
in liquid nitrogen and stored in aliquots at -70°C for further use. Table 5.1 shows the 
experimental protocol for cytochrome-c assay. A volume of 950 µl of the working 
solution (9 mg of cytochrome-c to 20 ml of assay buffer to obtain a concentration of 
0.45 mg/ml, 36 mM) was made up by adding 9 mg of cytochrome c to 20 ml of the 
assay buffer in a 1 ml cuvette. A volume of 50 µl of the test sample was added to the 
cuvette containing the working solution. For the sample that had interference from 
cytochrome c oxidase activity, a volume of 20 µl of cytochrome c oxidase inhibitor 
solution was used for the positive control reaction. The positive control was obtained 
by diluting an aliquot of the cytochrome-c reductase (NADPH) to 10-fold with the 
enzyme dilution buffer. Each set of reactions required a total of 75 ml of the diluted 
positive control. A volume of 100 µl NADPH solutions was added to start the 
reaction. The blank reaction was measured by the value given by the reagents alone 
in absence of the enzyme (Table 5.1). 
167 
 
Table 5.1: Table below showing the reaction scheme outline to measure 

















Blank 950 50 NIL 100 NIL 
Unknown sample 950 50-X X 100 NIL 
Unknown with 
interference 








950 NIL 50 100 NIL 
* Note- NADPH solution contains 0.85 mg of NADPH per millilitre 
 




Unit definition: One unit could reduce 1.0 µmole of oxidized cytochrome-c in the 
presence of 100 µM, NADPH per minute at pH 7.8 at 25°C 
Units/ml = ΔA550/min x dil  x 1.1 
 
 
21.1 x Enzvol 
 
 
ΔA550/min = ΔAsample - ΔAblank 
 
dil = the dilution factor of the original enzyme sample 
 
Enzvol = volume of the enzyme sample (ml) 
 
21.1 = extinction coefficient (EmM) for reduced cytochrome c 
 
1.1 = Reaction volume (ml) 
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The reaction time was longer than 1 minute; divided the ΔA550 by the reaction time to 
obtain 





5.4.3    Statistical analysis 
 
 
Caspase-Glo® 3/7, Caspase-Glo® 9 and Cytochrme C experiments were performed in 
triplicate. The graphs of cell apoptosis luminescence on Y-axis and drug on X-axis 
were plotted, and the results were expressed as the mean ±Standard Deviation (SD) 
from  three  independent  experiments  (n=3).  A  statistical  analysis  was  performed 
using SPSS. All the data were evaluated for unpaired variables to compare two or 
more groups by paired Student‘s ―  t test‖ and ANOVA. Values of P < 0.05 is 








5.5.1 Activity  of  caspase  3/7  in  normal  and  cancerous  glial  cells  using 
liposomes with or without Momordica charantia (FA extracts) or PTX 
 
 
In chapter 4 of the study, it was discussed that liposome slightly enhances the 
anticancer activity, compared to the free extract solutions. The cytotoxic study, 
confirms that liposome merits, that the liposome enhanced the effect of Momordica 
charantia FA extracts from different countries (Africa, China and India). On the 
basis of the application in the chapter 4, it was necessary to investigate the molecular 
mechanism of cells death, adopting clinical anti-cancer techniques like gamma- 
irradiation, chemotherapy, suicide gene therapy or immunotherapy which can kill 
tumour  cells.  The  anticancer  active  constituents  can  activates  apoptosis  signal 
169 
 
transduction pathway either by intrinsic or extrinsic pathways (Fulda and Debatin, 
 
2006). To explore the mechanism of Momordica charantia extract and PTX with 
liposome-induced apoptosis via intrinsic or extrinsic pathway, the activation of 
caspase was analyzed using commercial caspase assay. Measuring caspases 3 and 7 
helps  in  understanding  apoptosis  evaluation.  Caspase  3  and  7  are  the  effecter 
caspases that execute some common features of the apoptotic pathway, like DNA 
fragmentation (Lakhani et al. 2006). This measurement was done indirectly through 
cleavage of a substrate by the caspases that gave a fluorescent product. Caspase-3 is 
one of the hallmarks of apoptosis and it is responsible for inducing apoptosis by 
cleaving a variety of substrates (Shu et al. 2009). Caspase 7 cleaves same substrates 
as caspase 3 (Fernandes-Alnemri et al. 1995). 
 
In a recent study it was also shown that breast cancer cells MCF-7 on treatment with 
Momordica charantia extract showed PARP nuclear protein or downstream substrate 
activated caspase 3/7 activities (Ray et al. 2010). Figure 5.2A/B in this study show 
caspase 3/7 activity in the cancerous (1321N1, Gos-3, U87-MG) cells and non- 
cancerous glial cells (SVGP12).  On treatment with drug-free liposomes, and 1.75 
mg/ml of Momordica charantia FA (India, Africa and China) extract liposomes and 
1.75 mg/ml of PTX liposomes generated from either SPC or HSPC proliposomes as 
compared  to  untreated  cancerous  and  non-cancerous  cells  after  24  hours  of 
incubation. Data are mean ± S.E.M, n=3 for different experiments in triplets (n=9). 
The results show a statistically significant (P < 0.05) increase in caspase 3/7 activity 
for all the samples compared to untreated cells. On treatment with Momordica 
charantia FA liposomes (SPC or HSPC) a significant (P < 0.05) increase in the 
caspase 3/7 activities was observed in all cell lines (1321N1, Gos-3, U87-MG and 
SVGP12),  regardless  of  the  plant  origin.  In  contrast,  no  significant  (P  >  0.05) 
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difference was observed in the release of caspase 3/7 when cells were treated with 
drug-free liposomes  (SPC or HSPC) as compared to the untreated cells. The release 
of caspase 3/7 was more pronounced in 1321N1 followed by Gos-3, U87-MG and 
SVGP12 on treatment with SPC liposomes including FA Momordica charantia 
extract. By contrast, on treatment with FA Momordica charantia extract using HSPC 
liposomes, the activity of capase 3/7 increased in Gos-3 followed by 1321N1, U87- 
MG and SVGP12. Both HSPC and SPC liposomes including Chinese Momordica 
charantia showed maximum caspase 3/7 activities followed by African Momordica 
charantia and Indian Momordica charantia. However, caspase 3/7 activities analysis 
on treatment of Momordica charantia extract included in the liposome (SPC and 
HSPC) showed less activity as compared to PTX liposomes (SPC and HSPC) in all 










Figure 5.2: Bar charts showing A) SPC and B) HSPC liposomes, encapsulated 
with and without (Drug free liposome) 1.8 mg /ml of Momordica charantia FA 
from Africa, India and China and PTX involves caspase 3/7 activation on the 
death of 1321N1, GOS-3, U87-MG and SVGP12 as compared to untreated cells. 
Data are mean ± S D; n=3 in triplicates *P < 0.05 for fruit extracts liposomal 
formulation compared to control. 
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5.5.2 Activity of caspase 9 in normal and cancerous glial cells using liposomes 
with or without Momordica charantia FA extract or PTX 
 
 
The caspase-9 can propagate cell death via intrinsic pathway (Bailey et al. 2005). 
The  Apaf-1/caspase-9 apoptosome-initiated the caspase activation cascade and in 
turn caspase-9 cleaves and activates downstream caspases such as caspase-3 and 
caspase 7 (Slee et al. 1999; Srinivasula et al. 1999). The relaying an apoptotic signal 
from caspase-9 to cleavage of PARP is substituted by caspase-7 (Fang et al. 2012). 
Figure 5-3A/B shows the activity of caspase 9 in glioma cell lines (1321N1, Gos-3, 
U87-MG) and normal glial cells (SVGP12) measured following treatment for 24 
hours with either drug free liposomes, Momordica charantia FA (India, Africa and 
China) liposomes or PTX liposomes generated from SPC or HSPC phospholipids as 
compared to untreated (normal and cancerous glial) cells. Data are mean ± S.E.M, 
n=3 different experiments in triplets.   On treatment with either SPC or HSPC 
liposomes containing PTX or Momordica charantia extract from the three different 
origins (Africa, China and India), a significant (P < 0.05) increase in the caspase 9 
activity was found in all cell lines investigated. Using the extracts with SPC or HSPC 
liposomes, 1321N1 demonstrated the maximum caspase 9 activity followed by Gos- 
3, U87-MG and SVGP12. However, when PTX-loaded SPC liposomes were applied, 
caspase 9 activity was higher in SVGP12 normal cells followed by 1321N1, Gos-3, 
U87-MG cells. On treatment of cells with HSPC liposomes loaded with PTX similar 
capsase 9 activity was obtained compared to those using Momordica charantia 
liposomes. SPC liposomes caused higher caspase 9 activities than HSPC liposomes. 
The use of Chinese and African extracts with SPC or HSPC liposomes resulted in 
similar  caspase  9  activities,  followed  by  the  Indian  extract.  However,  extract- 
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liposome formulations, regardless of plant origin, phospholipid type and cell line, 








Figure 5.3: Bar charts showing A) SPC and B) HSPC liposomes, encapsulated 
with and without (Drug free liposome) 1.8 mg / ml of Momordica charantia FA 
from Africa, India  and  China  involves  caspase 9  activation  on the death  of 
1321N1, GOS-3, U87-MG and SVGP12 as compared to untreated cells. Data are 
mean ± S D; n=3 in triplicates *P < 0.05. 
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5.5.3 Cytochrome C release in 1321N1, Gos-3, U87-MG and SVGP12 glial cell 
lines, on treatment with SPC and HSPC liposome including Momordica 
charantia extracts or PTX 
 
 
Mitochondria play, a crucial and central regulatory role in apoptosis through 
cytochrome C pathway (reference). Mitochondria and radical species are intimately 
involved in the apoptosis. Increased oxidative stress from ROS and RNS changes the 
cellular redox potentials, depletes glutathione, and decreases reducing equivalents 
like NADP and NADPH. These intracellular changes are sufficient to induce the 
formation of mitochondrial permeability transition pores, leading to release of 
cytochrome  c  and  activation  of  the  caspases  cascade  (Bansal  et  al.  2012).  The 
intrinsic pathway releases mitochondrial cytochrome c as a consequence of opening 
of the Bax/Bak channel. It results in the assembly of the Apaf-1/caspase-9 
apoptosome and leads to activation of caspase-9 within this complex (Luo, 1998). In 
a  previous  study,  it  was  demonstrated  that  apoptosis  induced  by  Momordica 
charantia extract on human lung adenocarcinoma CL1-0 cells was through caspase- 
and mitochondria-dependent pathways, which change the antiproapoptotic Bcl-2 and 
proapoptotic Bax proteins (Li et al. 2012). In a recent investigation, Manoharan 
(2011) has demonstrated that cytochrome c is released using MC extracts, at an 
extract  concentration  of  800  μg.  In  comparison  to  the  present  findings,  it  is 
concluded that liposomes might enhance the release of cytochrome c, hence this may 
show the potential of liposomes. Figure 5.4 A/B shows cytochrome c release in the 
cancerous (1321N1, Gos-3, U87-MG) and non-cancerous glial cells (SVGP12) on 
treatment with either plain liposomes, Momordica charantia FA (India, Africa and 
China) with liposomes or PTX liposomes using SPC or HSPC phospholipids 
compared to untreated cells. Momordica charantia FA liposomes (SPC and HSPC) 
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significantly (P < 0.05) increased the cytochrome c release in all the cell lines 
(1321N1,  Gos-3,  U87-MG  and  SVGP12),  regardless  of  fruit  origin  (i.e.  Africa, 
China or India).  However, no increase (P > 0.05) in cytochrome c release on 
treatment with plain liposomes (SPC and HSPC) was observed for all cell lines. 
Cytochrome c release was more pronounced on treatment of Momordica charantia 
Chinese  FA,  followed  by  Indian  Momordica  charantia  and  African  FA,  which 
showed similar increase. PTX liposomes show more increase in the release of 
cytochrome c, in all the four glial cells as compared to Momordica charantia FA 
liposomes. The cytochrome c release of low-grade glioma is comparatively higher 
than high-grade glioma and normal glial cell on the treatment with drug free 
liposomes or Momordica charantia (India, Africa and China) liposomes and PTX 
liposomes. In conclusion, the increase in the cytochrome c release may justify that 
the particular extract within the liposome is able to show maximum apoptotic activity 









Figure 5.4: Bar chart showing cytochrome c realease of 13121N1, GOS-3, U87- 
MG and SVGP12 of untreated and 24hr treatment of Drug free liposome, 
Momordica charantia FA extract (African, Chinese and Indian) and PTX loaded 
within A) SPC ad B) HSPC liposomes. Data are mean ± S D; n=3; *P < 0.05 for 
treated compared to control. 
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5.5.4 Morphological characteristic of  cell lines untreated and treated with 
Momordica charantia extract or PTX included in liposomes and drug 
free liposome prepared from proliposome technology 
 
 
The photographs in this section give morphological description about, cancerous and 
non-cancerous glioma cells before and after treatment with either Momordica 
charantia extract or PTX included within SPC or HSPC liposome. The photograph 
was taken using an Inverted microscope under 10 X magnification. The photograph 
shows healthy growth of both cancerous and non-cancerous cells when they were 
untreated. But on treatment with liposome containing extract, they showed the 
shrinkage of the cell membrane. Glioma (1321N1, Gos-3 and U87-MG) cells on 
treatment with either Momordica charantia extracts or PTX within the liposomes 
shows less viable cells compared to the treated normal glial cells (SVGP12).  The 
photograph  in  the  Figure  5-8  shows  healthy  morphological  structures  of  Gos-3 
(Figure  5.5A)  and  1321N1  (Figure  5.5B)  cells  in  Dulbecco‘s  Modified  Eagle 
Medium (DMEM) and U87-MG (Figure 5.5C) and SVGP12 (Figure 5.5D) cells 
cultured in Eagle‘s Minimal Essential Medium (EMEM) media. Figure 5.5E shows 
shrinkage destruction and shrinkage of chromatins of U87-MG on treatment with 
PTX liposomes. Similarly, Figure 5.5F shows U87-MG cells on treatment with plain 
liposomes. Figure 5.5G is an image of GOS-3 after treatment with Momordica 
charantia liposome. Finally, figure 5.5G is an image of SVGP12 following 





A) Gos-3  B)1 3211'1 
 
 

















Figure 5.5: Photograph showing  untreated cell line 1321Nl (A), GOS-3 (B), U87- 
MG    (C)   and    SVGP12   (D)   with    no   destruction  of   the    chromatins or 
morphological features.    Vice  versa, treated  cell  lines;  U87-MG  with   PTX 
liposome  (E) and  drug free liposome  and  (F), Gos-3 (G) and  SVGP12  (H) treated 
with  Momordica  charantia  liposome  shows  shrinking and  destruction of  cells. 
The photographs are typical of 3 such different repeats. 
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5.5.5    Conclusion 
 
 
The results of this study have clearly demonstrated that drug free liposomes made 
from SPC and HSPC, PTX and crude extract of Momordica charantia from India, 
Africa and China loaded within SPC or HSPC liposomes can evoke significant 
decrease in cancer cell viability (cell death). Moreover, they seem to exert their anti- 
cancer effect on cells via apoptosis damaging the cell mitochondrial body, resulting 
in the elevation in cellular mediators as caspase-3/7 and caspase-9 and release of 
cytochrome  c.  Treatment  of  cells  with  drug  free  liposomes  prepared  from 
proliposome method employing with SPC or HSPC phospholipid had no significant 
(P > 0.05) effect on capase 3/7, caspase 9 and cytochrome c release in the cancerous 
and non-cancerous glial cells compared to untreated. From the results it can be 
conclude that drug free liposome does not kill cell via intrinsic pathway. On 
application of either PTX or Momordica charantia FA extract (Africa, China and 
India) with SPC or HSPC liposomes, there was more apoptotic activity in 1321N1 
cell line followed by Gos-3, U87-mg and SVGP12. Chinese Momordica charantia 
FA loaded in either SPC or HSPC liposomes showed maximum caspase activation 
and cytochrome c release as compared to African and Indian Momordica charantia 
FA. However, the maximum apoptotic activity was observed in SPC and HSPC 
liposomes loaded with PTX as compared to the Momordica charantia extracts. 
Apoptotic cells show distinctive morphology during the apoptotic process. The cell 
begins to shrink following the cleavage of lamins and actin filaments in the 
cytoskeleton. In summary, following 24hrs of treatment with Momordica charantia 
FA within SPC and HSPC liposome can lead to elevation in the activities of caspase 
3/7, caspase 9 and the release of cytochrome c. Momordica charantia FA inclusion 
within SPC and HSPC liposomes activates intrinsic mitochondrial apoptosis pathway 
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via activation of caspase cascade. Further experiments are required to investigate the 
sub-cellular and molecular mechanisms associated with the cell death including the 
involvement of kinase and gene expressions for apoptotic mediator. 
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6.1 General Discussion 
 
 
Plants  are  invaluable  source  of  potential  new  anti-cancer  drugs.  Momordica 
charantia is one of these plants with both edible and medical value and reported to 
possess anticancer activity (Fujii et al. 2000). To explore the potential cytotoxic 
effectiveness  of  the  extract  of  Momordica  charantia,  liposomes  prepared  from 
solvent-based proliposomes were used to evaluate the cytotoxic activity on cancerous 
and non-cancerous glial cells. Three variates of Momordica charantia were obtained 
from Africa, India and China for this study. The rationale was to investigate whether 
the different phenotypic Momordica charantia obtained from different climatic 
conditions and grown in different soil condition has any variation in their anticancer 
effect. These fruits from different countries were segregated into FA, SA and WF 
extracts and were included in SPC or HSPC liposomes. The Momordica charantia 
extract  liposomes  prepared  form  solvent-based  proliposomes  were  applied  on 




To investigate the anticancer effect of Momordica charantia extract with liposomes, 
the study involved: 
 
1.   Characterization of liposomes with regard to size, size distribution and zeta- 
potential. 
2.   Cytotoxic effect of liposomes including extract by using MTS assay 
 
3.   Molecular  mechanism  pathway  of  cell  death  by  –  caspase  3/7  activity, 
caspase 3 activity and cytochrome c release. 
183 
 
6.2 Characterization of liposomes generated from proliposomes 
 
 
Liposomes made from either SPC or HSPC were incorporated with either ethanol 
and water (1:10 v/v) extract of Momordica charantia (WF, FA and SA) or with the 
ethanol soluble anticancer drug paclitaxel. Ethanol-based proliposome technology 
was used for the preparation of liposomes. Ethanol-based proliposomes have been 
previously demonstrated to generate liposomes that offer superior entrapment 
efficiency of hydrophilic materials (Perrett et al. 1991; Elhissi et al. 2006). Ethanol- 
based proliposome method is safe, economic, convenient, time saving and self- 
preserved  against  microbial  contamination  and  can  instantly  generate  liposomes 
upon addition of aqueous phase and shaking (Perrett et al. 1991). Ethanol-based 
proliposome technology is also environmental friendly since no toxic solvents like 
chloroform or methanol are required to prepare the liposomes.  Liposome interaction 
with biological cells is determined by a number of factors such as particle size and 
zeta potential. 
 
There are many potential barriers to the effective delivery of a drug in its active form 
to solid tumours (e.g. brain tumour). Most small-molecular chemotherapeutic agents 
have a large volume of distribution following their administration (Speth et al. 1988; 
Chabner and Longo, 1996). Encapsulation of drugs in a macromolecular carrier, such 
as a liposome, may reduce the volume of distribution significantly and increase the 
concentration of the drug in the tumour site. The blood-brain barrier represents a 
formidable barrier for drug delivery to the central nervous system. Tight junctions, 
the lack of fenestrations, and a low transcellular pinocytic index severely limit the 
penetration of macromolecules to the brain (Levin et al. 1980; Seymour, 1992). 
Several groups have been able to show that even tumours located in the brain also 
have a ―leaky‖ microvasculature (Siegal et al. 1995; Hobbs et al. 1998). If this is the 
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case, it could be assumed that the leaky microvasculature may allow the liposomes to 
accumulate in the cancer-affected area. The accumulation of the liposome does not 
allow the cancerous cells to proliferate and do not affect normal cells. 
 
The drug free SPC and HSPC liposomes were generated from ethanol–based 
proliposomes or by thin-film method to target brain tumour. Size, size distribution 
and zeta potential of liposomes were analysed. Liposomes generated from 
proliposomes were smaller and their size distribution was narrower than vesicles 
prepared by the conventional thin film method. Also, size was smaller and size 
distribution  was  narrower  for  the  SPC  liposomes  as  compared  to  the  HSPC 
liposomes. However, SPC liposomes were more negatively charged than HSPC 
liposomes. Smaller particles with higher zeta potential exhibited higher stability but 
formed larger and and irregular shapes (Jong and Keun, 1999). 
 
Momordica charantia is an excellent source of phenolic compounds, antioxidants, 
and antimutagen useful for the treatment of cancer. Certain vegetables contain an 
abundance of polyphenolics, terpenoids, isoflavones, anthocyanins, amino acids, 
minerals, vitamins, and other antioxidants that are associated with protection from 
cancer (Islam et al. 2010). In this study the Momordica charantia was bought from 
the local  supermarkets  but  obtained  from  different  countries  (Africa,  China and 
India). They were grown, under different soil and climatic conditions. Momordica 
charantia extracts were segregated as FA, SA and WF from India, Africa and China 
respectively, and were included in SPC or HSPC liposomes using the proliposome 
technology. 
 
Momordica  charantia  extracts  from  the  three  countries  encapsulated  in  SPC 
 
phospholipids generated smaller size liposomes compared to HSPC phospholipids. 
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Also, the size distribution of the SPC liposomes containing Momordica charantia 
extracts  (FA,  SA  and  WF)  was  narrower  (Span  was  smaller  by  1-  2.5  units) 
compared to HSPC Momordica charantia extract liposomes. Except, Chinese 
Momordica charantia extracts on encapsulation with SPC phospholipid showed 
increased size distribution with the increasing concentrations (0.7-1.8 mg / ml) as 
compare to HSPC liposomes containing extract. Liposomes containing PTX using 
SPC were smaller than HSPC liposomes. However, the size distribution of PTX drug 
along with HSPC and SPC phospholipid showed vice versa results. Using PXT, the 
size distribution of HSPC liposomes was smaller than SPC liposomes (Figure 3-7 B). 
 
Lipid  composition  can  influence  the  liposomal  surface  charge.  Lack  of  surface 
charge can reduce physical stability of small unilamellar liposomes by increasing 
their aggregation (Kaye 1981; Sharma and Sharma 1997). However, negatively 
charged liposomes, were believed to be more rapidly removed from circulation than 
neutral or positively charged liposomes (Gabizon and Papahadjopoulos 1992). It has 
been reported that the negatively charged liposomes are predominantly taken up by 
cells through coated-pit endocytosis, while cationic liposomes may deliver their 
contents to cells either by fusion with cell membranes or through coated pit 
endocytosis (Sharma and Sharma 1997). Conventional method for the preparation of 
liposome is difficult to scale up, and phospholipids in liquid dispersion are liable to 
hydrolysis (Kensil and Dennis, 1881; Grit et al. 1989), and oxidation (Hunt and 
Tsang, 1981), as well as liposome may aggregate and lose the entrapped material. 
The net charge of liposomes is also an important factor and generally anionic and 
neutral liposomes survive longer than cationic liposomes in the blood circulation 
after intravenous injection (Wang et al. 2005; Woodle and Lasic, 1992). Moreover, 
ethanol-based proliposome technology is suitable for preparation of liposomes on a 
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large scale, comprising a stable alternative to the sophisticated and time consuming 
rotary evaporator thin film method. SPC liposomes with Momordica charantia 
extracts produced either slightly positive slightly negative or neutrally charged 
liposomes. Whereas HSPC liposomes along with Momordica charantia extracts (FA, 
SA and WF) from India and Africa and WF and SA extracts from China produce 
positively charged liposomes. In contrast, Chinese FA extract included in HSPC 
phospholipid produced highly negatively charged liposome. The zeta-potential of 
HSPC liposomes containing PTX was more negative compared to SPC liposomes. 




6.3 Growth curve of cancerous and non-cancerous glial cells 
 
 
The growth curve experiments in this study have indicated that the glioma cell line 
 
1321N1, Gos-3 and U87-MG proliferated faster than SVGP12, confirming that 
tumour cells could proliferate much faster than the normal cells (Mor et al. 2008). 
But sometimes even normal cells proliferate much faster (doubling time of 24 hours) 
than do most tumour cells (Pardee, 2002). The death of low-grade glioma 1321N1 
and Gos-3 occurs at the early stage as compared to the U87-MG high-grade glioma. 
Glioma cell lines 1321N1, Gos-3, U87-MG on treatment with drug free liposomes 
did not affect the viability of cells. Patients suffering from low-grade glioma are 
likely to respond to the chemotherapy as compared to high-grade glioma (Engelhard 
et al. 2003). 
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6.4 Cytotoxicity of liposomes generated from proliposomes on tissue culture 
 
 
The result of the study has demonstrated significant anticancer effect of Momordica 
charantia extracts from the fruit alone, seed alone and whole fruit from Africa, 
China and India encapsulated in liposomes and used for the treatment of cancerous 
and non-cancerous cells as compared to untreated glial cells. 
 
A number of preliminary studies have previously shown the anti-cancer activity of 
Momordica charantia against lymphoid, leukemia, lymphoma, choriocarcinoma, 
melanoma, breast, skin and prostate cancer (Licastro et al. 1980; Ng et al. 1994; Sun 
et al. 2001). Maximal anti carcinogenic activity was demonstrated following chronic 
treatment with hot water extract of Momordica charantia in uterine adenomyosis and 
mammary tumour growth in mice (Nagasawa et al. 2002; Singh et al. 1998). The 
beneficial anti-cancer effects of crude water-soluble extract of Momordica charantia 
have been reported previously by several other investigators (Ganguly et al. 2000; 
Jilka et al. 1983; Singh et al. 1998; Raman and Lau, 1996; Takemoto et al. 1982; 
Yeung et al. 1988). Moreover, a number of studies have been conducted using the 
crude preparation of Momordica charantia. In all these studies, the chemical profile 
of the extract was not reported in the investigations. Nevertheless, some studies have 
demonstrated marked biological activities of several compounds including charantin, 
MAP 30, Momordica and alpha, beta momorcharin extracted from Momordica 
charantia (Grover et al. 2004). 
 
All soluble compounds of either fruits or vegetables usually play important roles in 
preparing juices. Protein fractions obtained from the fruit and seed of Momordica 
charantia have the ability to inhibit cell growth, guanylate cyelase activity and 
ribosomal activity (Ram and Lau, 1996). It is hypothesised in the present project that 
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the distribution of active ingredients of Momordica charantia   is different with 
accordance to difference in soil constituents and climatic conditions. It is also 
hypothesised that the concentration of plant ingredients is not the same in different 
parts like the skin, flesh and seeds. Momordica charantia fruit pulp and seed 
compounds possess anti-oxidant activity. Momordica charantia fruit pulp shows 
higher antioxidant activity compared with Momordica charantia seed, which may be 
ascribed  to  their  different  phenolic  and  flavonoid  compositions.  Ethanol/water 
extracts of both pulp and seed powders exhibited higher anti-oxidant activities 
compared with other solvent extracts (Padmashree, 2011). 
 
The present study employed the extracts from either the green flesh, seed or whole 
fruit alone of Momordica charantia obtained from either Africa, India or China to 
investigate their anti-cancer effects. These experiments were designed to identify the 
anticancer effect on cancerous (1321N1, Gos-3 and U87-MG) and non-cancerous 
(SVGP12) cells. The results showed that the growth of the glioma cells 1321N1, 
Gos-3 and U87-MG was significantly inhibited at the higher concentrations of 
African, Chinese and Indian extracts (FA, SA and WF) of Momordica charantia on 
association with SPC or HSPC liposomes, compared to the liposome free Momordica 
charantia extracts (FA, SA and WF). Treatment of the normal glial cells SVGP12 on 
the treatment with African Momordica charantia SA associated with SPC liposomes, 
African Momordica charantia extracts (FA, SA and WF) associated with HSPC 
liposomes,  Chinese  (FA  and  SA)  associated  with  HSPC  liposomes  showed 
significant increase in SVGP12 cells at the lower concentrations and no significant 
change  at  the  higher  concentrations  was  observed.  The  cytotoxic  effect  of 
Momordica charantia extracts was increased on the association with SPC liposomes 
as  compared  to  Momordica  charantia  extract  associated  with  HSPC  liposomes. 
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Regardless of country of origin, the cytotoxic effect of Momordica charantia FA was 
higher than that of SA or WF extract. Chinese Momordica charantia FA extracts 
alone and associated with SPC or HSPC liposomes showed potent inhibition of 
glioma cells compared to untreated cells. Chinese phenotype extracts with or without 








FA extract of Momordica charantia obtained from Africa, China or India showed 
maximum cytotoxic effect on the glioma cell lines. The mechanism of apoptosis for 
cell death of cancerous and non-cancerous glial cells is believed to occur by intrinsic 
or extrinsic pathway. Regardless of fruit origin, the treatment with FA extract 
included in SPC or HSPC liposomes resulted in different release of caspase3/7, 
caspase 9, calcium and cytochrome c. Apoptosis is a programmed process of cell 
death and it is associated with damage of cell mitochondria to elevate intracellular 
mediators such as caspase 3 and caspase 9 and release of cytochrome c (Bernadi et 
al, 1994; Chandra et al 2002). In previous studies, it was shown that anticancer drugs 
exert   their   lethality   by   inducing   apoptosis   in   tumour   cells   targeting   both 
mitochondrial (intrinsic pathway) and death receptors (extrinsic pathway) (Gati et al. 
1991; Makin, 2002; Hajnoczy et al. 2006). Histologically, apoptotic cells are 
characterized by morphological alterations such as cell shrinkage, nuclear chromatin 
compaction, pyknosis, nuclear fragmentation, cytoplasmic condensation, and 
convolution of the nuclear and cell outlines. The receptor-mediated pathways is 
triggered by the activation of capase 8 which in turn cleaves and activates caspase 3 
(Ashkenazi and Dixit, 1998). Cysteine aspartases (caspases), a protease family, are 
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known to be required for apoptosis induced by various stimuli (Krepela, 2001). 
Among mammalian caspases, comprising at least 14 known members, caspase-3 is 
thought to be the main effecter of caspases and it has been identified as being 
activated in response to cytotoxic drugs (Krepela, 2001). Activation of caspase-3 is 
an important step in the execution phase of apoptosis and its inhibition blocks cell 
apoptosis (Budihardjo et al. 1999). In mammals, caspase-3 has been identified as key 
executors of apoptosis and is one of the most important caspases activated 
downstream of apoptotic pathways (Cohen, 1997). In addition, caspase-3 which 
activates caspase-activated DNase, causing apoptotic DNA fragmentation. The 
mitochondrial pathway is initiated by cytochrome c relaease from the mitochondria, 
which in turn promote the activation of of caspase 9, which is responsible for the 
activation of cell death protease. (Ashkenazi and Dixit, 1998; Chandra et al. 2002). 
The present findings have demonstrated that caspase 3/7, caspase 9 and cytochrome 
c were released in the glioma cell lines (1321N1, GOS-3, U87-MG) when the highest 
concentration of Momordica charantia extracts was used. Maximum level of caspase 
3/7, caspase 9 and cytochrome c release were observed when each glioma cell line 
was treated with Chinese Momordica charantia FA extract on association with SPC 
liposomes. Normal glial cells SVGP12 on treatment with Momordica charantia 
extract with SPC or HSPC liposomes showed a slight release of caspase 3/7 and 
caspase 9. The cytochrome c release from SVGP12 was higher than that occurred for 
the untreated SVGP12 cells. However, the  release of cytochrome c was less in 
SVGP12 when compared to the treated glioma cell lines 1321N1, GOS-3 and U87- 
MG. The PTX liposomes generated from SPC and HSPC liposomes caused 
significantly more release of caspase 3/7, caspase 9 and Cytochrome c as compared 
to the cell lines treated with Momordica charantia extract FA liposomes from SPC 
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and HSPC phospholipids. Low grade glioma showed more cytotoxic effect compare 
to high grade glioma. Momordica charantia with liposomes (HSPC or SPC) caused 
cell death in brain tumour cells via mitochandrial pathway. Similarly, the release of 
caspase 3/7, caspase 9 and cytochrome c was higher in low grade glioma compared 
to high grade glioma. The incidence of cancer is increasing worldwide, in spite of 
substantial progress in the development of anti-cancer therapies. One approach in 
controlling cancer could be its prevention by diet, which may inhibit one or more 
neoplastic   events   and   reduce   the   possibility   of   cancer   occurrence.   Dietary 
compounds offer great potential in the fight against cancer by inhibiting the 
carcinogenesis process through the regulation of cell homeostasis and cell-death 






The anti-tumor activity of Momordica charantia has recently begun to emerge. This 
research focuses on recent advancements in cancer chemopreventive and anti-cancer 
efficacy of bitter melon and its active constituents. The main objective of this project 
was to develop SPC and HSPC liposomes using the proliposome method to target 
brain tumour. Momordica charantia extracts (FA, SA and WF) and PTX associated 
with SPC or HSPC liposomes led to aggregation of liposomes and caused 
enlargement of the size and broadening of the size distribution of liposomes, which 
also had negative zeta potential measurements. These liposomes were prepared to 
target the brain tumour by employing such tumour cell lines as 1321N1, GOS-3, 
U87-MG investigate the effect compared to normal glial cell line SVGP12. The 
commercial anticancer drug, PTX liposome was used to compare the anti cancer 
effect  on  the  cancer  cell  line  as  compared  to  Momordica  charantia  extracts 
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liposomes. PTX liposomes (SPC or HSPC) could inhibit around 44-60 % of glioma 
cell lines (1321N1, Gos-3 and U87-MG), whereas, Momordica charantia extracts 
(WF, FA and SA) liposomes (SPC or HSPC) from different countries of origin could 
inhibit 60-80 % of glioma cells without effecting SVGP12 cells. Momordica 
charantia (FA, SA and WF) liposomes inhibited less glioma cell lines as compare to 
PTX liposomes. The effect of Momordica charantia liposomes on glioma cells was 
slightly more or had no effect as compare to drug without liposomes. Momordica 
charantia FA extract with or without liposomes was more effective to inhibit brain 
tumour as compared to Momordica charantia WF and SA extracts with or without 
liposomes. PTX liposomes generated from either SPC or HSPC liposomes caused 
significantly higher release of caspase 3/7, caspase 9 and cytochrome c as compared 
to the cell lines treated with Momordica charantia extract FA liposomes. Low-grade 
glioma shows more cytotoxic effect compared to high-grade glioma. It seems likely 
that high-grade glioma requires high doses of Momordica charantia extract to show 
the cytotoxic effect. Similarly, the realease of caspase 3/7, caspase 9 and cytochrome 
c was higher in low-grade glioma compared to high-grade glioma. In conclusion, 
proliposome method was developed to generate a stable and effective targeted 
liposome delivery system for Momordica charantia extracts (FA, SA and WF) or 
PTX to take these constituents selectively to glioma brain tumors. This targeted 
delivery system could potentially increase the anti-cancer activity as well as the 
therapeutic index of the drug compared to existing solution dosage forms. 
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6.7 Scope for 
 
 




1. Separation and isolation of active anticancer compounds from Momordica 
charantia and entrapping them individually in liposomes. 
2. Reducing the particle size of the liposomes by probe sonication, or extrusion 
to study the effects of that on the anticancer activity. 
3. To achieve easy and convenient mode of transport and handle, it is necessary 
to freeze dry or spray dry the liposomes for the treatment of brain tumour. 
The effects of drying on the anticancer activity can then be studied. 
4. Usage of either sucrose or trehalose as cryoprotectants may avoid oxidation 
and make liposomes more stable to circulate in the body for longer period of 
time. For tumour cells thrive on sugar molecule for the nutrition, therefore, 
liposomes  in  combination  with  Momordica  charantia  and  sucrose  or 
trehalose may serve to be more toxic to the tumour cells. This hypothesis 
should be studied in the future. 
5. Brain  tumour  cells  expresses  large  amount  of  iron-saturated  transferrin 
receptors. One approach is to prepare liposomes with higher specificity to 
bind to the tumour cells by using transferrin molecules in combination with 
Momordica charantia liposomes. A wide range of therapeutic agents into 
malignant sites can be delivered by transferrin-endocytosis process. 
6. Using  an  animal  model  to  surgically  operate  the  brain  and  inject  the 
Momordica charantia extracts liposomes inside the brain. This type of 
technology may cause sustains release of Momordica charantia for longer 
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PROLIPOSOME TECHNOLOGY AS AN APPROACH TO GENERATING 
ANTICANCER LIPOSOMES. 
 
J aiswal, S.R., Ma noha ran, G., Ahmed, W. and Elhissi, A.M.A. 
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A I MS 
The study involves the investigation of prol i posomes prepared  from speci fic phospholipids and a drug i nhibits growth of glioma. 
 
I NTRODUCTION R ESU LTS 
The interesting properties ofli posomc (Fig  I ) prepared    
,•, ,  ' from proliposomcs is that they are safe, biodegradable, 
o..;•"l-""'""physically and chemically  stable, and tumour  targeting • •' llj...,....,.. carrier  for drug  delivery  (Katare  et a/., 1990; Crom- 
melin and Sindel ar, 2002).  They can be manufactured 
on a large scal e from  phospholipids that are si mi lar to 
Fig I. Basic Structure ofliposomc.             the  lipid components present  in  the  biological   mem- 
brane (Fig  2). There arc two methods  to prepare  l iposomes    a)  Part iculate  based prol i po- 
some and  b) Solvent- based proliposome. 
Particulate  proliposomcs  arc dry, free-flowing carrier  particles  coated  with  phospholipids 
that generate  liposomes on addition of aqueous  phase (Payne  et al 1986). Secondly, a sol- 
vent  based prol iposome method  offers a rel atively simple  means of gen erating  liposomes 
with a high entrapment of hydroph ilic agents, by the addition  of aqueous phase to a con- 
centrated  alcoholic solution  of phospholipids (Perrett et al 1991). The aim of our project  is 
to  use  phospholi pids  to  manufacture  solvent-based proliposomes which  can  be used  to 
generate phosphol i pid  vesi cles  (liposomes)  (Fi g  I)  when  aqueous  phase  (e.g.  water)  is 
added.  In this study, the size  of  the vesicles  prepared  from  proliposomes  was compared 
wi th the conventi onal method of producing liposomes. The model  anticancer drug deri ved 
from the plant Momordi ca charantia  was entrapped i n liposomes and   the efficacy  of anti- 
cancer-liposome formul ations  on the vi ability of glioma  cell lines 1321 N l , and  U87-MG 
was eval uated . 
Li posom e Po·epamtion  Meth ods 
 
 
fig 4. Comparison of the particle size and charge prepared  from a} Thin film method and 
b) Solvent-based proliposome method. 
 
 
A.  Crude M. charantia w ith  liposo rn e 
r:- 
 
· m ,_  Fig   2. The structure of the 
taoslrol phospholipids  present   in  the 
£11u..&- s....    r ""1 •      biological membrane:   Phos- 
 
Concen t ration or crude M. cltarantia (Jag) 
atlditac:id .KJ·  ,_.. phati dic     acid,    Phosphati- B. A l pha- Beta l\11. charuntia  with liposonte  
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Cel ls like 1321NI and U87-MG 
Conce nt ration or Alpha-Beta M.cll.arantia (JIM) 
f ig 5.Dose dependent effect of(A) Crude M. charantia with liposome and (B) Alpha-Beta 
M. charantia with liposome on the cell  viability  of 1321 N 1 and U87-MG cel l  lines i s meas- 
ured by  MTS assay on  Teccan  plate reader after  24 hr$ of t reatment.  Data for treated cells 
compared to untreated (control) cells are mean± S.D. n""3. 
CONCU LSJON AND FUTURE WORK 
These results have indicated that the parti cle size of the l iposome, prepared 
from solvent-based proliposome  method was smaller compared  to th e lipo- 
some  prepared  from  thin film m ethod. Th e diameter of th e liposome  parti- 
cles  prepared  from  solvent-based  prol iposome  method  i ncreased  on  the 
presence of  the  crude  M. charantia  and  Alpha-Beta M. charantia. The 
diameter  of Alpha-Beta M. charantia  was slightly larger compared  to cru de 
M. charantia  (Fi g 4). On treatment of crude and Alpha-Beta M. charantia 
entrapped   liposomc  on  tissue  culture,  it  was  observed   that  A lph a-Beta 
M. charantia  and crude  M. charantia shows inhi bition of cell  viability of 
the  glioma  cell  li n es  I 321 N I    and    U87-MG  compared to  the  untreated 
(control)   1321 N I  and  U87-MG  cells  (Fig  5).  Electron  microscopy   and 
High   Performance  Liquid   Chromatography    (HPLC)    are   required   to 






Fig 3.  Liposomes preparation methods from thin film and Solvent based  proliposomes methods. The liposome 
prepared  from proliposomes are used for the treatment of glioma cell li nes 1 321 N l and U87M· G. 
A) Pa rticle  size an alysis:  Laser  diffraction  (Mal vern  Mastersizer) was  used  for particle 
size analysis. Sample was di luted with water and their average diameter  and size distri- 
bution were determined. 
B) Surface charge a n a lysis: A Zeta-Sizer is used  to measure  the zeta  potential  (surface 
charge) ofliposome.This was automati cally cal culated from the electrophoretic mobil ity. 
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AIMS 
The study involves the in vitro investigation of proliposomes prepared from specific phospholipids and drugs inhibiting the growth of glioma cell lines. 
INTRODUCTION 
The interesting properties of liposome prepared from proliposome is, they are  safe, biodegradable, physically and chemically stable, and tumour targeting carrier for drug delivery 
(Katare et al., 1990; Crommelin and Sindelar, 2002). They can also be manufactured on large scale from phospholipids that are similar to the phospholipids present in the 
biologi- cal  membrane.There are two methods to prepare liposomes using the proliposome approach : a) Particulate based proliposome and b) Solvent- based proliposome. 




Fig 1. Basic Structure of Liposome. 
 
METHODS 
solvent based proliposomes offer a relatively simple means of generating liposomes with a high entrapment of hydrophilic agents, by the addition of aqueous phase to  a concen- 
trated alcoholic solution of phospholipids (Perrett ela/., 1991). The aim of this studyis to use phosphoil pids to manufacture solvent-based proliposomes which can be used to gen- 
erate liposomes (fig 1) when aqueous phase (e.g. water) is added. The model anti-cancer drug derived from plants Momordica charantia  and taxol derived from pacific yew bark 
are entrappedin liposomes and the efficacy of anti-cancer liposome formulations on  the viability of glioma cell lines 1321N1, Gos-3, U87-MG and normal glial cell line SVGP12 
was investigated. 
 
A)   Particle size analysis: A  Malvern mastersizer 
2000 is used measurement of part cle size. Sample ,. 
is diluted with water and their average diameter and I: 
size distribution is determined using  dynamic l ight '- 
scattering.  The  technique  of  laser   diffraction is 




Fig 2. Glioma cell lines 1321N1,Gos-3,U87-MG and 
normalglial cells SVGP12 were treated with the  lipo- 
somes prepared from proliposomes containing drugs 
such as Crude M. charanua , alpha-beta M.chsrantis 
and  taxol. 
RESULTS 
a laser beam will scatter light at an  angle that is re- 
lated to their size. 
B) Surface charge analysis: A zeta-sizer is used to 
measure the zeta potential of liposomes. Zeta- 












Fig 4. (A) Cells treated with water + ethanoland drug free liposome were  compared with the un- 
treated cells of SVGP12 ,1321N1, Gos-3 and  U87-MG. 
Dose dependent effect of Crude M.chanrantia and Alpha-Beta M.charantia extract and liposome 
were examined on Teccan plate reader after 24 hrs  of treatment by measuring ATP release of the 
cells (B) SVGP12 (C) 1321N1(D) G os 3 and (E) U87·MG. 






Teccan plate reader after 24  hrs  of treatment with  (F) Ethanol + water alone and increasing con- 
centration of taxoldissolvedin ethanol + water and  (G) Taxol with drug free  liposome and increas- 
ing concentration of taxolbinded to liposome. 






Fig 3.A) Electron microscopy of the  liposomes prepared from proliposome showing oligolamellar structure with large 




CONCULSION AND FUTURE WORK 
On treatment with crude and alpha-beta M. charantia extract and entrapped with liposome on tissue culture, it is 
observed that Alpha-Beta and crude M. charanlia liposome shows slightly more inhibit on of cell viabil ty of  the 
glioma cell lines 1321N1, Gos-3 and U87-MG and not effecting normal cellline SVGP12, when compared to the 
untreated cell lines  (see fig 4). Taxol with liposome was observed to be more toxic to  the normal cell line 
SVGP12 and also seem to be promoting the growth of the glioma cell line 1321N1 and U87-MG as compared to 
the cells treated with taxol without liposome. Further experiments are  required to determine the mechanism of 
action of the drug inhibiting glioma. High Performance Liquid Chromatography (HPLC) is also required to deter- 
mine the entrapment efficiency of the drug. 
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The study involves lhe in vitro investigation of proliposomes prepared from specific phospholipids and drugs inhibiting the growth of glioma  celllines. 
INTRODUCTION 
The  interesting properties of  liposome pre- 
pared from proliposomeis, they are  safe, bio- 
degradable, physically and chemically stable, f·- 
- and tumour  targeting carrier  for drug  delivery 
(Katare  eta/., 1990;  Crommelin and Sindelar, 
2002).  They  can  be  manufactured on  large 
scale  from  phosphol ipids  that  are  similar  to 
the  phospholipids present   in  the   biological  
membrane. There  are two methods to prepare 
Fig 1. BasicStructureofLiposome.       liposome   a)  Particulate  based   proliposome 
and b) Solvent- based proliposome (alcohol-based proliposome). 
Particulate  proliposomes are  dry, free-flowing carrier particles coated  with 
phospholipids that generate liposomes on addition of aqueous phase (Payne 
l : 
et a/1986). Secondly, a solvent based  proliposome method offers a relatively     f : 
simple  means of generating liposomes with a high  entrapment of hydrophilc    I 
agents,  by the addition  of aqueous phase  to a concentrated alcoholic solu- 
tion of phospholipids (Perrett  et a/., 1991). The  aim of this project  is to use 
phospholipids to  manufacture alcohol-based  proliposomes which  can  be 
used  to generate  phospholipid vesicles  (liposomes) (see fig 1) when aque- 
ous phase  (e.g.  water)  is added. The model  anti-cancer drug  derived  from 
plants  Momordica charantia and  taxol derived  from pacific yew bark is used 
to  entrapped in liposomes and  investigate the  efficacy  of  anti-cancer lipo- 














A)Particle    size  analysis:   A 
Malvern   mastersizer   is    use 
Fig 4. (A)  Cells  treated with  water  + ethanol and drug  free liposome were  compared with the 
untreated cells of SVGP12,1321N1, Gos-3  and U87-MG. 
Dose  dependent effect  of Crude  M. chanrantia and Alpha-Beta M. charantia extract and lipo- 
some were examined on Teccan plate  reader after  24 hrs  of treatment by  measuring ATP re- 
lease of the cells (BlSVGP12 (Ct1321N1(DtGos-3 and (ElU87-MG. 
The cell viability of SVGP12,1321N1and U67-MG  cell lines were  measured by MTS assay on 
Teccan plate reader after 24 hrs of treatment with (F) Ethanol+ water alone and increasni g con· 
centration of taxol dissolved in ethanol + water and  (G)  Taxol wi th drug  free liposome and in- 
measurement  of   particel size creasing concentration of taxolbinded to liposome. 







Fig 2. Glioma celllines 1321N1, Gos-3,U87-MG and 
normal glial celll s SVGP12 were  treated with thelipo- 
somes prepared from proliposomes containing drugs 
such  as Crude  M. charantia, alpha-beta M. charantia 
and taxol. 
using  laser  diffraction.  Sample 
is diluted  with water and their 
average diameter  and  size  dis- 
tribution is determined using the 
dynamic light scattering.  The 
technique of laser diffraction is 
based  on the principle that par- 
ticles passing through a laser 
beam  will scatter light at an an- 
gle   that   is  directly   related   to 
their size. 
 
CONCULSION AND FUTURE  WORK 
On  treatment  with  crude  and  Alpha-beta M.  charantia extract   and  en- 
trapped with liposome on tissue culture, it is observed  that Alpha-Beta and 
crude M. charantia liposome shows slightly more inhibition of cell viability of 
the glioma  cell lines  1321N1, Gos-3  and U87-MG and not effecting normal 
cell line SVGP12, when compared to the untreated  cell lines  (fig 4). Taxol 
with  liposome  was  observed  to  be  more   toxic  to  the  normal  cell  line 
SVGP12 and also seem to be promoting the growth  of the glioma  cell line 
1321N1  and  U87-MG as compared  to the cells  treated  with taxol without 
liposome(fig 4). Further  experiments are required to determine the mecha- 
nism of action of the drug inhibiting glioma. High Performance Liquid  Chro- 
B) Surface charge analysis: A zeta-sizer is used to measure the zeta po- 





Fig 3.The electron microsoopy of the liposomes prepared from proliposome 
A)Drug free  liposome showing oligolamellar structure with  large  aqueous pores  having particle 
size  of  3.992m and  zeta-potential charge -8.270±0.675 B)  Crude  M.  charantia having oligo- 
lamellar and multi-lamellar structures having particle size of 4.730 IJffi and zeta-potential charge 
-o.930± 0.989 C) Alpha-beta M. charantia having oligo-lamellar and mult-i lamellar structure hav- 
ing particle size of 5.320 !Jm and zeta-potential charge -2.04  ± 1.33. 
matography (HPLC) is also  required to determine the surface morphology 
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